Study Title: 
Sponsor: 
IND Number: 
EudraCT Number: 
Clinical Trials.gov 
Identifier: 
Indication: 
Protocol ID: 
Gilead Study Clinical 
Program M anager: 
Gilead Medical 
Monitor: 
Protocol Version/Date: (rJ GILEAU 
CLINICAL STUDY PROTOCOL 
A Phase 3, Randomized, Double-Blind Study to Evaluate the Safety 
and Efficacy of GS-9883/Emu·icitabine/Tenofovir Alafenamide 
Versus Do lutegravir + Emu·icitabine/Tenofovir Alafenamide in 
HIV-1 Infected, Antireu·oviral Treatlnent-Nalve Adults 
Gilead Sciences, Inc. 
333 Lakeside Drive 
Foster City, CA 94404 
125,589 
2015-003988-10 
Not Available 
HIV -1 Infection 
GS-US-380-1490 
Name: 
Telephone: 
Fax: 
Name: 
Telephone: 
Fax: 
Original: PD 
PPD 
PPD 
Devi SenGuj)ta, MD 
PD 
PPD 
21 October 2015 
CONFIDENTIALITY STATEMENT 
The inf01mation contained in this document, pruiicularly unpublished data, is the prope1iy or 
under conu·ol of Gilead Sciences, Inc., and is provided to you in confidence as an investigator, 
potential investigator, or consultant, for review by you, your staff, and an applicable Institutional 
Review Board or Independent Ethics Committee. The infonnation is only to be us ed by you in 
connection with authorized clinical studies of the investigational dmg de scribed in the protocoL 
You will not disclose any of the infonnation to others without written authorization from 
Gilead Sciences, Inc., except to the extent necessruy to obtain infonned consent from those 
persons to whom the dmg may be administered. 
GS-9883/F/TAF 
Protocol GS -US-380-1490 Final
Gilead Sciences, Inc. Original
CONFIDENTIAL Page2 21 October 2015TABLE OF CONTENTS
TABLE OF CONTENTS .............................................................................................................................................. 2
LIST OF IN- TEXT TABLES ................................................................
........................................................................ 5
LIST OF IN- TEXT FIGURES ...................................................................................................................................... 5
PROTOC OL SYNOPSIS .............................................................................................................................................. 6
GLOSSARY OF ABBREVIA TIONS AND DEFINITION OF TERMS .................................................................... 12
1.INTRODUCTION .............................................................................................................................................. 15
1.1.Background ............................................................................................................................................ 15
1.2.GS-9883................................................................................................................................................. 16
1.2.1. General Information ............................................................................................................. 16
1.2.2. Preclinical Pharmacology and Toxicology ........................................................................... 16
1.2.3. Clinical Trials of GS -9883................................................................................................... 18
1.3.Information about Emtricitabine (Emtriva®, FTC) ............................................................................... 26
1.4.Information about Tenofovir alafenamide (TAF, GS -7340).................................................................. 26
1.4.1. Clinical Trials of Single Agent Tenofovir Alafenamide (TAF, GS -7340) 
or Fixed Dose Combination emtricitabine/tenofovir alafenamide 
(FTC/TAF) ........................................................................................................................... 27
1.4.2. Clinical Trials of FTC/TAF as part of 
elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide (E/C/F/TAF) ........................... 28
1.5.Information about GS -9883/emtricitabine/tenofovir alafenamide (GS -9883/F/TAF) ........................... 30
1.5.1. GS-US-141
-1233: Study of the Relative Bioavailability of GS -9883, 
FTC, and TAF betw een GS-9883/F/TAF and GS -9883 + F/TAF........................................ 30
1.6.Information about dolutegravir (DTG, Tivicay®)................................................................................... 31
1.7.Rationale for this Study ...............................................................
........................................................... 31
1.8.Risk/Benefit Assessment for the Study .................................................................................................. 31
1.9.Rationale for Dose Selection ...............................................................
................................................... 32
1.10.Compliance............................................................................................................................................ 34
2.OBJECTIVES ................................................................................................
..................................................... 35
3.STUDY DESIGN ................................................................................................................................................ 36
3.1.Endpoints ............................................................................................................................................... 36
3.2.Study Design .......................................................................................................................................... 36
3.3.Study Treatments ................................................................................................................................... 36
3.4.Duration of Treatment ............................................................................................................................ 37
3.5.Biomarker Testing .................................................................................................................................. 38
3.5.1. Biomarker Samples for Optional Pharmacogenomic Research ............................................ 38
3.5.2. Additional Sample Storage ................................................................................................... 38
4.SUBJECT POPULATION .................................................................................................................................. 39
4.1.Number of Subjects and Subject Selection ............................................................................................ 39
4.2.Inclusion Criteria .................................................................................................................................... 39
4.3.Exclusion Criteria ................................................................................................................................... 40
5.INVESTIGATIONAL MEDI CINAL PRODUCTS........................................................................................... 42
5.1.Randomization, Blinding and Treatment Codes .................................................................................... 42
5.1.1. Procedures for Breaking Treatment Codes ........................................................................... 42
5.2.Description and Handling ....................................................................................................................... 43
5.2.1. Formulation.......................................................................................................................... 43
5.2.2. Packaging and Labeling ....................................................................................................... 44
GS-9883/F/TAF 
Protocol GS -US-380-1490 Final
Gilead Sciences, Inc. Original
CONFIDENTIAL Page3 21 October 20155.2.3. Storage and Handling ........................................................................................................... 45
5.3.Dosage and Administration of GS -9883/Emtricitabine/Tenofovir alafe namide and 
Dolutegravir + Emtricitabine/Tenofovir alafenamide ............................................................................ 45
5.4.Prior and Concomitant Medications ....................................................................................................... 45
5.5.Accountability for Investigational Medicinal Product (IMP) ................................................................. 46
5.5.1. Investigational Medicinal Product Return or Disposal ......................................................... 46
6.STUDY PROCEDURES ................................
.................................................................................................... 47
6.1.Subject Enrollment and Treatment Assignment ..................................................................................... 47
6.2.Pretreatment Assessments ...................................................................................................................... 47
6.2.1. Screening Visit ..................................................................................................................... 47
6.2.2. Day 1 Assessments ............................................................................................................... 49
6.3.Randomization ....................................................................................................................................... 51
6.4.Treatment Assessments (Week 4 -96).................................................................................................... 51
6.5.Treatment Assessments (Post Week 96 until the Unblinding Visit) ...................................................... 54
6.5.1. Post Week 96 Assessments ................................
.................................................................. 54
6.5.2. Unblinding Visi t................................................................................................................... 55
6.6.Post-treatment Assessments ................................................................................................................... 56
6.6.1. Early Study Drugs Discontinuation Assessments ................................................................. 56
6.6.2. 30 Day Follow Up ................................................................................................................ 58
6.7.Criteria for Discontinuation of Study Treatment .................................................................................... 59
6.8.Blood and Urine Storage ........................................................................................................................ 59
6.9.Assessments for Premature Discontinuation from Study ....................................................................... 59
6.10.End of Study ........................................................................................................................................... 60
6.11.Post Study Care ...................................................................................................................................... 60
6.12.Virologic Failure .................................................................................................................................... 60
6.12.1. Management of Virologic Rebound ..................................................................................... 60
6.12.2. Subjects with HIV -1 RNA ≥ 50 copies/mL at Study Discontinuation, 
Week48 or Week 96............................................................................................................ 61
7.ADVERSE EVENTS AND T OXICITY MANAGEMENT ............................................................................... 62
7.1.Definitions of Adverse Events, Adverse Reactions, and Serious Adverse Events ................................. 62
7.1.1. Adverse Events ..................................................................................................................... 62
7.1.2. Serious Adverse Events ........................................................................................................ 62
7.1.3. Clinical Laboratory Abnormalities and Other Abnormal Assessments as 
Adverse Events or Serious Adverse Events ......................................................................... 63
7.2.Assessment of Adverse Events and Serious Adverse Events ...............................................................
..63
7.2.1. Assessment of Causality for Study Drugs and Procedures ................................................... 63
7.2.2. Assessment of Severity ........................................................................................................ 64
7.3.Investigator Requirements and Instructions for Reporting Advers
e Events and Serious 
Adverse Events to Gilead ....................................................................................................................... 64
7.3.1. Adverse Events ..................................................................................................................... 64
7.3.2. Serious Adverse Events ........................................................................................................ 65
7.4.Gilead Reporting Requirements ............................................................................................................. 66
7.5.Toxicity Management ...............................................................
............................................................. 66
7.5.1. Grades 1 and 2 Laboratory Abnormality or Clinical Event .................................................. 66
7.5.2. Grade 3 Laboratory Abnormality or Clinical Event ............................................................. 67
7.5.3. Grade 4 Laboratory Abnormality or Clinical Event ............................................................. 67
7.5.4. On-Treatment ALT Flare and Post -Treatment Exacerbation of Hepatitis B 
Management ......................................................................................................................... 67
7.5.5. On-Treatment Hepatitis C Management ............................................................................... 69
7.6.Special Situations Reports ...................................................................................................................... 69
7.6.1. Definitions of Special Situations .......................................................................................... 69
7.6.2. Instructions for Reporting Special Situations ....................................................................... 70
GS-9883/F/TAF 
Protocol GS -US-380-1490 Final
Gilead Sciences, Inc. Original
CONFIDENTIAL Page4 21 October 20158.STATISTICAL CONSIDER ATIONS................................................................................................................ 72
8.1.Analysis Objectives and Endpoints ........................................................................................................ 72
8.1.1. Analysis Objectives .............................................................................................................. 72
8.1.2. Primary Endpoint ................................................................................................................. 72
8.1.3. Secondary Endpoint ............................................................................................................. 72
8.2.Analysis Conventions ............................................................................................................................. 72
8.2.1. Analysis Sets ........................................................................................................................ 72
8.3.Data Handling Conventions ................................................................................................................... 74
8.4.Demographic Data and Baseline Characteristics ................................................................................... 74
8.5.Efficacy Analysis ................................................................................................................................... 74
8.5.1. Primary Analysis ................................
.................................................................................. 74
8.5.2. Secondary Analyses ............................................................................................................. 76
8.6.Safety Analysis ....................................................................................................................................... 76
8.6.1. Extent of Exposure ............................................................................................................... 76
8.6.2. Adverse Events ..................................................................................................................... 77
8.6.3. Laboratory Evaluations ........................................................................................................ 77
8.6.4. Other Safety Evaluations ...................................................................................................... 77
8.7.Pharmacokinetic Analysis ...................................................................................................................... 78
8.8.Patient Reported Outcomes (PRO) ...............................................................
.......................................... 78
8.9.Sample Size............................................................................................................................................ 78
8.10.Data Monitoring Committee ...............................................................
................................................... 78
9.RESPONSIBILITIES ................................................................
.......................................................................... 79
9.1.Investigator Responsibilities .................................................................................................................. 79
9.1.1. Good Clinical Practice .......................................................................................................... 79
9.1.2. Institutional Review Board (IRB)/Independent Ethics Committee (IEC) 
Review and Approval ........................................................................................................... 79
9.1.3. Informed Consent ................................................................................................................. 79
9.1.4. Confidentiality ...................................................................................................................... 80
9.1.5. Study Files and Retention of Records.................................................................................. 80
9.1.6. Case Report Forms ...............................................................
................................................ 81
9.1.7. Investigational Medicinal Product Accountability and Return ............................................. 82
9.1.8. Inspections ............................................................................................................................ 82
9.1.9. Protocol Compliance ............................................................................................................ 82
9.2.Sponsor Responsibilities ................................
........................................................................................ 82
9.2.1. Protocol Modifications ......................................................................................................... 82
9.2.2. Study Report and Publications ............................................................................................. 83
9.3.Joint Investigator/Sponsor Responsibilities ........................................................................................... 83
9.3.1. Payment Reporting ............................................................................................................... 83
9.3.2. Access to Information for Monitoring .................................................................................. 83
9.3.3. Access to Information for Auditing or Inspections .............................................................. 84
9.3.4. Study Discontinuation .......................................................................................................... 84
10.REFERENCES ................................................................................................................................................... 85
11.APPENDICES .................................................................................................................................................... 86
Appendix 1.Investigator Signature Page .................................................................................................... 87
Appendix 2.Study Procedures Table (Blinded Phase) ............................................................................... 88
Appendix 3.Management of Clinical and Laboratory Adverse Events ...................................................... 92
Appendix 4.GSI Grading Scale for Severity of Adverse Events and Laboratory Abnormalities ............... 93
Appendix 5.Definitions of Stage 3 Opportunistic Illnesses in H IV (CDC Guidelines) ........................... 117
Appendix 6.Pregnancy Precautions, Definition for Female of Childbearing Potential, and 
Contraceptive Requirements ................................................................................................. 119
GS-9883/F/TAF 
Protocol GS -US-380-1490 Final
Gilead Sciences, Inc. Original
CONFIDENTIAL Page5 21 October 2015LIST OF IN -TEXT TABLES
Table1-1. GS-US-141-1218: GS -9883 Mean (%CV) PK Parameters Follow ing Single Doses 
of GS-9883 in Healthy Subjects (GS -9883 PK Analysis Set; Part A: Single Dosing) ...........20
Table1-2. GS-US-141-1218: GS -9883 Plasma Pharmacokinetic Parameters by GS -9883 Dose 
Following Multiple -Dose Administration of GS -9883 (Analysis Set: GS -9883 PK 
Part B: Multiple
-Dose)........................................................................................................... 21
Table1
-3. GS-US-141-1218: Statistical Comparison of GS -9883 Pharmacokinetic 
Parameters 
Following Single -Dose Adm inistration of GS -9883 in the Fasted and Fed States 
(GS-9883 PK Analysis Set) .................................................................................................... 22
Table1
-4. Trough GS -9883 Plasma Concentrations at Steady State Follow ing GS-9883 
Administration Under Fas ting Conditions and Corresponding Protein -Adjusted 
IQ95 Values (GS-9883 PK Analysis Set) ...............................................................
................ 23
Table1-5. GS-US-141-1219: Trough GS -9883 Plasma Concentrations at Steady State 
Following GS-9883 Administration Under Fasting Cond itions and Corresponding 
Protein-Adjusted IQ 95Values................................................................................................
.33
Table5-1. Prior and Concomitant Medications ....................................................................................... 46
LIST OF IN -TEXT FIGURES
Figure1
-1.GS-US-141-1219: Mean and 95% CIs of Change from Baseline in HIV -1 RNA 
(log10copies/mL) (PP Analysis Set) ....................................................................................... 23
Figure3-1.Study Schema ...............................................................
.......................................................... 37
Figure6-1.Virologic Rebound Schema .................................................................................................... 61
GS-9883/F/TAF 
Protocol GS -US-380-1490 Final
Gilead Sciences, Inc. Original
CONFIDENTIAL Page6 21 October 2015PROTOCOL SYNOPSIS
Gilead Sciences, Inc.
333 Lakeside Drive
Foster City, CA 94404
StudyTitle: A Phase3, Randomized, Double -Blind Study  to Evaluate the Safety  
and Efficacy  of GS-9883/Emtricitabine/Tenofovir Alafenamide 
Versus Dolutegravir + Emtricitabine/Tenofovir Alafenamide i n 
HIV-1 Infected, Antiretroviral Treatment -Naïve Adults
IND Number:
EudraCT Number:
Clinical Trials.gov 
Identifier:125,589 
2015-003988-10
Not Available 
Study Centers 
Planned:Approximately  75 centers in North America
Approximately 2 centers in Asia
Approximately  25 centers in Europe
Objectives: The primary  objective of this study  is as follows:
To evaluate the efficacy  of a fixed dose combination (FDC) 
containing GS -9883/emtricitabine/tenofovir alafenamide 
(GS-9883/F/TAF) versus dolutegravir (DTG) + a FDC containing 
emtricitabine/tenofovir alafenamide (F/TAF) in HIV-1 infected, 
antiretroviral treatment- naïve adult subjects as determined by  the 
achievement of HIV -1RNA 50copies/mL  at Week 48
The secondary  objectives of this study  are as follows: 
To evaluate the efficacy , safety and tolerability of the two 
treatment groups through Weeks 48 and 96 
Study Design: Randomized, double -blind, multicenter, active -controlled study  to 
evaluate the safet y and efficacy of GS -9883/F/TAF FDC versus DTG 
+ F/TAF FDC in HIV -1 infected, antiretroviral treatment -naïve adult 
subjects. Subjects who provide written consent and meet all eligibility  
criteria will be randomized in a 1:1 ratio to one of the following two 
treatment groups:
Treatment Group 1: FDC of GS-9883 50 mg/emtricitabine 200 mg/ 
tenofovir alafenamide 25 mg (GS-9883/F/TAF) + Placebo to match 
dolutegravir 50 mg and Placebo to match FDC of emtricitabine 
200mg/tenofovir alafenamide 25 mg (F/TAF) administered orally , 
once daily, without regard to food (n=300 )
GS-9883/F/TAF 
Protocol GS -US-380-1490 Final
Gilead Sciences, Inc. Original
CONFIDENTIAL Page7 21 October 2015Treatment Group 2: Dolutegravir 50 mg + FDC of emtricitabine 
200 mg/tenofovir alafenamide 25 mg (F/TAF) + Placebo to match 
FDC of GS -9883 50 mg/emtricitabine 200 mg/tenofovir alafenamide 
25mg (GS-9883/F/TAF) administered orall y, once daily, without 
regard to food (n=300)
Randomization will be stratified b y HIV-1 RNA level 
(≤ 100,000 copies/mL , > 100,000 to ≤ 400,000 copies/mL , or 
>400,000 copies/mL) at screening, CD4+ cell count (< 50cells/μL, 
50 – 199cells/μL, or ≥ 200 cells/μL) at screening, and region 
(USvs.Ex-US) at randomization.
Number of Subjects 
Planned:Approximately  600 subjects in total.
300 subjects in each Treatment Group 1 and Treatment Group2
Target Population: Antiretroviral treatment- naïve (except theuse for pre-exposure 
prophylaxis(PrEP)or post-exposure prophy laxis(PEP), up to 
onemonth prior to screening ), HIV-1 infected adults with plasma 
HIV-1 RNA levels ≥ 500copies/mL  and a screening genot ype 
showing sensitivity  to FTC and tenofovir ( TFV).
Duration of 
Treatment:Subjects will be treated for at least 96 weeks. Subjects’ treatments 
will be unblinded after the last subject completes the Week 96 visit
and Gilead completes the Week 96 anal ysis. Subjects will continue to 
take their blinded stud y drug and attend visits every 12 weeks unt il 
treatment assignments have been unblinded. At the Unblinding Visit , 
subjects in a country  where GS -9883/F/TAF FDC is not available will 
be given the option to receive GS-9883/F/TAF 
FDC in an open label 
extension phase for 48 weeks, or until the product becomes accessible 
to subjects through an access program, or until Gilead Sciences elects 
to discontinue the study  in that country , whichever occurs first. 
After Week 96 Visit, subjects in the UnitedKingdom (UK)will stop 
taking study drug and complete a 30day follow up visit and return to 
the standard of care .
Subjects who complete the study  through the Unblinding Visit and do 
not continue on theopen-label GS-9883/F/TAF FDCextension phase , 
will be required to return to the clinic 30 day s after unblind ing visit 
for a 30-Day Follow-Up Visit.
GS-9883/F/TAF 
Protocol GS -US-380-1490 Final
Gilead Sciences, Inc. Original
CONFIDENTIAL Page8 21 October 2015Diagnosis and Main 
Eligibility  Criteria:Medically  stable HIV -1 infected subjects who meet the following 
criteria:
Plasma HIV -1 RNA levels ≥ 500 copies/mL  at screening
Antiretroviral treatment naïve ( ≤ 10 days of prior therapy  with 
any antiretroviral agent following a diagnosis of HIV -1 infection) 
except theuse for PrEP or PEP, up to one month prior to 
screening .
Screening genot ype report must show sensitivity  to FTC and TFV
Estimated GFR ≥ 30 mL /min according to the Cockcroft -Gault 
formula for creatinine clearance
Study Procedures/
Frequency :After screening procedures, eligible subjects will be randomized 1:1 
to Treatment Group1 or Treatment Group 2 and treated for 96 weeks. 
Following the Day 1 visit, subjects will be required to return for stud y 
visits at Weeks 4, 8, and 12, and then every  12 weeks from Week 12 
through Week 96.  After 96 weeks, subjects will continue to take their 
blinded study  drugs and attend study  visits every  12 weeks until 
treatment assign ments have been unblinded (except the UK) .
For all eligible subjects, blood will be collected at Day  1,Weeks 4, 8, 
12, and then every  12 weeks through the Unblinding Visit .
Laboratory  analyses (hematology , chemistry , and urinaly sis), HIV-1 
RNA, CD4+ cell c ount, and complete or s ymptom-directed ph ysical 
examinations will be performed at the Screening, Day  1 and all 
subsequent study  visits.
Adverse events and concomitant medications will be assessed at each 
visit.
Test Product, Dose, 
and Mode of 
Administration:FDC of GS -9883 50 mg/emtricitabine 200 mg/tenofovir alafenamide 
25mg (GS-9883/F/TAF) administered orall y, once daily, without 
regard to food.
Reference Therapy, 
Dose, and Mode of 
Administration:Dolutegravir 50 mg + FDC of emtricitabine 2 00 mg/tenofovir 
alafenamide 25 mg (F/TAF) administered orall y, once dail y, without 
regard to food.
GS-9883/F/TAF 
Protocol GS -US-380-1490 Final
Gilead Sciences, Inc. Original
CONFIDENTIAL Page9 21 October 2015Criteria for 
Evaluation:
Safety: Adverse events and clinical laboratory tests to evaluate the safety  and 
tolerability  of the treatment regimens.
Efficacy: The primary  efficacy endpoint is:
The proportion of subjects who achieve HIV -1 RNA 
<50copies/mL at Week 48 as defined b y the United States (US) 
Food and Drug Administration (FDA) snapshot algorithm
The secondary  efficacy endpoints include:
The proportion of subjects who achieve HIV -1 RNA 
50copies/mL  at Week 96 as defined b y the US FDA snapshot 
algorithm
The proportion of subjects who achieve HIV -1 RNA 
<20copies/mL at Weeks 48 and 96 as defined by  the US FDA 
snapshot algorithm
The change from baseline in log10 HIV- 1 RNA and in CD4+ cell 
count at Weeks 48 and 96
Pharmacokinetics: An intensive pharmacokinetic (PK) substudy  will be performed at the 
Weeks 4 and 8 visits in a subset of subjects (target n=30) at stud y 
sites able to conduct this testing.
For all subjects on stud y drug, a single an ytime pre or post -dose PK 
blood sample will be collected at Weeks 8, 24, and 36. 
For all subjects on stud y drug, a trough PK blood sample will be 
obtained 20-
28 hours following the last dose at Weeks 4 and12.  
Following an observed dose, one post- dose PK blood sample will be 
collected between 1 and 4 hours post -dose.
For intensive PK substudy, the following PK parameters for GS -9883 
may be explored as applicable:
Cmax, Tmax, Clast, Tlast, Ctau,T 1/2,AUCtau,AUC0-last , Vz/F, CL ss/F.
The concentration of GS -9883 may  be summarized using descriptive 
statistics. The pharmacokinetics of GS -9883 may  be evaluated using 
population approaches. TAF and FTC concentrations may  be 
analyzed and PK 
may be summarized as applicable.
GS-9883/F/TAF 
Protocol GS-US-380-1490 
Gilead Sciences, Inc. 
Optional Genomic 
Testing: 
Optional Peripheral 
Blood Mononuclea r 
Cell Substudy: 
Patient Reported 
Outcomes: 
Statistical Methods: 
CONFIDENTIAL PD Final 
Original 
Sh01i F01m 36 Health Smvey (SF-36), HIV Symptoms Distress 
Module, Work Productivity and Activity Impainnent Questionnaire 
(WP AI) and Pittsbmgh Sleep Quality Index (PSQI) will be 
administered at Day 1, Weeks 4, 12 and 48. 
The primruy analysis will consist of a non-inferiority test of 
GS-9883/F /TAF versus DTG + FITAF, with respect to the prop01iio n 
of subjects who achieve HIV -1 RNA < 50 copies/mL at Week 48 as 
defined by the US FDA snapshot algorithm. It will be concluded that 
GS-9883/F /TAF is non-inferior to DTG + FITAF if the lower bound 
of the 2-sided 95% confidence interval (CI) of the difference 
(GS-9883/F/TAF-DTG + F/TAF) in the response rate (HIV-1 RNA 
< 50 copies/mL as defined by the US FDA snapshot algorithm) is 
greater than -12%; i.e., a mru·gin of 12% is applied to non-inferiority 
assessment. The 95% CI will be constmcted using a nonnal 
approximation method based on stratified Mantel-Haenszel 
prop01iions , where stratificat ion factors include baseline HIV -1 RNA 
level(:::; 100,000 copies/mL, vs. > 100,000 copies/mL) and region 
(US vs. Ex-US). 
The proportion of subjects who achieve HIV -1 RNA < 50 copies/mL 
at Week 96 and the proportion of subjects who achieve HIV -1 RNA 
< 20 copies/mL at Weeks 48 and 96 as defmed by the US FDA 
snapshot algorithm will also be summarized. The 95% Cis will be 
Page 10 21 October 2015 
GS-9883/F/TAF 
Protocol GS -US-380-1490 Final
Gilead Sciences, Inc. Original
CONFIDENTIAL Page11 21 October 2015constructed in the same manner as described for the primary  efficacy 
endpoint. 
The change from baseline in log10 HIV -1 RNA and CD4+ cell count 
at Weeks 48 and 96 will be summarized using descriptive statistics. 
The differences and the associated 95% CIs will be constructed using 
an Analysis of Variance (ANOVA) model, including treatment 
(GS-9883/F/TAF vs. DTG + F/TAF), baseline HIV- 1 RNA level 
(100,000copies/mL  vs. 100,000copies/mL ),and region 
(USvs.Ex-US) as fixed effects in the model.
Adverse events, clinical laboratory  assessments, and pharmacokinetic 
parameters will be summarized using descriptive statistics.  
A total of approximately  600 HIV -1 infected subjects, randomized in 
a 1:1 ratio to 2 treatment groups (300 subjects per treatment group), 
achieves at least 95% power to detect a non -inferiority  margin of 12% 
in Week 48 response rate (HIV -1 RNA < 50 copies/mL  as defined b y 
the US FDA snapshot algorithm) difference betwee n the 2treatment 
groups. For the sample size and power computation, it is assumed that 
both treatment groups have a response rate of 91 %(based on Gilead 
Studies GS -US-292-0104 and GS -US-292-0111), that the 
non-inferiority margin is 12 %, and that the sign ificance level of the 
test is at a one -sided 0.025 level.
This study  will be conducted in accordance with the guidelines of Good Clinical Practice (GCP) 
including archiving of essential documents.
GS-9883/F/TAF 
Protocol GS -US-380-1490 Final
Gilead Sciences, Inc. Original
CONFIDENTIAL Page12 21 October 2015GLOSSARY OF ABBREVIATIONS AND DEFINITION OF TERMS
C degrees Celsius
F degrees Fahrenheit
AE adverse event
ALT alanine aminotransferase
ANC absolute neutrophil counts
ARV antiretroviral
AST aspartate aminotransferase
AUC area under the plasma/serum/peripheral blood mononuclear cell concentration versus time 
curve
BID twice a day 
BUN blood urea nitrogen
CBC complete blood count
CI confidence interval
CLcr creatinine clearance
Cmax the maximum observed serum/plasma/peripheral blood mononuclear (PBMC) 
concentration of drug
CMH Cochran-Mantel-Haenszel
CNS central nervous system
COBI, /co cobicistat (GS -9350)
Ctau the observed drug concentration at the end of the dosing interval
CPK creatine phosphokinase
CRF case report form(s)
CRO contract (or clinical) research organization 
CYP cytochrome P450
DHHS Department of Health and Human Services
DNA deoxyribonucleic acid
DSPH Drug Safety and Public Health
DTG dolutegravir , Tivicay
ECG electrocardiogram
eCRF electronic case report form(s)
eGFR estimated glomerular filtration rate
FAS full analysis set
EVG elvitegravir
E/C/F/TAF elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide 
E/C/F/TDF elvitegravir/cobicistat/emtricitabine /tenofovir disoproxil fumarate, Stribild
FAS full analysis set
FDA (United States) Food and Drug Administration
FDC fixed dose combination
FTC/TAF emtricitabine/tenofovir alafenamide 
FSH follicle-stimulating hormone
FTC, F emtricitabine, Emtriva
GS-9883/F/TAF 
Protocol GS -US-380-1490 Final
Gilead Sciences, Inc. Original
CONFIDENTIAL Page13 21 October 2015GCP Good Clinical Practice (Guidelines)
GGT gamma glutamyl transferase
GLSM geometric least squares mean
GSI Gilead Sciences, Inc.
GS-9883/F/TAF GS-9883/emtricitabine/tenofovir alafenamide
HAART highly active antiretroviral therapy
HBV hepatitis B virus
HBcAb hepatitis B core antibody
HBsAb hepatitis B surface antibody
HBsAg hepatitis B surface antigen
HCV hepatitis C virus
HDPE high-density polyethylene
hERG human Ether -à-go-go-Related Gene
HIV Human Immunodeficiency Virus
HIV Sx HIV Symptoms  Distress Module
HLA human leukocyte antigen
IB investigator’s brochure
ICH International Conference on Harmonisation
IDMC Independent Data Monitoring Committee
IND Investigational New Drug (Application)
INSTI integrase strand -transfer inhibitors
IRB institutional review board
IWRS interactive web response system
KS Kaposi’s sarcoma
LDH lactate dehydrogenase
LLN lower limit of the normal range
MedDRA Medical Dictionary for Regulatory Activities
mg milligram
MH Mantel-Haenszel
min minute
mmHg millimeters mercury
nM nanoMolar
NNRTI non-nucleoside reverse transcriptase inhibitor
NOAEL no observed adverse effect level
NRTI nucleoside/nucleotide reverse transcriptase inhibitor
PEP post-exposure prophxylaxis
P-gp P-glycoprotein
PI protease inhibitor
PK Pharmacokinetic
PSQI Pittsburgh Sleep Quality Index
GS-9883/F/TAF 
Protocol GS -US-380-1490 Final
Gilead Sciences, Inc. Original
CONFIDENTIAL Page14 21 October 2015PT preferred term 
PT prothrombin time 
PTM placebo-to-match
QD once daily 
RAL raltegravir
RNA ribonucleic acid
SA single agent
SAE serious adverse event
SF-36 Short Form 36 Health Survey
SUSAR Suspected Unexpected Serious Adverse Reaction
TAF tenofovir alafenamide 
TDF tenofovir disoproxil fumarate, Viread
TFV-DP tenofovir diphosphate (TFVpp)
tmax the time (observed time point) of C max
TSH thyroid stimulating hormone
UGT1A1 uridine 5'-diphospho -glucuronosyltransferase 
UGT uridine glucuronosyltransferase
ULN upper limit of the normal range
UK United Kingdom
US United States
WPAI Work Productivity and Activity Impairment Questionnaire
GS-9883/F/TAF 
Protocol GS -US-380-1490 Final
Gilead Sciences, Inc. Original
CONFIDENTIAL Page15 21 October 20151. INTRODUCTION
1.1. Background
Human immunodeficiency  virus-1 (HIV-1) infection is a life -threatening and serious disease that 
is of major public health interest around the world. There are approximately  2.4millionpeople in 
North America and Western and Central Europe living with HIV -1 and 36million people 
worldwide {36201}. The infection, if left untreated or suboptimally  treated, is characterized by  
deterioration in immune function, ultimately resulting in death. Therape utic strategies for the 
treatment of HIV -1 disease have been significantly  advanced by  the availability  of highly active 
antiretroviral therapy (HAART); the introduction of HAART was associated with a dramatic 
decrease in acquired immune deficiency  syndrome (AIDS)-related morbidity  and mortalit y 
{27881}, {5125}, {8284}.
The success of potent and well- tolerated ART means that mor bidity and mortality  in the 
HIV-infected population is increasingly  driven by  non-AIDS–
associated comorbidities. C linical 
attention has become more focused on the optimization of tolerability , long-term safety , and 
adherence of potent ART regimens { 29705}. In addition, t here remains a significant medical need 
for new,effectivetherapies that take into consideration HIV genetic variability , 
the aging 
HIV-infected population, ARV resistance, non-HIV comorbidities, and regimen simplification.
For ART-naive HIV -infected patients, current treatment guidelines suggest that initial therapy  
consist of 2 nucleos(t)ide reverse transcriptase inhibitors (N[t]RTI) and either 
an integrase 
strand-transfer inhibitor (INSTI) or the boosted protease inhibitor darunavir {34898
}. 
Virologically  suppressed, HIV-infected patients may  switchfrom their current regimen because 
of safety or tolerability concerns or for regimen simplification . All patient populations may  
benefit from o
nce-daily fixed-dose combination (FDC) regimens as these have been shown to 
provideincreased adherence and improved clinical and virologic outcomes {21053},{29702}
Tenofovir (TFV) is a nucleotide analog that inhibits HI V-1 reverse transcription. While tenofovir 
disoproxil fumarate (TDF), an oral prodrug of TFV, i s apreferred NtRTI for initial therapy , 
nephrotoxicity  is an identified risk, and reduc tions in bone mineral densit y (BMD) have been 
shown that are larger than those seen with other NRTI s. 
Tenofovir alafenamide (TAF) is als o an 
oral prodrug of TFV. TAF is more stable in plasma than TDF ,provides higher intracellular 
levels of the active phosphory lated metabolite tenofovir diphosphate (TFV -DP),and 
approximately  90% lower circulating levels of TFV relative to TDF at the clini cal doses. 
Thedistinct metaboli sm of TAF offers the potential for an improved clinical profile compared 
with TDF .
GS-9883 is a potent inhibitor of HIV -
1 integrase that is being evaluated for the treatment of 
HIV-1 infection.  Antiviral testing has shown t hat GS-9883 is active against a broad panel of 
HIV-1 viral lab strains and clinical isolates.  GS -9883 is fully  active against a panel of mutant 
viruses with resistance to NRTI s, non-nucleoside reverse-transcriptase inhibitors (NNRTIs), and 
protease inhibi tors (PIs).  I ntegrase mutant viruses that are resistant to the INSTI s raltegravir 
(RAL) and elvitegravir (EVG) remain largel y sensitive to GS -9883.
GS-9883/F/TAF 
Protocol GS -US-380-1490 Final
Gilead Sciences, Inc. Original
CONFIDENTIAL Page16 21 October 2015Gilead Sciences (Gilead)has coformulated GS-9883 with the N RTI emtricitabine (FTC; F ) and 
the NtRTI  tenofovir alafenamide (TAF) into an FDC tablet that is suitable for once -daily use. 
This GS-9883/F/TAF FDC may  provide a potent, convenient, tolerable, and practical regimen 
for the long -term treatment of patients with HIV infection.
1.2. GS-9883
1.2.1. General Information
GS-9883, a potent inhibitor of HIV -1 integrase is being evaluated for the treatment of HIV 
infection. Antiviral testing has shown that GS -9883 is active against a broad panel of HIV- 1 viral 
lab strains and clinical isolates. GS- 9883 is fully  active against a panel of mutant viruses with 
resistance to NRTIs , NNRTIs,and PIs. Integrase mutant viruses that are resistant to the I NSTIs
RAL and EVG remain largely  sensitive to GS-9883.
1.2.2. Preclinical Pharmacology and Toxicology
A core battery  of safety pharmacology studies have been conducted with GS -9883. These 
include assessments of cytotoxicity , off-target receptor and ion -channel binding, effects on 
human Ether -à-go-go-
Related Gene (hERG) potassium current and papillary  muscle action 
potential, and in vivo studies in rats and dogs that evaluated effects of GS -9883 on all major 
organ systems. The volume of distribution of GS -9883 ranged between 0.09 and 0.22 L/kg in the 
preclinical species, which indicates that the distribution of GS -9883 is limi ted to the extracellular 
compartment due to its high binding to plasma proteins. The projected half -life of GS -9883 in 
humans is approximately  20hours based upon the estimates of clearance and volume of 
distribution .
1.2.2.1. Pharmacology
GS-9883 has I C50values ranging from 1.5 to 2.4 nM, similar to the inhibitory  effect of DTG and 
EVG. GS -9883 is highl y potent against HIV replication in MT4 cells with an EC 50(50% 
effective inhibitory  concentration) value of 1.9 nM and a protein adjusted EC 95value of 361 nM. 
GS-9883does not show significant cy totoxicity  against dividing and non- dividing human 
PBMCs, primary  human hepatocy tes and various non-target human cell lines.
GS-9883 is mainly  metabolized by  uridine 5'-diphospho -glucuronos yltransferase (UGT1A1) and 
CYP3A. GS-
9883 does not inhibit major human CYP isoforms or UGT1A1 at concentrations up 
to 25M. Consequently , GS-9883 is unlikely  to be a clinicall y relevant inhibitor of these
enzymes, and is not expected to inhibit the metabolic clearance of drugs metabolized by  these 
enzymes. GS-9883 onl y modestly inhibits renal transporter OCT2 (I C50= 0.42 M). As a result, 
GS-9883 is not expected to significantl y interfere with the key transporter responsible for 
creatinine tubular elimination at the clinically projected C max. Additionally , the risk that GS -9883 
will affect the OCT2 -mediated excretion of co -administered drugs is considered to be low.
GS-9883 does not activate AhR and onl y weakly activates PXR at concentrations up to 50 M 
(less than 5% and 40% o f activation, respectivel y, compared to positive control compound). 
Therefore, GS -9883 is not expected to act as an inducer through PXR- or AhR-mediated 
pathways at the doses and exposure lev els projected in clinical use.
GS-9883/F/TAF 
Protocol GS -US-380-1490 Final
Gilead Sciences, Inc. Original
CONFIDENTIAL Page17 21 October 20151.2.2.2. Toxicology
Single oral doses of GS -9883 up to 1000 mg/kg were well -tolerated in rats (AD -141-2286). The 
increase in exposure was limited (< 2-fold) between 100 and 300 mg/kg and similar exposure 
was observed between 300 and 1000 mg/kg suggesting saturation of absorption at 300 mg/kg 
(AUC0-242205 gh/mL and 1931 gh/mL, respectively ). In monkey s, single oral doses of 
GS-9883 up to 1000 mg/kg were well- tolerated (AD -141-2284). The increase in exposure was 
limited (< 2-fold) between 300 to 1000 mg/kg (AUC 0-24803gh/mL and 1078 gh/mL, 
respectivel y).
In 2-week (TX -
141-2029) and 26- week (TX -141-2031) oral toxicity  studies in rats at doses up to 
300 mg/kg/day , GS-9883 was well- tolerated with no GS -9883-related effects on clinical 
observations, bod y weight, food consumption, ophthalmic exami nations, and anatomic 
pathology .  The high dose of 300 mg/kg/day  was considered the maximum feasible dose based 
upon saturation of absorption. The no observed effect level (NOEL) in the 26- week stud y was 
considered to be the high dose of 300 mg/kg/day.  Atthe NOEL, GS -9883 exposures in the rat 
were considered to be approximately  12
-/31-fold higher (males/females) than the projected 
steady state human exposure of GS- 9883 following administration of GS -9883/F/TAF 
(50/200/25 mg) QD under fed conditions.
In a 39-week study  in monkey s (TX-141-2032), following administration of 1000 mg/kg/day  
(high dose) of GS-9883 for 39 weeks , pathology  data indicated minimal to marked bile duct 
hyperplasia and minimal or moderate hepatocy te hypertrophy  in both sexes, and minim al 
regenerative h yperplasia and minimal or slight neutrophil infiltrate in males.  The macroscopic 
finding of rough surface on the liver in one male administered 1000 mg/kg/day  correlated with 
moderate hepatocy te hypertrophy and marked bile duct hyperplasia.
After a 4-week recovery 
period, GS -9883-related microscopic liver findings included marked bile duct hy perplasia, slight 
hepatocyte hypertrophy, minimal regenerative h yperplasia, and slight lymphocyte infiltrate in 
one male and slight bile duc t hyperplasia in one female administered 1000 mg/kg/day , while the 
other two animals in the high dose group had no hepatobiliary  findings. Minimally to mildly  
increased ALT activities (≤ 3.5-fold versus baseline values) , 
likelyassociated with liver findin gs, 
exhibited reversibility . There were no other adverse findings in the study , including clinical 
observations ,or effects on body  weight, bod y weight change, food consumption, ECGs, 
hematology , coagulation, clinical chemistry , urinalysis, and ophthalmosc opy
.  
No GS-9883-related effects were observed in the mid
-dose group (200 mg/kg/day ) which was 
considered the no
-observed- effect-level (NOEL).  The estimated margin of exposure at the 
NOEL was approximately  4.7-fold based on expected human exposure with the once dail y 
dosing of the GS -9883/F/TAF (50/200/25 mg) tablet.
A standard battery  of in vitro and in vivo studies was performed to assess the genotoxic potential 
of GS-9883. There was no evidence of mutagenic or clastogenic activity  in an in vitro bacte rial 
reverse mutation assay  (Study TX-
141-2026), a chromosomal aberration assay  in human 
lymphocytes (Study  TX-141-2027), or in a rat micronucleus test (Stud y TX-141-2029).
GS-9883/F/TAF 
Protocol GS -US-380-1490 Final
Gilead Sciences, Inc. Original
CONFIDENTIAL Page18 21 October 20151.2.3. Clinical Trials of GS-9883
Clinical trials entailing the use of GS- 9883 include:
GS-US-141-1218, a Phase 1 double blind, randomize d, placebo- controlled, first -in-human, 
single-and multiple -ascending dose stud y evaluating the safet y, tolerability, and PK of oral 
GS-9883 in healthy  subjects and a randomized, open- label, 2-cohort, 3
-period, crossover, PK 
study evaluating the drug interaction potential between F/TAF FDC tablet and GS- 9883 in 
healthy subjects (completed)
GS-US-141-1219, a Phase 1b randomized, double -blinded, sequential cohort
placebo
-controlled study  of the safet y, PK, and antiviral activity  of GS-9883 in HIV -1 
infected subjects study of the pharmacokinetics and antiviral activity  of GS-7340 (8mg, 
25mg, 40mg) in HIV infected subjects (completed)
GS-US-141-1233, a Phase 1,Open -label, Two-Cohort, Multiple -Period, Fixed-Sequ ence, 
Crossover Study  to Evaluate 1) the Relative Bioavailability  ofTwoGS-
9883/Emtricit
abine/Tenofovir Alafenamide (75/200/25 mg and 50/200/25 mg )Fixed-Dose 
Combination Tablets Versus a GS-9883 (75 mg) Tablet and a Emtricitabine/Tenofovir 
Alafenamide (200/25 mg) Fixed- Dose Combination Tablet Administered Simultaneously  and 
2) the Effect of Food on the Pharmacokinetics of GS- 9883, Emtricitabine and Tenofovir 
Alafenamide When Administered as GS -9883/Emtricitabine/Tenofovir Alafenamide 
(75/200/25 mg and 50/200/25 mg) Fix
ed-DoseCombination Tablets(ongoing)
GS-US-141-1479, a Phase 1, open- label, parallel -group, adaptive single -dose study  to 
evaluate the PK of GS -
9883 in subjects with normal and impaired renal function (completed)
GS-US-141-1480, a Phase 1 partiall y-blinded, randomized, placebo- and positive -controlled 
study to evaluate the effect of GS- 9883 on the QT/QTc interval in healthy  subjects 
(completed)
GS-US-141-1481, a Phase 1 study to evaluate the pharmacokinetics, metabolism, and 
excretion of GS -9883 in healthy  subjects (completed)
GS-US-141-1485, a Phase 1 adaptive stud y to evaluate transporter, CYP -mediated and 
UGT1A1 drug- drug interactions between GS -9883 and probe drugs (ongoing)
GS-US-141-1487, a Phase 1 r andomized, Blinded, Placebo- Controlled Phase 1 Study  
Evaluating the Effect of GS- 9883 on Renal Function as Assessed b y Markers of Glomerular 
Filtration Rate (ongoing)
GS-US-
311-1790, a Phase 1Randomized, Open Label, Drug Interaction Study  Evaluating the 
Effect of F/TAF FDC Tablet or GS -9883 
on the Pharmacokinetics of a Representative 
Hormonal Contraceptive Medication, Norgestimate/Ethiny l Estradiol (ongoing)
GS-9883/F/TAF 
Protocol GS -US-380-1490 Final
Gilead Sciences, Inc. Original
CONFIDENTIAL Page19 21 October 2015GS-US-380-1761, a Phase 1 Study  to Evaluate Pharmacokinetic Drug -Drug Interaction 
Potential between GS -9883/Emtricitabine/Tenofovir Alaf enamide Fumarate 
(GS-9883/F/TAF) and Ledipasvir/Sofosbuvir (LDV/SOF) Fixed -Dose Combination (FDC) 
Tablets (ongoing)
GS-US-141-1475, a Phase 2 Randomized, Double -Blinded Study  of the Safety  and Efficacy  
of GS-9883 + Emtricitabine/Tenofovir Alafenamide Versu s Dolutegravir + 
Emtricitabine/Tenofovir Alafenamide in HIV -1 Infected, Antiretroviral Treatment- Naive 
Adults (ongoing)
Please refer to the GS -
9883/F/TAF Investigators’ Brochure for further information about these 
studies.
1.2.3.1. Phase 1 Safet yand Pharmacokineti cs
StudyGS-US-141-1218 was a four part, first -in-human study .  Parts A and B were randomized, 
double-blind, placebo -controlled, single and multiple ascending dose studies of GS- 9883 in 
healthy male and female subjects.  Part C was an open label, fixed seq uence food effect stud y 
evaluating the effect of food on the PK of GS
-9883.  Part D was a randomized, open -label, 
2-cohort, 3- period, crossover PK study  evaluating the drug interaction potential between 
FTC/TAF FDC tablet and GS -9883 in healthy  subjects.
There was no difference in the overall incidence or ty pe of AEs when GS -9883 was administered 
in the fasted and fed states. There was no difference in the overall incidence of AEs when 
GS-9883 or FTC/TAF was each administered alone or in combination.
No deaths or pregnancies were reported. No Grade 3 or 4 AEs or SAEs, were reported in any  
cohort.
Changes in serum creatinine were observed in this study , presumably  via inhibition of the renal 
transporter OCT2.  In the MAD cohorts (fasted), serum creatinine cha nge at Day  14 ranged from 
0.05 mg/dL for the 5 mg cohort to 0 .18mg/dL for the 300 mg/dL cohort.  In Part D (DDI), 
conducted in the fed state (regular meal), subjects received 100 mg GS -9883 monotherapy  for 
7days and 100 mg GS -9883 with FTC/TAF for 7 day s, the mean serum creatinine change at 
Day7 was 0.14 mg/dL following GS -
9883 and 0.17 mg/dL following GS- 9883 + FTC/TAF.  All 
changes returned to baseline after discontinuation of GS-9883.
The majority  of laboratory  abnormalities were Grade 1 or Grade 2 in severity. Grade3 laboratory  
abnormalities included 10 subjects with Grade 3 urine dipstick tests for blood.  All of these 
subjects were female, none of the labs were considered b y the Investigator to be clinically 
significant, and all were associated with menstruation. No other Grade 3 or 4 laboratory  
abnormalities were observed.
Based on results in study GS- US-141-1218, pharmacokinetic profile of GS -9883 was 
characterized b y rapid absorption with time to peak plasma concentrations (median t maxof 
cohorts) ranging between 1 and 4 hours following administration under fasted conditions. 
GS-9883/F/TAF 
Protocol GS -US-380-1490 Final
Gilead Sciences, Inc. Original
CONFIDENTIAL Page20 21 October 2015GS-9883 exposures were appropriatel y dose proportional following single dose 25 -100mg dose 
administration, with decreasing dose proportional at higher doses.  The half -life of GS-9883 was 
approximately  18hours, with no changes observed across studied dose range as evidenced by  
parallel terminal phase slopes . A high-fat meal increased AUC infand Cmax (geometric mean, 84% 
and 101%, respectivel y) following 100 mg single doseadministration. Steady  state was achieved 
after 4-6days of once daily  dosing of GS -9883 with average accumulation ratios for AUC 24hr
of1.6.
Table1-1. GS-US-141-1218: GS -9883 Mean (%CV) PK Parameters Following 
Single Doses of GS -9883 in Healthy Subjects (GS -9883 PK Analysis 
Set; Part A: Single Dosing)
GS-9883 PK 
Parameter
Mean 
(%CV)5mg
(N=6)25 mg
(N=6)50 mg
(N=6)100 mg
(N=6)300 mg
(N=6)600 mg
(N=6)
Cmax (ng/mL)691.2
(22.1)1618.3
(26.7)3965.0
(40.1)6998.3
(36.1)14605.0 
(27.1)20050.0
(7.5)
Tmax(hr)1.25 
(1.00-1.50)2.00
(1.00-3.00)3.00
(1.50-4.00)2.25
(1.50-3.00)3.50
(2.00-6.00)3.5
(2.00-4.00)
AUCinf 
(ng.hr/mL)13059.7
(25.1)35718.2 
(21.3)78399.5 
(29.7)163028.2 
(24.3)355917.3 
(32.9)454446.8 
(19.9)
T1/2 (hr)18.51
(16.81-19.99)18.08
(16.63-19.64)16.72
(15.77-17.11)18.90
(17.96-20.05)18.14
(17.86-20.53)17.89
(16.38-19.52)
T1/2and Tmax: Median (Q1, Q3)
Table1-2presents GS -9883 plasma PK parameters following administration of GS -9883 
(5,25, 50, 100, and 300mg) once daily for 7 days . Following administration of either GS -9883 
(5,25, 50, 100, or300 mg) once dail y for 7 days, the PK absorption profile observed on Day s 1 
and 7 was similar to that observed in P art A (SAD). The median T maxvalues ranged from 1.5 to 
2.5hours on Day  1 and 1.5 to 4.0 hours on Day 7. Linearit y was observed comparing GS -9883 
AUC and C maxon Days 1 and 7 over the dose range of 25 to 50 mg. Stead y state levels of 
GS-9883 were achieved between Stud y Days 4 to 6 of dosing and maintained through Day 14. 
Accumulation is approximately  1.6-fold, which is consistent with the observed half -life of the 
GS-9883 (approximately  18 hours).
GS-9883/F/TAF 
Protocol GS -US-380-1490 Final
Gilead Sciences, Inc. Original
CONFIDENTIAL Page21 21 October 2015Table1-2. GS-US-141-1218: GS -9883 Plasma Pharmacokinetic Parameters by 
GS-9883 Dose Following Multiple -Dose Administration of GS -9883 
(Analysis Set: GS -9883 PK Part B: Multiple -Dose)
GS-9883 PK Param eter Mean
(%CV)aMultiple-Dose GS-9883
5mg
(N=6)25mg
(N=6)50mg
(N=6)100mg
(N=6)300mg
(N=6)
Day 1AUC0-24 (hr*ng/mL)9033.6
(8.2)27,775.1
(28.3)58,371.4
(18.9)79,773.8
(18.9)180,714.3
(17.6)
Cmax(ng/mL)709.7
(9.5)2220.0
(35.6)4648.3
(18.7)6248.3
(26.8)13,716.7
(19.1)
Tmax(hr)1.50
(1.50, 1.50)1.75
(1.00,3.00)1.50
(1.00, 2.00)2.50
(2.00, 3.00)2.50
(2.00, 4.00)
Day 7AUCtau (hr*ng/mL)14,392.0
(16.7)50,008.2
(26.6)89,710.1
(22.7)126,785.8 
(23.7)277,200.2 
(16.7)
Cmax(ng/mL)982.5
(7.9)3455.0
(24.1)6538.3
(17.6)9396.7
(20.8)19,900.0 
(21.2)
Ctau(ng/mL)400.83
(26.9)1322.00
(27.8)2241.67
(28.2)3145.00 
(26.1)6758.33 
(21.6)
Tmax(hr)1.50
(1.00, 2.00)3.00
(2.00, 3.00)1.75
(1.50,2.00)1.75
(1.50,3.00)4.00
(2.00, 4.00)
Accumulation Ratio of AUC (%)160.5
(19.0)182.2
(17.1)154.0
(15.9)158.5
(12.1)157.5
(22.6)
aData are presented as mean (%CV), except for T max, andt½, which are presented as median (Q1, Q3)
Table1-3presents the GLSM ratios and associated 90% CIs for the test (fed) versus reference 
(fasted) treatments for the primary  plasma PK parameters of GS -9883. Administration of a single 
dose of GS -9883 100
mg with food (high- calorie/high -fat breakfast) increased the GL SM values 
of Cmaxand AUC inf101% (90% CI of GL SM ratio 165.93% to 242.74%) and 84% (90% CI of 
GLSM ratio 152.05% to 222.59%), respectivel y. There were no apparent changes in clearance 
and t1/2following administration with food, indicating that food enhanced the bioavailability of 
GS-9883 by improving its solubility  and/or absorptio n.
GS-9883/F/TAF 
Protocol GS -US-380-1490 Final
Gilead Sciences, Inc. Original
CONFIDENTIAL Page22 21 October 2015Table1-3. GS-US-141-1218: Statistical Comparison of GS -9883 Pharmacokinetic 
Parameters Following Single -Dose Administration of GS -9883 in the 
Fasted and Fed States (GS -9883 PK Analysis Set)
GS-9883 PK Param eter Mean (%CV)
% GLSM Ratio 
(90% CI)Test
GS-9883 100 m g Fed
(n=8)Reference
GS-9883 100 m g Fasted
(n=8)
AUCinf(hr*ng/mL) 214,146.3 (15.9) 117,777.1 (23.3) 183.97 (152.05, 222.59)
AUClast(hr*ng/mL) 209,259.9 (15.1) 115,681.7 (24.0) 183.58 (151.91, 221.86)
Cmax(ng/mL) 11,268.8 (15.1) 5885.0 (34.9) 200.69 (165.93, 242.74)
CI = confidence interval; GLSM = geometric least squares mean
1.2.3.2. Phase 1b Proof of Concept
The first HIV -1 positive human subjects were dosed in the fasted state with 10 days of GS -9883 
in study (GS-US-141-1219).  Four cohorts of 5 subjects each were randomized 4:1 to receive 
GS-9883 or placebo to match at doses of 5 mg, 25 mg, 50 mg, and 100 mg once dail y for 
10days. 
GS-9883 was generall y well tolerated at the doses evaluated. A total of 9 of 20subjects had an 
AE in this study . The most frequentl y reported AEs across all subjects were diarrhea (2 subjects), 
and headache (3subjects).  No other AE was reported in more than 1 subject. There was no 
increase i n the incidence of AEs with increasing doses of GS-9883. 
The majority  of AEs were considered by  the investigator to be not rel ated to study  drug. A total 
of 2subjects experienced mild diarrhea that was considered related to study  drug (1 in the 5 mg 
cohort, 1 in the 100 mg cohort).   
No deaths or pregnancies were reported. No Grade 3 or 4 AEs, SAEs, or AEs leading to 
discontinuation of study  drug were reported in any  cohort. 
The majority  of laboratory  abnormalities were Grade 1 or Grade 2 in severity . No Grade 3 
treatment emergent laboratory
 abnormalities were observed.   Median serum creatinine changes 
at Day 10 were: 0.05 mg/dL  (5 mg), 0.04 mg/dL (25 mg), 0.06 mg/dL (50 mg), and 0.15 mg/dL 
(100 mg).  These changes in serum creatinine a ppeared to be transient and returned close to 
baseline values on discontinuation of study  drug. One Grade 4 new onset laboratory  abnormality  
was seen in 1 subject who received 5 mg GS- 9883.  This was a Grade 4 CPK seen on Day 17, 
7days following his last dose of study  medication.  The subject was as ymptomatic.  The 
Investigator felt that this was unrelated to study  medication and was due to resumption of cry stal 
methamphetamine use b y the subject. An adverse event of elevated CK was reported unrelated to
study medication.   
GS-9883/F /TAF 
Protocol GS-US-380-1490 
Gilead Sciences, Inc. Final 
Original 
Based on PK infonnation collected in study GS-US-141-1219 , which was in line with PK 
observed in study GS-US-141-1218 , the median IQ for each dose were calculated and aTe 
presented in the Table below. 
Table 1-4. Trough GS-9883 Plasma Concentrations at Steady State Following 
GS-9883 Administration Under Fasting Conditions and 
Corresponding Protein-Adjusted IQ9s Values (GS-9883 PK Analysis 
Set) 
GS-9883 dose n Median (range) C1au,ss (ng!mL) Median (range) paiQ9/ 
5 mg 4 206.5 (146.0 to 342.0) 1.3 (0.9 to 2.1) 
25mg 4 797.5 (714.0 to 1900.0) 4.9(4.4to 11.7) 
50 mg 4 2170.0 (852.0 to 3020.0) 13.4 (5.3 to 18.6) 
100mg 4 4190.0 (3730.0 to 5970.0) 25.9 (23.0 to 36.9) 
a. The protein adjusted IQ95 (pal09s) value is estimated based on steady-state C1au values and the in vitt·o paiC95 value for 
wild-type HIV-1 (162 ng/ml). 
The mean and 95% Cis of change from baseline in HIV -1 RNA (log10 copies/mL) are presented 
in Figure 1-1. 
Figure 1-1. 
:J' 2 
~ 
·~ 1 
8 GS-US-141-1219: Mean and 95% Cis of Change from Baseline in 
HIV-1 RNA (log10 copies/mL) (PP Analysis Set) 
• = GS-9883 5 mg 
0 = GS-9883 25 mg 
!:::. = GS-9883 50 mg 
D = GS-9883100 mg 
<> =Placebo ---.......... -----2 
-1 
-2 
-3 
-5l....r-"""T--,--"T"'"-.,....."""'"""r--"""""''--,..--r--'T"""-T""""""""""'_"""T_""T""_"T"'"_T"""""""'"""r""'"""""""''--,...T-5 
BL 2 3 4 7 
G$-9883 5 mg (n=): 3 3 3 3 3 
Gs-9883 25 mg (n=): 4 3 4 3 4 
GS-9883 50 mg (n=): 4 4 4 4 4 
GS-9883100 mg (n=): 4 4 4 3 4 
Placebo (n=): 4 4 4 4 4 8 9 10 
Day 
3 3 3 
4 4 4 
4 4 4 
4 4 4 
4 4 4 11 
3 
4 
4 
4 4 14 
3 
4 
4 
4 
4 
NOTE: Baseline value was the last available value collected prior to the time of the first dose of study dmg. 
CONFIDENTIAL Page23 17 
3 
3 
4 
4 
4 
21 October 2015 
GS-9883/F/TAF 
Protocol GS -US-380-1490 Final
Gilead Sciences, Inc. Original
CONFIDENTIAL Page24 21 October 2015Mean viral load change on Day  11 was -2.08 log 10in the 25mg cohort, -2.06 log 10in the 50mg 
cohort, and - 2.43 log 10in the 100 mg cohort. Time weighted average change from baseline at 
Day 11 (DAVG11) was - 0.92 log 10in the 5 mg cohort, -1.33 log 10in the 25 mg 
cohort, -1.37 log10in the 50 mg cohort and -1.61 log 10in the 100 mg cohort.  Viral suppression 
(HIV-1 RNA < 50copies/mL ) was everachieved by the end of the stud y (Day17)by 1subject 
(25.0%) in the GS -9883 50mg group and 2subjects (50%) in the GS -9883 100 mg group .
1.2.3.3. Summary  of Phase 2 Study  (GS-US-
141-1475)
Study GS-US-141-1475 is an ongoing Phase 2, randomized, double -blind, mult icenter, 
active-controlled study  to assess the safety  and efficacy  of a regimen containing 
GS-9883+F/TAF versus dolutegravir (DTG)+F/TAF in HIV -infected, antiretroviral therapy  
(ART)-naive adult subjects. 
Eligible subjects were randomized in a 2:1 ratio to one of the following treatment groups, 
stratified by  HIV-1 RNA level ( ≤ 100,000 copies/mL , 100,000copies/mL 
to400,000copies/mL , or >400,000 copies/mL) at screening:
Treatment Group 1: GS-9883 75 mg + F/TAF (200/25 mg) + placebo -to-match DTG 
50mg once dail y
Treatment Group 2: DTG 50 mg + F/TAF (200/25 mg) + placebo -to-match GS -
9883 
75mg once daily
Interim data at Week 12 are summarized below.
  Data from the Week 24 primary  endpoint are 
included in the GS -9883/F/TAF Investigator’s Brochure .
1.2.3.4. Subject Disposition and Baseline Characteristics
A total of 98 subjects were randomized and treated i n the study : 65 subjects in the 
GS-9883+F/TAF group and 33 subjects in the DTG+F/TAF group . At the time of the Week 12 
data analysis, 2 subjects (2.0%) had prematurel y discontinued study  treatment, one in each 
treatment group; both subjects were lost to fo llow-up.
Demographic and baseline characteristics were similar between the 2 treatment groups.
Key baseline disease characteristics (ie, viral load, CD4 cell count, and estimated glomerular 
filtration rate [eGFR] using the Cockcroft -Gault method [eGFR CG]) were similar between the 
2treatment groups ( Table1-4
). 
Median (Q1, Q3) baseline HIV -1 RNA was 4.45 (3.96, 4.79) log 10copies/mL , with 82.7% of 
subjects having ≤ 100,000 copies/mL  at baseline; 5 subjects had > 400,000copies/mL  at 
baseline; 4 of these subjects were randomized to GS -9883+F/TAF and 1 subject was randomized 
to DTG+F/TAF.
Median (Q1, Q3) baseline CD4 cell count was 444 (316, 595) cells/μL , with 41.8% of subjects 
having ≥ 500 cells/ μL at baseline. Median (Q1, Q3) baseline eGFR CGwas 125.3 (1 05.7, 
147.0)mL/min.
GS-9883/F/TAF 
Protocol GS -US-380-1490 Final
Gilead Sciences, Inc. Original
CONFIDENTIAL Page25 21 October 20151.2.3.5. Efficacy Results
Virologic success at Week 12 when assessed using the US FDA snapshot algorithm, defined as 
plasma HIV -1 RNA < 50 copies/mL , was similar between the 2 treatment groups as follows: 
GS-9883+F/TAF 93.8%; DTG+F/TAF 93.9% (s tratum-
adjusted difference in percentages: 
−1.3%; 95% CI: −12.9% to 10.2%; p=0.79).
Following initiation of study  drug, the increases from baseline in CD4 cell count were similar 
between treatment groups. Mean (SD) ba seline CD4 cell counts were as follow s: 
GS-9883+F/TAF 471 (190.9) cells/μL ; DTG+F/TAF 507 (271.0) cells/μL ; p=0.35. The mean 
(SD) change in CD4 cell count from baseline to Week 12 was similar between the 2 treatment 
groups as follows: GS -9883+F/TAF +170 (150.0) c ells/μL; DTG+F/TAF +173 (220 .5)cells/μL 
(difference in L SM: 0; 95% CI : −76 to 76; p = 1.00).
Interim Virology Resistance Data
Through Week 12, no emergent drug resistance was detected.  
1.2.3.6. SafetyResults
Adverse Events
The overall incidence of treatment -emergent AEs was balanced betw een treatment groups as 
follows: GS- 9883+F/TAF 58.5%, 38 subjects; DTG+F/TAF 57.6%, 19 subjects) .The most 
common TEAEs (occurring in > 1 subject) b
y treatment group were as follows:
GS-9883+F/TAF: diarrhea and headache (6.2%, 4 subjects each); and fatigue and nausea 
(3.1%, 2 subjects each)
DTG+F/TAF: nausea (12.1%, 4 subjects); diarrhea (9.1%, 3 subjects); and fatigue, 
flatulence, and furuncle (6.1%, 2 subjects each)
Most treatment -emergent AEs wer e Grade 1 in severity . Grade 3 or 4 AEs were reported in onl y 
1 subject (diabetic ketoacidosis); this event was also reported as an SAE, and 1 other SAE 
(appendicitis) was reported. Neither SAE was considered related to study  drug by the 
investigator, resulted in study  drug discontinuation, or required interruption of study  drug, and 
both SAEs resolved. 
The overall incidence of study  drug-related treatment -
emergent AEs was balanced between 
treatment groups as follows: GS- 9883+F/TAF 12.3%, 8 subjects; DTG+F /TAF 15.2%, 5 
subjects. Most study  drug-related treatment- emergent AEs were Grade 1 in severit y. Grade2 
study drug-related treatment -emergent AEs (somnolence and headache) were reported in 
1subject. No Grade 3 or 4 treatment -emergent AEs or treatment -emergent SAEs were 
considered related to study  drug.
No deaths, pregnancies, or AEs leading to premature study drug discontinuation were reported.
GS-9883/F/TAF 
Protocol GS -US-380-1490 Final
Gilead Sciences, Inc. Original
CONFIDENTIAL Page26 21 October 2015Clinical Laboratory Evaluations
The percentage of subjects with at least 1 treatment- emergent laboratory  abnorma lity (ie, at least 
1 grade level increase from baseline in graded abnormality ) was similar between treatment 
groups as follows: GS -9883+F/TAF 70.3%, 45 subjects; DTG+F/TAF 75.0%, 24 subjects.  The 
majority of treatment -emergent laboratory  abnormalities w ere Grade1 or2 in severity . The 
percentage of subjects with at least 1 Grade 3 or 4 treatment- emergent laboratory abnormalit y 
was similar between treatment groups as follows: GS
-9883+F/TAF 10.9%, 7 subjects; 
DTG+F/TAF 12.5%, 4 subjects. Grade 4 treatment -emergent laboratory  abnormalities (creatine 
kinase) were reported in only  2subjects.
There were no clinicall y significant changes from baseline or differences between treatment 
groups in the median values for hematology , chemistry , or metabolic parameters. Changes from 
baseline in serum creatinine were similar between treatment groups. Median (Q1, Q3) changes in 
serum creatinine at Week 12 were as follows: GS -9883+F/TAF 0.11 (0.06,0.16)mg/dL; 
DTG+F/TAF 0.14 (0.06,0.24)mg/dL. Chang es from baseline in eGF R were similar between 
treatment groups. Median (Q1, Q3) changes in eGFR at Week 12 were as follows: 
GS-9883+F/TAF −12.2 (−18.0,−6.4)mL/min; DTG+F/TAF −15.8 (−30.1, −9.5)mL/min.
1.3. Information about Emtricitabine (Emtriva®, FTC) 
Emtricitabine ( 5-fluoro-1-[(2R, 5S)-2-(hydroxymethyl)-[1, 3]-oxathiolan -5-yl] cytosine, FTC) is 
a NRTI that has demonstrated potent and selective inhibition of the HI V. In HIV-infected adults, 
FTC is administered as a 200 mg QD dose concurrently  with other ARVdrugs. The 200 mg FTC 
capsule formulation was approved b y the US Food and Drug Administration (FDA) for 
marketing on 2 July 2003 and is available under the name Emtriva®. In the European Union 
(EU), marketing authorization was granted for both the 200 mg Emtrivacapsule formul ation 
and a 10mg/mL Emtrivaoral Solution formulation on 24 October 2003, with indications for 
the treatment of HIV infection concurrently  with other antiretroviral drugs in both adult and 
pediatric patients. 
Further information is available in the curr ent Prescribing Information for Emtriva®.
1.4. Information about Tenofovir alafenamide (TAF, GS -
7340)
Tenofovir alafenamide (GS- 7340, TAF) is a second generation oral prodrug of tenofovir (TFV), 
a nucleotide analog that inhibits HI V-1 reverse transcription. Tenofovir is metabolized 
intracellularl y to the active metabolite, tenofovir diphosphate (TFV -DP), a competitive inhibitor 
of HIV-1 reverse transcriptase (RT) that terminates the elongation of the viral DNA chain.  The 
intracellular metabolism of TAF and T FV are consistent with the 600 -fold enhancement in 
anti-HIV activity  in cell culture of TAF over TFV.
Please refer to the GS -9883/F/TAF Investigator’s Brochure for further information.
GS-9883/F/TAF 
Protocol GS -US-380-1490 Final
Gilead Sciences, Inc. Original
CONFIDENTIAL Page27 21 October 20151.4.1. Clinical Trials of Single Agent Tenofovir Alafenamide (TAF, GS -7340) or 
Fixed Dose Combination emtricitabine/tenofovir alafenamide (FTC/TAF)
Clinical trials entailing the use of tenofovir alafenamide include:
GS-US-120-1101, a Phase 1/2 study  of the pharmacokinetics and antiviral activity  of 
GS-7340 (50 mg and 150 mg) in HIV -infected subjects (completed)
GS-US-120-0104, a Phase 1b study  of the pharmacokinetics and antiviral activity  of 
GS-
7340 (8 mg, 25 mg, 40 mg) in HIV infected subjects (completed)
GS-US-120-0107, a Phase 1, partially- blinded, randomized, placebo- and positive controlled 
study to evaluate the effect of GS- 7340 on the QT/QTc interval in healthy  subjects 
(completed)
GS-US-120-0108, a Phase 1, open- label, parallel -design stud y to evaluate the 
pharmacokinetics of GS -7340 in subjects with severe renal impairment (completed)
GS-US-120-0109, a Phase 1 study  to evaluate the pharmacokinetics, metabolism and 
excretion of GS -7340 (completed)
GS-US-120-0114, a Phase 1, open- label, parallel -group, single dose study  to evaluate the 
pharmacokinetics of tenofovir alafenamide in subjects with normal and impaired hepatic 
function (completed)
GS-US-120-0117, a Phase 1 single -dose study  evaluating the pharmacokinetic drug 
interaction potential between rilpivirine and tenofovir alafenamide (completed)
GS-US-120-0118, a Pharmacokin etic study  evaluating the drug interaction potential of
tenofovir alafenamide with a boosted protease inhibitor or unboosted integrase inhibitor in
healthy subjects (completed)
GS-US-
311-1386, a Phase 1 study  to determine the effect of food on the pharmacokinetics of 
tenofovir alafenamide when administered as F/TAF FDC in health y volunteers (completed)
GS-US-311-0101, a Phase 1 healthy  volunteer study  
evaluating the drug interaction potential
between once -daily FTC/GS-7340 fixed -dose combination and efavirenz (EFV) or
COBI-boosted darunavir (DRV) (completed)
GS-US-311-1088, a Phase 1, Relative Bioavailability  Study of Emtricitabine/Tenofovir
Alafenamide Fixed Dose Combination Tablet to evaluate the formulation performance of
emtricitabine (FTC) and tenofovir alafenamide (TAF) fixed dose combination tablets relative
to co-administration of individual agents (completed).
GS-US-311-1089, a Phase 3 study  of the safety  and efficacy  of FTC/TAF in HIV infected,
virologicall y suppressed patients (ongoing).
GS-9883/F/TAF 
Protocol GS -US-380-1490 Final
Gilead Sciences, Inc. Original
CONFIDENTIAL Page28 21 October 2015In StudyGS-US-311-1386, the effect of food (high- calorie, high- fat meal) on the PK of the TAF 
component of the F/TAF FDC was evaluated. The GL SM ratio of the AUC lastof TAF when 
administered with a high -fat meal was 177% (90% CI: 166% to 188%), and the TAF Cmax
GLSM ratio was 84.5% (90% CI:74.9% to 95.4%). This ~75% increase in TAF plasma 
exposure and ~15% decrease in TAF plasma C maxwhen administered with food was 
accompanied b y a delay in T max(increase from 1.00 hour under fasted conditions to 2.00 hours 
under fed conditions). The exposures of TAF observed under fed or fasted conditions in this 
study are within the range of exposures observed in the E/C/F/TAF clinical development 
program and are commensurate with safe and effective plasma levels of TAF ( see investigator 
brochure for further details). Therefore, the changes in TAF exposures when F/TAF is 
administered with food should not result in differences in efficacy  and thus are not clinicall y 
relevant. TAF can be administered without regard for food and these findings can be 
extrapolated to F/TAF (as FTC can be taken without regard to food) .
1.4.2. Clinical Trials of FTC/TAF as part of 
elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide (E/C/F/TAF) 
Clinical trials usingtenofovir alafenamide, coform
ulated into the E/C/F/TAF STR include: 
GS-US-292-0101, a Phase 1 healthy  volunteer study  evaluating the relative bioavailability  of 
EVG, FTC, TFV, and COBI administered as E/C/F/TAF STR relative to E/C/F/TDF or TAF
(completed)
GS-US-292-0103, a Phase 1 he althy volunteer study  to evaluate the pharmacokinetics and 
relative bioavailabilit y of the E/C/F/TAF STR relative to the individual components at 
GS-7340 doses of 10 mg (STR) or 25 mg Single Agent (SA) (completed)
GS-US-
292-0102, a Phase 2 randomized, double -blinded study  of the safet y and efficacy of 
E/C/F/TAF STRversus E/C/F/TDF STRin HIV-1 infected, antiretroviral treatment- naive 
adults (ongoing)
GS-US-292-
0104 and GS -US-292-0111 , Phase 3 randomized, double -blinded study  of the 
safety and efficacy of E/C/F/TAF STRversus E/C/F/TDF STRin HIV-1 infected, 
antiretroviral treatment- naive adults ( ongoing)
GS-US-292-0109, a Phase 3 o pen-label study to evaluate s witching from a TDF-c ontaining 
combination regimen to a T AF-containing combination single tablet regimen (STR) in 
virologicall y-suppressed, HIV -1 positive subjects(ongoing)
GS-US-292-0112, a Phase 3 Open -label Safet y Study of 
Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide single -tablet Regimen in H IV-1 
positive patients with mild to moderate renal impairment (ongoing)
GS-US-
292-0117, a Phase3, two-part study to evaluate the efficacy of Tenofovir 
Alafenamide versus placebo added to a failing regimen followed by  treatment with 
Elvitegravir/Cobicistat /Emtricitabine /Tenofovir Alafenamide in HIV -1 positive, 
antiretroviral treatment-experienced adults (ongoing)
GS-9883/F/TAF 
Protocol GS -US-380-1490 Final
Gilead Sciences, Inc. Original
CONFIDENTIAL Page29 21 October 2015GS-US-292-0119, a Phase 3 open - label study to evaluate switching from optimized stable 
antiretroviral regimens containing darunavir to 
Elvitegravir/Cobicistat/Emtricitabine/ Tenofovir Alafenamide (E/C/F/TAF) single tablet 
regimen (STR) plus darunavir (DRV) in treatment experienced HIV -1 positive a dults
(ongoing)
GS-US-
292-0106, aPhase 2/3, open -label study of the pharmacokinetics, safety,and 
antiviral activity of the Elvitegravir /Cobicistat/Emtricitabine/Tenofo vir Alafenamide 
(E/C/F/TAF) single tablet regimen (STR) in HIV-1 infected antiretroviral treatment- naive 
adolescents (ongoing).
Study GS-US-
292-0101 is a Phase 1 study  of 40 subject s evaluating the relative bioavailability  
of two different formulations of E/C/F/TAF STR, each with TAFdose of 25 mg or 40 mg, versus 
E/C/F/TDF STR or TAF 25 mgalone. Exposures of EVG, COBI, and FTC were comparable 
between E/C/F/TAF vs E/C/F/TDF regardless of formulation (monolay er or bi-layer). In 
contrast, TAF exposures were ~2.2 -fold higher (and corres ponding tenofovir exposures ~ 3-fold 
higher) when administered as E/C/F/TAF (25mg) vs TAFsingle agent (SA) 25mg for both 
formulations of the 
E/C/F/TAF, likel y mediated by inhibition of P -gp-mediated intestinal
secretion of 
TAFby COBI.
Study GS-US-292-0103 is a completed Phase 1 healthy  volunteer study whichevaluatedthe PK
and relative bioavailability  of the E/C/F/TAF STR relative to the ind ividualcomponents at TAF
doses of 10 (STR) or 25 mg SA. Resultsindicate that when dosed as the E/C/F/TAF10 mg STR, 
TAFand TFV exposures were comparable to those observed with TAF25mg dosed alone. 
Exposures of EVG, COBI, and FTC were also comparable b etween the STR and individually  
dosedformulations. 
Study GS-US-
292-0102 is an ongoing, randomized, active-controlled Phase 2 study , compares 
E/C/F/TAF (10 mg)versus Stribild®(STB, E/C/F/TDF) in treatment- naïve, HIV -1 infected 
subjects. At Week 48, the E/C/F/TAF demonstrated potent ant iviral efficacy  (HIV-1 RNA 
<
50copies/mL) similar to STB (88.4% [99/112] vs 87.9% [51/58] using the snapshot 
algorithm); in the E/C/F/TAF group , no patient had emergent resistance to 1 or more components 
of the E/C/F/TAF. Importantly , E/C/F/TAF demonstrated a potential benefit over E/C/F/TDF in 
terms of renal and bone safet y: smaller median decreases in eGFR (mL /min) (at Week 48, 
E/C/F/TAF -5.5 vs E/C/F/TDF -10.0 [P<0.001) and smaller median percentage decreases in 
BMD (at Week 48, spine E/C/F/TAF - 1.00 vs E/C/F/TDF -3.37 [p<0.001], hip -0.62 
vs -2.39[p<0.001]).
Studies GS -US-292-0104 and GS-US -292-0111 are ongoing , Phase 3 randomized, doubl e-
blinded studies of the safe t
yandefficacyof E/C/F/TAF versus E/C/F/TDF in HI V-1 infected, 
antiretroviral treatment -naive adults. The interim Week 48 key conclusions from pooled data 
showed that E/C/F/TAF once dai ly was noninferior to STB once daily when administered for
48weeks to HIV- infected, ART -naive adults, as asse ssed using the US Food and Drug 
Administration (FDA )-defined snapshot algorithm with H IV
-1 RNA < 50copies/mL  
(E/C/F/TAF 92.4%; STB 90.4%; diff erence in percentages: 2.0%, 95%CI: - 0.7% to4.7%).  
GS-9883/F/TAF 
Protocol GS -US-380-1490 Final
Gilead Sciences, Inc. Original
CONFIDENTIAL Page30 21 October 2015Administration of E/C/F/TAF resulted in > 90% lower plasma TFV and higher intracellular 
TFV-DP relative to STB.  E/C/F/TAF showed an improved renal and bone safe typrofile with 
significant ly less decline in hip and spine BMD, less increase in serum creatinine and reduction 
in estimated glomerular filtration rate (eGFR) .
1.5. Information about GS -9883/emtricit abine/tenofovir alafenamide 
(GS-9883/F/TAF )
Please refer to the GS -9883/F/TAF Investigator’s Brochure for further information.
1.5.1. GS-US-141-1233: Study of the Relative Bioavailability of GS -9883, FTC, and 
TAF between GS-9883/F/TAF and GS-9883 + F/TAF
Study GS
-US-141-1233 is an ongoing Phase 1, open -label,2-cohort, multiple -period,
fixed-sequence, crossover study  conducted at a single center in the USto evaluate 1) the relative 
bioavailability  (BA) of 2 GS -9883/F/TAF (75/200/25 mg and 50/200/25 mg) FDC tablets 
compared with the GS -9883 (75 mg) tablet and the F/TAF (200/25 mg) FDC tablet administered 
simultaneously  and 2) the effect of food on the PK of GS-9883, FTC, and TAF when 
administered as GS -9883/F/TAF (75/200/25 mg and 50/200/25 mg) FDC tablets. 
Cohort 1 evaluated the relative BA and food effect of GS -9883/F/TAF (75/200/25 mg) FDC 
tablet in a 3 -period sequence. Following review of preliminary data from Cohort 1, Cohort 2 was 
added to the study  via protocol amendment. Cohort 2 will evaluate the relative BA and food 
effect of GS -9883/F/TAF (50/200/25 mg) FDC tablet in a 4 -period sequence. 
The in-life portion of Cohort 1 is complete; preliminary results are summarized below. The 
in-life portion of Cohort 2 is ongoing. 
Cohort 1 Results:
Pharmacokinetic Results Under fasted conditions, GS -9883 AUC infand Cmaxwere 27% and 
31% higher, respectivel y, following GS -
9883/F/TAF (75/200/25 m g) FDCadministration 
than following administration of single-agentGS-9883 (75 mg ) with the F/TAF (200/25 mg) 
FDC. FTC and TAF exposure was similar following administration of GS -9883/F/TAF 
(75/200/25 mg) or single-agentGS-9883 (75 mg) with the F/TAF (200/25mg) FDC . 
Compared with administration under fasted conditions, administration of theGS-9883/F/TAF 
(75/200/25 mg) FDCwith a high- fat meal resulted in a 46% higher GS- 9883 AUC infand a 
27% higher GS -9883 C max. The impact of food on TAF and FTC exposure was similar to that 
previously  observed for F/TAF (Study  GS-US-311-1386). GS-9883/F/TAF may  be taken 
without regard to food.   Based on these results, Cohort 2 was added to the study  via protocol 
amendment to evaluate the relative BA of the GS-9883/F/TAF (50/ 200/25mg)FDC tablet 
compared with the single-agentGS-9883 (75 mg) tablet and the F/TAF (200/25 mg) FDC 
tablet administered simultaneously .
GS-9883/F/TAF 
Protocol GS -US-380-1490 Final
Gilead Sciences, Inc. Original
CONFIDENTIAL Page31 21 October 2015Safety Results
Of the 28 subjects included in the Safet y Analysis Set for Cohort 1, 12 subjects (43%) had at 
least 1treatment-emergent AE. All treatment emergent AEs were assessed as Grade 1 or2in 
severity. No deaths or other SAEs occurred during this study, and no subject discontinued the 
study due to an AE.
1.6. Information about dolutegravir (DTG, T ivicay®)
Formore detailed information, refer to the current Prescribing I nformation and local product 
labeling for dolutegravir .
1.7. Rationale for t his Study
HIV standard of care has relied upon nucleos(t)ide backbones for effective and durable virologic 
suppression, but nucleos(t)ide -associated toxicities are increasingl y important as HIV -infected 
patients are often diagnosed earlier, initiate therapy  earlier, and look toward lifelong therapy  
(often greater than 50 years). Where patients have access to treatment, morbidi ty and mortality  
are driven b y non–AIDS-associated comorbidities, which are observed earlier than in 
HIV-uninfected age -matched controls despite the best available ART. The contribution of 
specific nucleos(t)ides, including abacavir and tenofovir disoproxi l fumarate, to long -term 
morbidity  and mortality  is increasingl y important in this context.   
The GS-9883/F/TAF FDC has the potential to offer a simple, once -dail
y regimen containing a 
second generation INSTI that provides a high barrier to resistance, doe s not require a boosting 
agent, and offers an effective and safer alternative to standard nucleos(t)ide based regimens, 
without the need for HLA testing or close monitoring of renal or bone toxicities.  I t could 
provide a FDC treatment that avoids the ris k of hypersensitivity  reactions, would not contribute 
to an increased risk of cardiovascular events, could be used in patients with chronic hepatitis B 
or C infection or renal impairment, and that could be continued
as patients age and confront 
non-HIV-related comorbidities .
The objective of this study  is to evaluate the safet y and efficacy of a FDC containing GS-
9883/F/TAF versus DTG + a FDC of F/TAF.  
Dolutegravir is a second generation, unboosted 
INSTI, providing a once daily  unboosted option with rapid viral suppression, good tolerability , 
and a high barrier to resistance and is on the DHHS Treatment Guidelines as a preferred INSTI. 
By keeping the backbone of F/TAF constant in both arms, we will be able to compare GS-9883 
with DTG in a single variable de sign trial. This design is an extension of the ongoing Phase 2 
study, given that a single variable design is considered the best direct evidence of benefit.
1.8. Risk/Benefit Assessment for the Study
All patients with HI V-1 infection should receive effective antiretroviral therap y. Potential risks 
associated with all classes of ARVs include immune reconstitution sy ndrome, lipody strophy, and 
lactic acidosis with steatosis.  The risk of class effects is considered to be low.  I mportant 
identified risks appropriately  managed by  study inclusion/exclusion criteria as well as through 
GS-9883/F/TAF 
Protocol GS -US-380-1490 Final
Gilead Sciences, Inc. Original
CONFIDENTIAL Page32 21 October 2015close clinical and laboratory  monitoring during the study , are as follows: hy persensitivity  
reaction to dolutegravir, including liver injury ,and allergy  to any components of the tablets.  
Interim data will also be reviewed b y an independent data monitoring committee.  Potential 
benefits may  include provision of a new antiretroviral therap y that is not currentl y available and 
which may have fewer side effects than alternative therapies.  Other potential benefits include 
provisions of fixed dose combination therap y, and the knowledge that patient participation will 
contribute to the body  of knowledge of HIV therapies.  
The overall benefit-risk assessment for GS -9883/F/TAF and DTG + F/TAF is favorable at this 
time.
1.9. Rationale for Dose Selection
FTC
The 200 mg dose of FTC represents the marketed dose for this agent that is currentl y available as 
single agent capsules (EMTRI VA) and as a component of a number of fixed -dose combination 
tablets, including: TRUVADA, ATRIPLA, COMPLERA (EVIPLERA) , and STRI BILD.
TAF
Based upon results of the Phase 1 Study  GS-US-120-0104, in which various doses of TAF 
(8mg, 25 mg, and 40 mg) were administered t o HIV-infected subjects in 10 day s of 
monotherap y, the range of exposure achieved with TAF 25 mg was chosen as the reference 
exposure. I n this study , TAF 25 mg resulted in near -maximal antiviral activity  and plasma TFV 
exposure > 90% lower relative to TDF.
The recommended dose of TAF is based on ensuring that patients have a TAF s ystemic exposure 
that is within the range of the reference exposure achieved with TAF 25 mg, or with TAF 10 mg 
when administered with the boosting agent COBI as E/C/F/TAF, for whic h an extensive safet y 
and efficacy  database exists. Specifically , TAF 25 mg is recommended with third agents that do 
not have a clinicall y relevant effect on TAF exposure. Study GS-US-141-1418 showed that 
GS-9883 does not have a clinically  relevant effect on TAF exposure. Therefore, the dose of TAF 
25mg is appropriate for the GS -9883/F/TAF FDC.
GS-9883
The dose of GS -9883 for Phase 2 was selected based upon data from Study GS-US-141-1219 
(Table1-5), in which HIV-1 -infectedsubjects were administered 5, 25 , 50, or 100 mg doses of 
GS-9883 monotherap y under fasting conditions for 10 day s. 
GS-9883/F/TAF 
Protocol GS -US-380-1490 Final
Gilead Sciences, Inc. Original
CONFIDENTIAL Page33 21 October 2015Table1-5. GS-US-141-1219: Trough GS -9883 Plasma Concentrations at Steady 
State Following GS -9883 Administration Under Fasting Conditions 
and Corresponding Protein -Adjusted IQ 95Values
GS-9883 dose nMedian (range) C tau,SS(ng/mL) Median (range) paIQ 95a
5 mg 4 206.5 (146.0 –342.0) 1.3 (0.9 –2.1)
25 mg 4 797.5 (714.0 –1900.0) 4.9 (4.4 – 11.7)
50 mg 4 2170.0 (852.0 –3020.0) 13.4(5.3 – 18.6)
100 mg 4 4190.0 (3730.0 –5970.0) 25.9(23 –36.9)
aThe paIQ 95value is estimated based on steady -state C tauvalues and the in vitro paIC 95value for wild -type HIV -1 
(162ng/mL).
Source: Data on File
Single-agent GS-9883 was well toleratedatall doses admi nistered.The range of GS-9883 
plasma exposure at steady  state (C tau,SS) observed in the 50 -mg cohort correlated with protein 
adjusted 95% inhibitory  quotient (paIQ 95) values ranging from 5.3 to19, while the range of 
GS-9883 plasma exposure at stead y state (C tau,SS) observed in the 100 -mg cohort correlated with 
paIQ95values ranging from 23 to 37 ( Table1-5). 
Based on PK/PD analy ses, exposure following a 75 -mg dose of single- agent GS-9883 is 
expected to provide near -maximal virologic response, with a predicted paIQ 95of approximately
 
20, providing considerable coverage above the target concentration of 162 ng/mL (paI C95).  
GS-9883 (75 mg) single agent coadministered with F/TAF (200/25 mg) is currentl y being 
evaluated in a Phase 2 study , GS-US-141-1475 (GS -9883+F/TAF vs DTG+F/TAF). The 
Week12 interim data from this study, support the safet y and efficacy of GS -9883 exposures 
obtained with the 75 mg dose of the single agent .
GS-9883/F/TAF FDC Dose Selection
A fixed dose formulation of GS -9883/F/TAF is being developed for use in Phase 3 studies. 
Preliminary  results from the relative bioavailability  (rBA) study  (GS-US-141-1233) of 
GS-9883/F/TAF (75/200/25 mg) showed that GS -9883 plasma exposure was higher (with C max
and AUC infincrease of 31% and 27%, respectively) following administration of the FDC as 
compared with exposure following administration of GS
-9883 (75 mg) + F/TAF (200/25 mg) 
under fasted conditions
. The increase in GS -9883 exposures associated with the FDC 
formulation results in an estimated mean paIQ 95of 24.3, compared to an estimated mean paIQ 95
of 19.2 for the GS -9883 (75 mg) single agent coadministered with F/TAF , in the fasted state. 
In order to bridge exposures of GS -9883 in the FDC to the exposure obser ved with GS -9883 
75mg administered as a single agent, and to bridge to the safe and effective exposures observed 
in the Phase 2 study  GS-US-141-1475, a lower strength GS -9883/F/TAF FDC is being 
developed for use in the Phase 3 studies. Comparability  of GS-9883 exposures will be confirmed 
in an rBA stud y of GS-9883/F/TAF (50/200/25 mg) and GS -9883 (75 mg) + F/TAF prior to 
initiation of dosing in the Phase 3 studies.
GS-9883/F/TAF 
Protocol GS -US-380-1490 Final
Gilead Sciences, Inc. Original
CONFIDENTIAL Page34 21 October 20151.10. Compliance
This study  will be conducted in compliance with this protocol, Good Clinical Practice (GCP), 
and all applicable regulatory  requirements.
GS-9883/F/TAF 
Protocol GS -US-380-1490 Final
Gilead Sciences, Inc. Original
CONFIDENTIAL Page35 21 October 20152. OBJECTIVES
The primary  objective of this study  is:
To evaluate the efficacy  of a fixed dose combination (FDC) containing 
GS-9883/emtricitabine/tenofovir alafenamide (GS- 9883/F/TAF) versus dolutegravir (DTG)+ 
a FDC containing emtricitabine/tenofovir alafenamide (F/TAF) in HIV-1 infected, 
antiretroviral treatment- naïveadult subjects as determined b y the achievement of 
HIV-1RNA 50copies/mL  at Week 48
The secondary  objectives of this study  are:
To evaluate the efficacy , safety and tolerability of the two treatment regimens through 
Weeks48 and96
GS-9883/F/TAF 
Protocol GS -US-380-1490 Final
Gilead Sciences, Inc. Original
CONFIDENTIAL Page36 21 October 20153. STUDY DESIGN
3.1. Endpoints
The primary  endpoint is:
The proportion of subjects whoachieve HIV -1 RNA <50 copies/mL at Week 48 as defined 
by the US FDA snapshot algorithm.
The secondary  endpoints of this study  include:
The proportion of subjects who achieve HIV -1 RNA < 50 copies/mL at Week 96 as defined 
by the US FDA snapshot algorithm
The proportion of subjects who achieve HIV -1 RNA < 20 copies/mL at Weeks 48 and 96 as 
defined b y the US FDA snapshot algorithm
The changefrom baseline in log 10HIV
-1 RNAand CD4+ cell count at Weeks 48 and 96
3.2. Study Design
This protocol describes a randomized, double -blind, multicenter, active -controlled study  to 
evaluate the safet y and efficacy  of GS-9883/F/TAF FDC versus DTG + FDC of FTC/TAF in 
HIV-1 infected, antiretroviral treatment- naïve adult subjects.
3.3. Study Treatments
Subjects who provide written informed consent and meet all eligibility  criteria will be 
randomized in a 1:1 ratio to one of the following two treatment groups:
Treatment Group 1: FDC of GS- 9883 50 mg/emtricitabine 200 mg/ tenofovir alafenamide 
25mg (GS-9883/F/TAF) + Placebo to match dolutegravir 50 mg and Placebo to match FDC of 
emtricitabine 200 mg/tenofovir alaf enamide 25 mg (F/TAF) administered orally , once dail y, 
without regard to food (n=300)
Treatment Group 2: Dolutegravir 50 mg + FDC of emtricitabine 200 mg/tenofovir alafenamide 
25 mg (F/TAF) + Placebo to match FDC of GS -9883 50 mg/emtricitabine 200 mg/tenof ovir 
alafenamide 25 mg (GS-9883/F/TAF) administered orall y, once daily, without regard to food 
(n=300)
Randomization will be stratified b y HIV-1 RNA level ( ≤ 100,000 copies/mL, > 100,000 to 
≤400,000 copies/mL , or >400,000 copies/mL) at screening, CD4+ cell count (< 50cells/μL, 
50 -199cells/μL, or ≥ 200 cells/μL) at screening, and region (US vs. Ex -US) at randomization.
GS-9883/F/TAF 
Protocol GS -US-380-1490 Final
Gilead Sciences, Inc. Original
CONFIDENTIAL Page37 21 October 20153.4. Duration of Treatment
Subjects will be treated for at least 96 weeks. Subjects’ treatments will be unblinded after the last 
subject com pletes the Week 96 visit and Gilead completes the Week 96 analy sis. Subjects will 
continue to take their blinded study  drug and attend visits every  12 weeks until treatment 
assignments have been unblinded.  At the Unblinding Visit , subjects in a country  where 
GS-9883/F/TAF FDC is not available will be given the option to receive GS-9883/F/TAF FDC 
in an open label extension phase for 48 weeks, or until the product becomes accessible to 
subjects through an access program, or until Gilead Sciences elects to discontinue the study  in 
that country , whichever occurs first. 
After Week 96 Visit, subjects in the United Kingdom will stop taking study drug and complete a 
30 day follow up visit and return to the standard of care.
Figure3-1. Study Schema
a.Following the Day 1 visit, subjects will be required to return for study visits at Weeks 4, 8, 12, and then every 12weeks 
through Week 96.
b.After Week 96, subjects will continue to take their blinded study drug and attend visits every 12 weeks until treatment
assignments have been unblinded. Subjects’ treatments will be unblinded after the last subject completes the Week 96 visit
and Gilead completes the Week 96 analysis.  After the Week 96 Visit, subjects in the United Kingdom will stop taking study 
drug and complete a 30 day follow up visit and return to the standard of care.
c.Once Gilead Sciences provides unblinded treatment assignments to the Investigators, all subjects will return to the clinic
(preferably within 30 days) for an Unblinding Visit. At the Unblinding Visit, subjects in a country where GS -9883/F/TAF 
FDC is not available will be given the option to receive GS-
9883/F/TAF FDC in an open label extensio n for 48 weeks, or 
until the product becomes accessible to subjects through an access program, or until Gilead Sciences elects to discontinue 
the study in that country, whichever occurs first.
d.Subjects who complete the study through the Unblinding Visit a nd do not continue on theopen-label GS-9883/F/TAF FDC
extension phase will be required to return to the clinic 30 days after the completion of study drugs for a 30 -Day Follow -Up 
Visit.

GS-9883/F/TAF 
Protocol GS-US-380-1490 
Gilead Sciences, Inc. 
3.5. Biomarker Testing 
3.5.1. Biomarker Samples for Optional Pharmacogenomic Research 
PPD 
3.5.2. Additional Sample Storage Final 
Original 
For subjects who provide additional consent, residual blood and urine samples taken throughout 
the study will be stored. Stor ed samples may be used by the Sponsor or its research partners to 
help answer questions about the study dmg, and HIV disease and its associated conditions, or to 
provide additional safety data. At the conclusion of this study, these samples may be retained in 
storage by Gilead Sciences for a period up to 15 years. 
CONFIDENTIAL Page 38 21 October 2015 
GS-9883/F/TAF 
Protocol GS -US-380-1490 Final
Gilead Sciences, Inc. Original
CONFIDENTIAL Page39 21 October 20154. SUBJECT POPULA TION
4.1. Number of Subjects and Subject Selection
Approximately  600 subjects who meet the eligibility  criteria will be enrolled.
4.2. Inclusion Criteria
Subjects must meet all of the following inclusion criteria to be eligible for participation in this 
study.
1.The ability  to understand and sign a written informed consent form, which must be obtained 
prior to initiation of study procedures
2.Age 18years
3.Antiretroviral treatment naïve ( ≤ 10 days of prior therapy  with any antiretroviral agent 
following a diagnosis of HIV -1 infection) except the use for PrEP (pre -exposure proph ylaxis) 
or PEP (post -exposure prophy laxis), up to one month prior to screening
4.Plasma HIV -1 RNA levels 500copies/mL at screening
5.Normal ECG ( or if abnormal, determined by  the Investigator to be not clinically  significant)
6.Adequate renal function:
Estimated glomerular filtration rate ≥ 30mL/min(≥ 0.50mL/sec)according to the 
Cockcroft -Gault formula {2202}:
a.Male: (140–age in years) (wt in kg) CLcr (mL/min)
72(serum creatinine in mg/dL)
         (140–age in years) (wt in kg)         CLcr (mL/sec)
            72(serum creatinine in umol/L) 0.6786  
b.Female: (140–age in years) (wt in kg) 0.85 CLcr (mL/min)
72(serumcreatinine in mg/dL)
         (140–age in years) (wt in kg)          0.85  CLcr (mL/sec)
72(serum creatinine in umol/L) 0. 6786
7.Hepatic transaminases (AST and ALT) 5upper limit of normal (ULN)
8.Total bilirubin 1.5mg/dL(26 umol/L) , or normal direct bilirubin
GS-9883/F/TAF 
Protocol GS -US-380-1490 Final
Gilead Sciences, Inc. Original
CONFIDENTIAL Page40 21 October 20159.Adequate hematologic function (absolute neutrophil count ≥ 750/mm3(≥0.75 GI/L); 
platelets ≥50,000/mm3(≥ 50 GI/L); hemoglobin ≥ 8.5 g/dL(
≥85 g/L))
10.Serum amy lase ≤ 5 × ULN (subjects with serum amy lase > 5 ×ULN will remain eligible if 
serum lipase is ≤ 5
×ULN)
11.Females of childbearing potential must agree to utilize protocol recommended highl y 
effective contraceptive methods or be non -heterosexually  active or practice sexual abstinence 
(as defined in Appendix 6) from screening, throughout the duration of the study  period, and 
for 30 day s following the last dose of study  drug.
a)Female subjects who utilize hormonal contraceptive as one of their birth control methods 
must have used the same method for at least 3 months prior to study  drug dosing.
12.Male subjects who engage in heterosexual intercourse must agree to use protocol specified 
method(s) of contraception (as described in Appendix 6) throughout the study period and for 
90 days following the last dose of study  drug.
13.Male subjects must agree to refrain from sperm donation from first study  drug dose until at 
least 90 day s following the last study  drug dose
14.Life expectancy  ≥ 1 year
15.Screening genot ype report provided b y Gilead Sciences must show sensitivity to FTC and 
TFV 
4.3. Exclusion Criteria
Subjects who meet any of the following exclusion criteria are not to be enrolled in this study .
1.
An opportunistic illness indicative ofstage 3 HIV diagnosed within the 30 days prior to 
screening (refer to Appendix 5)
2.Subjects experiencin g decompensated cirrhosis (eg, ascites, encephalopathy , or variceal 
bleeding)
3.Have been treated with immunosuppressant therapies or chemotherapeutic agents within 
3months of study  screening, or expected to receive these agents or s ystemic steroids during 
the study (eg, corticosteroids, immunoglobulins, and other immune -or cytokine-based 
therapies)
4.Current alcohol or substance use judged b y the Investigator to potentiall y interfere with 
subject study  compliance
5.A history of or ongoing malignancy  (including untreated carcinoma in -situ) other than 
cutaneous Kaposi's sarcoma (KS), basal cell carcinoma, or resected, non -invasive cutaneous 
squamous carcinoma. Subjects with biopsy -confirmed cutaneous KS are eligible, b ut must 
not have received an y systemic therap y for KS within 30 days of Day 1 
and are not 
anticipated to require s ystemic therap y during the study
GS-9883/F/TAF 
Protocol GS -US-380-1490 Final
Gilead Sciences, Inc. Original
CONFIDENTIAL Page41 21 October 20156.Active, serious infections (other than HIV -1 infection) requiring parenteral antibiotic or 
antifungal therap ywithin 30 days prior to Day  1
7.Participation in any other clinical trial , including observational studies,without prior 
approval from the sponsor is prohibited while participating in this trial
8.Any other clinical condition or prior therapy  that, in the opinion of the I nvestigator, would 
make the subject unsuitable for the stud y or unable to comply  with the dosing requirements
9.Any known allerg ies to the excipients of GS -9883/F/TAF FDC or DTG + F/TAF FDC 
tablets
10.Females who are pregnant (as confirmed b y positive serum pregnancy  test)
11. Females who are breastfeeding
12.Subjects receiving ongoing therap y with any of the following medications in the table below, 
including drugs not to be used with FTC, TAF, GS -9883andDTG
Drug Class Agents Disallowed *
Antiarrhythmic Agent Dofetilide
Anticonvulsants Phenobarbital, Phenytoin, Carbamazepine , Oxcarbazepine
Antimycobacterials Rifampin, Rifapentine
Antiretrovirals Any antiretroviral drug that is not part of the study regimen
GI Motility Agents Cisapride
Herbal/NaturalSupplements St. John’s Wort, Echinaccea
*Administration of any of the above medications must be discontinued at least 30 days prior to the Day 1 visit and for the
duration of the study.
13. Acute hepatitis in the 30 day s prior to study  entry
14. Screening HBV DNA with HBV viral load > 9 log IU/mL, if determined to be HBV infected
15.Active tuberculosis infection
GS-9883/F/TAF 
Protocol GS -US-380-1490 Final
Gilead Sciences, Inc. Original
CONFIDENTIAL Page42 21 October 20155. INVESTIGA TIONAL  MEDICINAL PRODUCTS
5.1. Randomization, Blinding and Treatment Codes
Subjects will be assigned a screening number at th e time of consent. Randomization and Day1 
visits cannot occur until the Investigator has received the results of the screening genotype 
reportand subject eligibility has been confirmed .
Once eligibility  has been confirmed and prior to or during the Day  1visit, the Investigator or 
designee will randomize the subject using the Interactive Web Response System (IWRS). Once a 
subject number has been assigned to a subject, it will not be reassigned to any  other subject. The 
subject number assignment and random ization may  be perform ed up to 3 days prior to the 
in-clinic Day 1 visit provided that all screening procedures have been completed and subject 
eligibility  has been confirmed.
Subjects will be randomized in a 1 :1ratio to Treatment Group1 or Treatment Gro up 2. 
Randomizationwill be stratified by  HIV-1 RNA level ( ≤ 100,000 copies/mL, > 100,000to 
≤400,000 copies/mL , or >400,000 copies/mL) at screening, CD4+ cell count (< 50cells/μL, 
50 – 199cells/μL, or ≥ 200 cells/μL) at screening and region (US vs. Ex -US) at randomization.
The IWRS will assignstudy drug bottle numbers of blinded FDC of GS -9883/F/TAF + Placebo 
to match DTG + F/TAF FDC, or DTG + F/TAF FDC+ Placebo to match FDC of 
GS-9883/F/TAF at each study  visitfor each subject. 
5.1.1. Procedures for Breaki ng Treatment Codes
In the event of a medical emergency  where breaking the blind is required to provide medical care 
to the subject, the investigator may  obtain treatment assignment directly  from the I WRS system 
for that subject. Gilead strongly recommends but does not require that the investigator contact 
the Gilead medical monitor before breaking the blind. Treatment assignment should remain 
blinded unless that knowledge is necessary  to determine subject emergency medical care. The 
rationale for unblinding must be clearl y explained in source documentation and on the e lectronic 
case report form ( eCRF), along with the date on which the treatment assignment was 
obtained. The investigator is requested to contact the Gilead medical monitor promptly  in case of 
any treatment unblinding.
Blinding of stud y treatment is critical to the integrity  of this clinical trial and therefore, if a 
subject’s treatment assignment is disclosed to the investigator, the subject will have study  
treatment discontinued. All subjects wi ll be followed until study  completion unless consent to do 
so is specificall y withdrawn by the subject.
GileadDrug Safet y and Public Health (DSPH) may independentl y unblind cases for expedited 
reporting of suspected unexpected serious adverse reactions (S USARs).
GS-9883/F/TAF 
Protocol GS -US-380-1490 Final
Gilead Sciences, Inc. Original
CONFIDENTIAL Page43 21 October 20155.2. Description and Handling 
5.2.1. Formulation
5.2.1.1. GS-9883/Emtricitabine/Tenofovir alafenamide (GS -9883/F/TAF) 
50mg/200mg/25 mg and Placebo to Match Tablets
GS-9883 50 mg/Emtricitabine 200 mg/Tenofovir alafenamide 25 mg tablets are capsule -shaped, 
film-coatedpurplish-brown, debossed with "GSI" on one side of the tablet and "9883" on the 
other side of the tab let. Eachtablet core contains 5 0 mg of GS -9883, 200 mg of emtricitabine, 
and 25 mg of tenofovir alafenamide . In addition to the active ingredients, the GS-9883/F/TAF
tablets contain croscarmellose sodium, magnesium stearate, and microcry stalline cellulose. The 
tablet cores are film- coated with 
iron oxide red, iron oxide black, polyethylene glycol, polyvinyl 
alcohol, talc, and titanium dioxide .
The placebo to match (PTM) GS -9883/F/TAF tablets are capsule -shaped, film -coated 
purplish
-brown, debossed with "GSI" on one side of the tablet and "98 83" on the other side and 
are identical in phy sical appearance to GS-9883/F/TAF tablets. The placebo tablets contain 
microcrystalline cellulose, lactose monohy drate, croscarmellose sodium and magnesium stearate. 
The tablet cores are film -coated with iron oxide red ,iron oxide black, polyethylene glycol, 
polyvinyl alcohol, talc, and titanium dioxide .
5.2.1.2. Dolutegravir (DTG) 50 mg and Placebo to Match Tablets
Dolutegravir 50 mg tablets are round, film -coated yellow, debossed with “50” on one side and 
debossed with “SV 572” on the other side. Each tablet core contains 50 mg of dolutegravir .In 
addition to the active ingredient, DT G tablets contain D -mannitol, microcrystalline cellulose, 
povidone K29/32, sodium starch gly colate and sodium steary l fumarate. The tablet cores are 
film-coated with iron oxide y ellow, poly ethylene glycol, polyvinyl alcohol, talc and titanium 
dioxide.
The placebo to match (PTM) DTG tablets are round, film coated y ellow, debossed with “50” on 
one side and debossed with “SV 572” on the other side.  PTM DTG tablets are identical in 
physical appearance to DTG 50 mg tablets. The placebo tablet cores contain micr ocrystalline 
cellulose, lactose monohy drate, croscarmellose sodium and magnesium stearate. The tablet cores 
are film-coated with iron oxide y ellow, poly ethylene glycol, polyvinyl alcohol, talc and titanium 
dioxide.
5.2.1.3. Emtricitabine/Tenofovir alafenamide (F/TAF) 200 mg/25 mg and Placebo to 
Match Tablets
Emtricitabine 200 mg/t enofovir a lafenamide 25 mg tablets are rectangular -shaped, film-coated 
blue, debossed with "GSI" on one side of the tablet and "225 " on the other side of the tab let. 
Eachtablet core 
contains 200 mg of emtricitabine and 25 mg of tenofovir alafenamide . In 
additionto the active ingredients, the F/TAF tablets contain croscarmellose sodium, magnesium 
stearateand microcry stalline cellulose. The tablet cores are film- coated with FD&C blue 
#2/indigo carmine aluminum lake ,polyethylene glycol, polyvinyl alcohol, talc and titanium 
dioxide.
GS-9883/F/TAF 
Protocol GS -US-380-1490 Final
Gilead Sciences, Inc. Original
CONFIDENTIAL Page44 21 October 2015The placebo to match (PTM) F/TAF tablets are rectangular -shaped, film-coated blue, debossed 
with "GSI" on one side of the tablet and "225 " on the other side of th e tablet.  PTM F/TAF 
tablets are identical in physical appearance to F/TAF 200 mg/25 mg tablets. The placebo tablet 
cores contain microcry stalline cellulose, lactose monohy drate, croscarmellose sodium and 
magnesium stearate. The tablet cores are film -coated with FD&C blue #2/indigo carmine 
aluminum lake ,polyethylene glycol, polyvinyl alcohol, talc and titanium dioxide .
5.2.2. Packaging and Labeling
5.2.2.1. GS-9883/Emtricitabine/Tenofovir alafenamide (GS-9883/F/TAF) 
50mg/200mg/25 mg and Placebo to Match Tablets
GS-9883/F/TAF tablets and PTM GS -9883/F/TAF tablets are packaged in white, high densit y 
polyethylene (HDPE) bottles. Each bottle contains 30 tablets, silica gel desiccant and pol yester 
packing material.  Each bottle is enclosed with a white, continuous thr ead, child -resistant 
polypropylene screw cap with an induction -sealed and aluminum- faced liner.
Study drug(s) to be distributed to centers in the US and other participating countries shall be 
labeled to meet applicable requirements of the United States Fo od and Drug Administration 
(FDA), EU Guideline to Good Manufacturing Practice -Annex 13 (I nvestigational Medicinal 
Products), and/or other local regulations. 
5.2.2.2. Dolutegravir (DTG) 50 mg and Placebo to Match Tablets
Dolutegravir 50 mg tablets and PTM Dolutegravir 50 mg tablets are packaged in white, high
density polyethylene (HDPE) bottles. Each bottle contains 30 tablets.  Each bottle is enclosed 
with a white, continuous thread, child -resistant poly propylene screw cap with an induction -
sealed and aluminum- faced liner.
Study drug(s) to be distributed to centers in the US and other participating countries shall be 
labeled to meet applicable requirements of the United States Food and Drug Administration 
(FDA), EU Guideline to Good Manufacturing Practice -Annex 13 (Investigational Medicinal 
Products), and/or other local regulations.
5.2.2.3. Emtricitabine/Tenofovir Alafenamide (F/TAF) 200 mg/25 mg and Placebo to 
Match Tablets
Emtricitabine/t enofovir a lafenamide (F/TAF) 200 mg/25 mg and Placebo to Match tablets are 
packaged in white, high density  polyethylene (HDPE) bottles. Each bottle contains 30 tablets, 
silica gel desiccant, and poly ester packing material.  Each bottle is enclosed with a white, 
continuous thread, child -resistant poly propylene screw cap with an induction -sealed and 
aluminum -faced liner.
Study drug(s) to be distributed to centers in the US and other participating countries shall be 
labeled to meet applicable requirements of the United States Food and Drug Administration 
(FDA), EU Guideline to Good Manufact uring Practice -Annex 13 (I nvestigational Medicinal 
Products), and/or other local regulations.
GS-9883/F/TAF 
Protocol GS -US-380-1490 Final
Gilead Sciences, Inc. Original
CONFIDENTIAL Page45 21 October 20155.2.3. Storage and Handling
Study drugs should be stored at controlled room temperature of 25°C (77°F); excursions are 
permitted between 15°C and 30°C (59°F and 86°F).  Storage conditions are specified on the 
label.  Until dispensed to the subjects, all bottles of study  drugs should be stored in a securel y 
locked area, accessible only  to authorized site personnel.
To ensure the stabilit y and proper identification, studydrug(s) should not be stored in a container 
other than the container in which they  were supplied.
Consideration should be given to handling, preparation, and disposal through measures that 
minimize drug contact with the body . Appropriate precautions shoul d be followed to avoid direct 
eye contact or exposure through inhalation when handling.
5.3. Dosage and Administration of GS-9883/Emtricitabine/Tenofovir 
alafenamide 
and Dolutegravir + Emtricitabine/Tenofovir alafenamide
Study drugs GS -9883/F/TAF FDC , DTG + F/T AF FDC and placebo-to-matchtabletswill be 
provided b y GileadSciences.
Treatment Group 1: FDC of GS
-9883 50 mg/emtricitabine 200 mg/ tenofovir alafenamide 
25mg (GS-9883/F/TAF) + Placebo to match dolutegravir 50 mg and Placebo to match FDC of 
emtricitabi ne 200 mg/tenofovir alafenamide 25 mg (F/TAF) administered orally , once dail y, 
without regard to food 
Treatment Group 2: Dolutegravir 50 mg + FDC of emtricitabine 200 mg/tenofovir alafenamide 
25 mg (F/TAF) + Placebo to match FDC of GS -9883 50 mg/emtricita bine 200 mg/tenofovir 
alafenamide 25 mg (GS-9883/F/TAF) administered orall y, once daily, without regard to food 
Subjects will be instructed to bring all stud y medication in the original container at each clinic 
visit for drug accountability .  The Investigator will be responsible for maintaining accurate 
records for all stud y drug bottles dispensed and tablets returned. The inventory  and dispensing 
logs must be available for inspection by  the study  monitor. Study  medication supplies, including 
partially used or empt y bottles, must be accounted for b y the stud y monitor prior to destruction 
or return. 
5.4. Prior and Concomitant Medications
The use of medications for the treatment of HIV, other than study  drug, is prohibited.
Medications listed in the following table and use of herbal/natural supplements are excluded or 
should be used with caution while subjects are participating in the study .  Subjects will refrain 
from consumption of grapefruit juice and Seville orange juice throughout participation in the
study. 
GS-9883/F/TAF 
Protocol GS -US-380-1490 Final
Gilead Sciences, Inc. Original
CONFIDENTIAL Page46 21 October 2015Table5-1. Prior and Concomitant Medications
Drug Class Agents Disallowed* Use Discouraged and To Be Used With Caution
Acid Reducing Agents
Antacids
Buffered medicationsConcentration of study drug may decrease w ith 
antacids. Subjects may not take antacids (eg, Tums or 
Rolaids); the ulcer medication sucralfate (Carafate); 
or vitamin or mineral supplements that contain 
calcium, iron or zinc for a minimum of 2 hours 
before and 6 hours after any dose o f study drug.
Antiarrhythmic Agent Dofetilide
AnticonvulsantsPhenobarbital, Phenytoin, 
Carbamazepine, Oxcarbazepine
Antimycobacterials Rifampin, Rifapentine
AntiretroviralsAny antiretroviral drug that is 
not part of the study regimen
GI Motility Agents Cisapride
Herbal/Natural 
SupplementsSt. John’s Wort, Echinaccea
Oral Hypoglycemic 
AgentMetformin: close monitoring is recommended. A 
dose adjustment of Metformin may be necessary.  
Limit total daily doses of Metformin to 1000mg 
when initiating study medication or if initiating 
metformin while on study drug.
*Administration of any of the above medications must be discontinued at least 30 days prior to the Day 1 visit and for the 
duration of the study. 
Should subjects have a need to initiate treatment with any  excluded concomitant medication, the 
Gilead Sciences Medical Monitor must be consulted prior to initiation of the new medication. In 
instances where an excluded medication is initiated prior to discussion with the Sponsor, the 
Investigator must notify  Gilead Sciences as soon as he/she is aware of the use of the excluded 
medication.
5.5. Accountability for Investigational Medicinal Product (IMP)
The investigator is responsible for ensuring adequate accountability  of all used and unused IMP. 
This includes acknowledgement of receipt of each shipment of I MP (quantity  and condition). All 
used and unused IMP dispensed to subjects must be returned to the site.
Study Drug accountability  records will be provided to each study  site to:
Record the date received and quantity  of IMP kits 
Record the date, subject number, subject initials, the IMP kit number dispensed
Record the date, quantity of used and unused IMP returned, along with the initials of the 
person recording the information
5.5.1. Investigational Medicinal Product Return or Disposal
Study drug return and disposal will be performed as outlined in Section9.1.7.
GS-9883/F/TAF 
Protocol GS -US-380-1490 Final
Gilead Sciences, Inc. Original
CONFIDENTIAL Page47 21 October 20156. STUDY PROCEDURES
The study  procedures to be conducted for each subject enrolled in the study  are presented in 
tabular form in Appendix 2and described in the text that follows. 
The investigator must document an y deviation from protocol procedures and notify  the sponsor 
orcontract research organization (CRO).
6.1. Subject Enrollment and Treatment Assignment
It is the responsibility  of the Investigator to ensure that subjects are eligible for study  prior to 
enrollment. Please refer to Section 6.3fordetails about randomization and treatment assignment .
6.2. Pretreatment Assessments
6.2.1. Screening Visit
Subjects will be screened within 30 -days before Day  1 to determine eligibility  for participation in 
the study. The following will be performed and documented at screening:
Obtain written in formed consent
Obtain medical history including history  of HIV-1 disease-related events and prior 
medications within 30days of the screening visit
Complete phy sical examination (urogenital/anorectal exams will be performed at the 
discretion of the Investi gator)
12-lead ECG performed supine
Height 
Vital signs measurement (blood pressure, pulse, respiration rate, an d temperature), including 
weight
Urine collection for the following laboratory  procedures:
Urinalysis
Blood sample collection for the followin g laboratory  analyses:
Serum pregnancy  test (females of childbearing potential only ). If the test is positive, the 
subject will not be enrolled
GS-9883/F/TAF 
Protocol GS -US-380-1490 Final
Gilead Sciences, Inc. Original
CONFIDENTIAL Page48 21 October 2015Chemistry  profile: alkaline phosphatase, AST, ALT, GGT, total bilirubin, direct and 
indirect bilirubin, total protein, albumin, LDH, CPK, bicarbonate, BUN, calcium, 
chloride, creatinine, glucose, phosphorus, magnesium, potassium, sodium, uric acid, 
amylase(reflex lipase testing is performed in subjects with total amy lase 1.5ULN) 
and TSH.
Estimated glomerular filtration rate according to the Cockcroft -Gault formula:
Male: (140–age in years) (wt in kg) CLcr (mL/min)
72(serum creatinine in mg/dL)
         (140 –age in years) (wt in kg)         CLcr (mL/sec)
72(serum creatinine in umol/L) 0.6786  
Female: (140–age in years) (wt in kg) 0.85 CLcr (mL/min)
72(serum creatinine in mg/dL)
        (140 –age in years) (wt in kg)          0.85  CLcr (mL/sec)
72(serum creatinine in umol/L) 0. 6786
Hematology  profile: complete blood count (CBC) with differential and platelet count
CD4+ cell count
Plasma HIV -1 RNA 
Hepatitis BVirus (HBV) blood panel: Hepatitis B virus surface antigen serology  
(HBsAg), Hepatitis B virus surface antibody (HBsAb)and Hepatitis B virus core
antibody (HBcAb)
■ The following will be conducted b y the central laboratory if the following criteria are 
met:
○If positive HBsAg, reflex testing f or plasma HBV DNA, HBeAg (if negative, 
reflex HBeAb) and quantitative HBsAg. 
○If positive HBcAb with negative HBsAg 
and negative HBsA b, reflex testing for 
plasma HBV DNA (if positive, reflex HBeAg). If HBeAg is performed and found 
to be negative, reflex HB eAb.
Hepatitis C virus (HCVAb) serology . Subjects who are HCVAb positive will have a 
HCV RNA test performed.  
HIV-1 genotype testing(protease and reverse transcriptase). The HIV
-1 PR/RT genot ype 
testing may  not be performed for subjects that fail to meet other screening criteria.
Review of adverse event s and concomitant medications
GS-9883/F/TAF 
Protocol GS -US-380-1490 Final
Gilead Sciences, Inc. Original
CONFIDENTIAL Page49 21 October 2015Subjects meeting all of the inclusion criteria and none of the exclusion criteria will return to the 
clinic within 30 -days after screening for the Day 1 Visit.
From the time of obtaining informed consent through the first administration of investigational 
medicinal product, record all serious adverse events (SAEs), as well as any adverse events 
related to protocol -mandated procedures on the adverse events case report form (eCRF) .  All 
other untoward medical occurrences observed during the screening period, including 
exacerbation or changes in medical history  are to be captured on the medical history  eCRF.  See 
Section7Adverse Events and Toxicity  Management for additional detail s.
6.2.2. Day 1 Assessments
The following evaluations are to be completed at the Day1 Visit. The Investigator must have 
received the results from the screening genotype report and confirmed eligibility before 
proceeding with the Day 1 visit. The subject must complete all study  procedures before being 
administered the study  drug:
Review of AEs and changes in concomitant medications
Complete phy sical examination (urogenital/anorectal exams will be performed at the 
discretion of the Investigator)
Vital signs meas urement (blood pressure, pulse, respiration rate, and temperature), including 
weight
12-leadECG performed supine
Short Form 36 Health Survey  (SF-36), HIV Sy mptoms Distress Module , Work Productivity  
and Activity  Impairment Questionnaire (WPA I) and Pittsbur gh Sleep Quality  Index (PSQ I) 
to be completed b y the subject.  Subject is to read questionnaire b y himself/herself and 
write/mark answers directly  onto questionnaires.
Urinecollection for the following laboratory  procedures:
Urinalysis
Urine pregnancy  test (females of childbearing potential only ); positive urine pregnancy  
tests will be confirmed with a serum test. If the test is positive, the subject will not be 
able to participate
Urine storage sample for possible additional clinical testing
Blood samplecollection for the following laboratory  analyses:
Chemistry  profile: alkaline phosphatase, AST, ALT, GGT, total bilirubin, direct and 
indirect bilirubin, total protein, albumin, L
DH, CPK, bicarbonate, BUN, calcium, 
chloride, creatinine, phosphorus, magnes ium, potassium, sodium, uric acid, amy lase 
(reflex lipase testing is performed in subjects with total amy lase 1.5ULN)andTSH.
GS-9883/F/TAF 
Protocol GS-US-380-1490 
Gilead Sciences, Inc. Final 
Original 
- Metabolic assessments: Fasting (no food or drinks, except water, at least 8 homs prior to 
blood collection) glucose and lipid panel (total cholesterol, HDL, direct LDL, and 
triglycerides). If the subject has not fasted prior to the visit, the visit may proceed, but the 
subject must retum within 72 homs in a fasted state to draw blood for the metabolic 
assessments. 
-Estimated glomemlar filtration rate according to the Cockcroft-Gault f01mula 
- Hematol ogy profile: complete blood cmmt (CBC) with differential and platelet cmmt 
-Plasma HIV-1 RNA 
- CD4+ cell count 
-Plasma storage sample for safety, virology, or PK testing 
-Subjects who meet the defmition of HBV infection at Screening Visit (positive senun 
HBsAg or Positive HBcAb with quantifiable HBV DNA), will have plasma HBV DNA 
tested. 
• Optional Peripheral Blood Mononuclear cell (PBMC) Substudy: 
• 
• Optional blood sample collection for the following laboratory analyses if 
pharmacogenomic consent is obtained 
I 
I 
I 
I 
CONFIDENTIAL Page 50 21 October 2015 
GS-9883/F/TAF 
Protocol GS -US-380-1490 Final
Gilead Sciences, Inc. Original
CONFIDENTIAL Page51 21 October 20156.3. Randomization
Once eligibility  has been confirmed and prior to or during the Day 1 visit, the Investigator or 
designee will randomize the subject using the Interactive Web Response System (IWRS). Once a 
subject number has been assigned to a subject, it will not be reassigned to any  other subject. The 
subject number assignment and randomization may be performed up to 3 days prior to the 
in-clinic Day 1 visit provided that all screening procedures have been completed and subject 
eligibility  has been confirmed.
6.4. Treatment Assessments (Week 4 -96)
The following evaluations are to be completed at the end of Weeks 4,8, 12, 24, 36, 48, 60, 72, 
84 
and96 unless otherwise specified .  
Study visits are to be completed within ± 2 day s of the protocol -specified visit date based on the 
Day 1 visit through Week 12 and completed within ± 6 day s of the protocol -specified visit date 
through Week 96, unless otherwise specified.  The visit window at Weeks48 willand96 willbe 
± 6 weeks of the protocol -specified visit date, and these clinical visit windows coincide with the 
Week 48 and Week 96 statistical anal ysis window for HIV -1 RNA.
Regularly  scheduled evaluations will be made on all subjects whether or not they  continue to 
receive study  drug.
Review of AEs and changes in concomitant medications
Complete physical examination (Weeks24 and 48) (urogenital/anorectal exams will be 
performed at the discretion of the Investigator) or sy mptom-directed phy sical examination as 
needed 
Vital signs measurement (blood pressure, pulse, respiration rate, and temperature), including 
weight
12-leadECG perfo rmed supine (Weeks 24and 48)
Short Form 36 Health Survey  (SF-36), HIV Sy mptoms Distress Module , Work Productivity  
and Activity  Impairment Questionnaire (WPA I) and Pittsburgh Sleep Quality  Index (PSQ I) 
to be completed b y the subject at Weeks 4, 12 and 48. Subject is to read questionnaire b y 
himself/herself and write/mark answers directl y onto questionnaires.
Urine collection for the following laboratory  procedures:
Urinalysis
Urine pregnancy  test (females of childbearing potential only ); positive urine pre gnancy 
tests will be confirmed with a serum test. If the test is positive, the subject will be 
discontinued
Urine storage sample for possible additional clinical testing
GS-9883/F/TAF 
Protocol GS -US-380-1490 Final
Gilead Sciences, Inc. Original
CONFIDENTIAL Page52 21 October 2015Blood sample collection for the following laboratory  analyses:
Chemistry  profile: alkaline phosphatase, AST, ALT, GGT, total bilirubin, direct and 
indirect bilirubin, total protein, albumin, LDH, CPK, bicarbonate, BUN, calcium, 
chloride, creatinine, glucose, phosphorus, magnesium, potassium, sodium, uric acid, and 
amylase (reflex lipase testing is performed in subjects with total amy lase 1.5ULN). 
At Weeks 12, 24, 48, 72 and 96 analyses of glucose will be done as part of the fasting 
metabolic assessments and not as part of the chemistry  profile. At Weeks 24, 48, 72
and96,TSH will also be anal yzed.
Metabolic assessments: Fasting (no food or drinks, except water, at least 8 hours prior to 
blood collection) glucose and lipid panel (total cholesterol, HDL, direct LDL , and 
triglycerides). If the subject has not fasted prior to the visit, the visit may  proceed, but the 
subject must return within 72 hours in a fasted state to draw blood for the metabolic 
assessments. (Weeks 12, 24, 48, 72 and 96)
Estimated glomerular filtration rate according to the Cockcroft- Gault formula 
Hematology  profile: complete blood count (CBC) with differential and platelet count
Plasma HIV -1 RNA
CD4+ cell count
Plasma storage sample for safety, virology , or PK testing
Plasma HBV DNA (for subjects who meet the defini tion of HBV infection)
■ At Weeks 12, 24 and 48 (for subjects who meet the definition of HBV infection) the 
following will be conducted by  the central laboratory : HBsAb, HBsAg (qualitative 
and quantitative) and HBeAg (if negative, reflex HBeAb)
Pharmacokinet ic Blood Collection for subjects who are on stud y drug. Details of 
pharmacokinetic blood sampling procedures and sample management will be documented in 
the Pharmacokinetic Sample Collection, Processing, Storage, and Shipment Manual .
Single Anytime, Trough and Post Dose PK Samples for all subjects on study drug: 
■ Subjects will have a single anytime pre or post -dose PK blood at Weeks 8, 24 
and36.
GS-9883/F/TAF 
Protocol GS-US-380-1490 
Gilead Sciences, Inc. Final 
Original 
• Observed dosing at the clinic: Subjects will have a trough PK blood sample collected 
between 20-28 hours following their last dose at Weeks 4 and 12. Subjects must be 
instructed to not take their study <hugs on the moming of their visit for the tr·ough 
sample collection. Subjects will then take an observed dose of study <hug at the clinic. 
A single post dose PK blood sample will be collected between 1 and 4 hours post 
dose. If the subject has taken their dose of study <hugs prior to the visit, the visit may 
proceed, but the subject must retum within 72 hours for the tr·ough PK blood sample 
collection. In the event a subject routinely takes their study dmg in the evening, a 
single post dose sample may be <h·awn at Weeks 4 and 12 as the subject will not be 
instructed to change their dosing time to accommodate this tr·ough PK <h·aw. 
• Dosing diaries will be collected from subjects for the single anytime PK and tr·ough 
PK collection. If a dosing diaty is not retumed the site may ask the subject for the 
time of the last dose and if it was taken with or without food. 
-Optional Pharmacokinetic (PK) Substudy: 
• Optional Peripheral Blood Mononuclear cell (PBMC) Substudy: 
I 
I 
I 
CONFIDENTIAL Page 53 21 October 2015 
GS-9883/F/TAF 
Protocol GS -US-380-1490 Final
Gilead Sciences, Inc. Original
CONFIDENTIAL Page54 21 October 20156.5. Treatment Assessments (Post Week 96 until the Unblinding Visit)
6.5.1. Post Week 96 Assessments
After Week 96, subjects will continue to take their blinded study  drugs and attend visits every  
12 weeks until treatment assignments have been unblinded, at which point they  will return for an 
Unblinding Visit (refer to Section 
6.5). Study  visits are to be completed within 6days of the 
protocol-specified visit date unless otherwise specified.
At the Week 96 Visit, subjects in the United Kingdom will stop taking study drug and complete a 
30 day follow up visit and return to the standard of care.
Review of AEs and changes in concomitant medications
Symptom-directed phy sical examination as needed
Vital signs measurement (blood pressure, pulse, respiration rate, and temperature), including 
weight
Urinecollection for the following laboratory  procedures:
Urinalysis
Urine pregnancy  test (females of childbearing potential only ); positive urine pregnancy  
tests will be confirmed with a serum test. If the test is positive, the subject will be 
discontinued.
Urine storage sample for possible additional clinical testing
Blood samplecollection for the following laboratory  analyses:
Chemistry  profile: alkaline phosphatase, AST, ALT, GGT, total bilirubin, direct and 
indirect bilirubin, total protein, albumin, L
DH, CPK, bicarbonate, BUN, calcium, 
chloride, creatinine, glucose, phosphorus, magnesium, potassium, sodium, uric acid, and 
amylase (reflex lipase testing is performed in subjects with total amy lase 1.5ULN).
Every 24 weeks , analyses of glucose will be done as part of the fasting metabolic 
assessments and not as part of the chemistry  profile.In addition, TSHwill also be 
analyzedevery 24 weeks.
Metabolic assessments: Fasting(no food or drinks, except water, at least 8 hours prior to 
blood collection) glucose and lipid panel (total cholesterol, HDL, direct LDL , and 
triglycerides). If the subject has not fasted prior to the visit, the visit may  proceed, but the 
subject must return within 72 hours in a fasted state to draw blood for the metabolic 
assessments. (Every 24 weeks)
Estimated glomerular filtration rate according to the Cockcroft -Gault formula
GS-9883/F/TAF 
Protocol GS -US-380-1490 Final
Gilead Sciences, Inc. Original
CONFIDENTIAL Page55 21 October 2015Hematology  profile: comple te blood count (CBC) with differential and platelet count
Plasma HIV -1 RNA
CD4+ cell count
Plasma storage sample for safety, virology , or PK testing
Plasma HBV DNA (for subjects who meet the definition of HBV infection)
Subjects who meet the criteria for virologic failurewill be managed according to the 
Management of V irologic Rebound Section 6.12.1and 6.12.2.
Document study drug dispensation and accountability  for all study  drugs dispensed.
6.5.2. Unblinding Visit
Once Gilead Sciences provides unblinded treatment assignments to the Investigators, all subjects 
will return to the clinic (within 30 days± 6 days) for an Unblinding Visit .At the Unblinding 
Visit, subjects in a country where GS -9883/F/TAF FDC is not available will be given the option 
to receive GS-9883/F/TAF FDC in an open label extension phase for 48 weeks, or until the 
product becomes accessible to subjects through an access program, or until Gi leadSciences 
elects to discontinue the study  in that country , whichever occurs first . 
Subjects who receive the open-labelGS-9883/F/TAF FDC will r eturn for study  visits every  
12weeks.
Subjects who 
choose to not receive the open label GS- 9883/F/TAF FDC w ill be required to 
return to the clinic for a 30-Day Follow-up visit following the Unblinding Visit.   Subjects who 
have discontinued drug study prior to the Unblinding Visit will not be eligible for the open- label 
rollover extension; these subjects will be asked to continue attending the scheduled study  visits 
through the Unblinding Visit and discontinue the study  after the Unblinding Visit.
The following will be performed at the Unblinding Visit:
Review of AEs and changes in concomitant medications
Complete physical examination (urogenital/anorectal exams will be performed at the 
discretion of the Investigator)
Vital signs measurement (blood pressure, pulse, respiration rate, and temperature), including 
weight
12-lead ECG performed supine
Urine collection for the following laboratory  procedures:
Urinalysis
GS-9883/F/TAF 
Protocol GS -US-380-1490 Final
Gilead Sciences, Inc. Original
CONFIDENTIAL Page56 21 October 2015Urine pregnancy  test (females of childbearing potential only ); positive urine pregnancy  
tests will be confirmed with a serum test. If the test is positive, the subject will not be 
able to participate.
Urine storage sample for possible additional clinical testing
Blood sample collection for the following laboratory  analyses:
Chemistry  profile: alkaline phosphatase, AST, ALT, GGT, total bilirubin, direct and 
indirect bilirubin, total protein, albumin, L DH, CPK, bicarbonate, BUN, calcium, 
chloride, creatinine, phosphorus, magnesium, potassium, sodium, uric acid, and am ylase 
(reflex lipase testing is performed in subjects with total amy lase 1.5ULN), and TSH
Metabolic assessments :Fasting(no food or drinks, except water, at least 8 hours prior to 
blood collection) glucose and lipid panel (total cholesterol, HDL, direct LDL , and 
triglycerides). If the subject has not fasted prior to the visit, the visit may  proceed, but the 
subject must re turnwithin 72 hours in a fasted state to draw blood for the metabolic 
assessments .
Estimated glomerular filtration rate according to the Cockcroft -Gault formula
Hematology  profile: complete blood count (CBC) with differential and platelet count
Plasma HIV -1 RNA
CD4+ cell count
Plasma storage sample for safety, virology , or PK testing
Plasma HBV DNA (for subjects who meet the definition of HBV infection)
Document study  drug dispensation, if applicable, and accountability  for all study  drugs 
dispensed
Subjects who wish to continue in the Open -Label Rollover extension study will receive open 
label GS-9883/F/TAF.
6.6. Post-treatment Assessments
6.6.1. Early Study Drugs Discontinuation Assessments
If the subject discontinues s tudy drugprior to the Unblinding Visit, the sub ject will be asked to 
return to the clinic within 72 hours of stopping study  drugs for the Earl y Study Drugs 
Discontinuation Visit. The subject will be asked to continue attending the scheduled study visits 
through the Unblinding Visit.
GS-9883/F/TAF 
Protocol GS -US-380-1490 Final
Gilead Sciences, Inc. Original
CONFIDENTIAL Page57 21 October 2015At the Early Study Drugs Discontinuation Visit, any evaluations showing abnormal results 
indicating that there is a possible or probable causal relationship with the study drug , will
be repeated weekly (or as often as deemed prudent by the Investigator) until the 
abnormality is resolved, returns to Day 1, or is otherwise explained.
The following evaluations are to be completed at the Earl y Study Drugs Discontinuation Visit:
Review of AEs and changes in concomitant medications
Complete phy sical examination (urogenital/anorecta l exams will be performed at the 
discretion of the Investigator)
12-lead ECG performed supine
Vital signs measurement (blood pressure, pulse, respiration rate, and temperature), including 
weight
Urine collection for the following laboratory  procedures:
Urinalysis
Urine pregnancy  test (females of childbearing potential only ); positive urine pregnancy  
tests will be confirmed with a serum test
Urine storage sample for possible additional clinical testing
Blood sample collection for the following laboratory analyses:
Chemistry  profile: alkaline phosphatase, AST, ALT, GGT, total bilirubin, direct and 
indirect bilirubin, total protein, albumin, LDH, CPK, bicarbonate, BUN, calcium, 
chloride, creatinine, glucose, phosphorus, magnesium, potassium, sodium, uric aci d, and 
amylase (reflex lipase testing is performed in subjects with total amy lase 1.5ULN), 
and TSH
Estimated glomerular filtration rate according to the Cockcroft -Gault formula
Hematology  profile: complete blood count (CBC) with differential and plate let count
Plasma HIV -1 RNA
CD4+ cell count
Plasma storage sample for safety, virology , or PK testing
Plasma HBV DNA (for subjects who meet the definition of HBV infection)
HIV
-1 genotype/phenotype testing for subjects with virologic failure
Drug accountabi lity
GS-9883/F/TAF 
Protocol GS -US-380-1490 Final
Gilead Sciences, Inc. Original
CONFIDENTIAL Page58 21 October 20156.6.2. 30 Day Follow Up
Subjects who complete the study  through the Unblinding visit and who do not participate in the 
open-label rollover extension, will be required to return to the clinic 30 days after the completion 
of study drug for the 30 Day  Follow Up visit.
Subjects in the United Kingdom will complete a 30 day  follow up visit after the completion of 
the Week 96 visit and return to the standard of care.
Subjects who permanently discontinue stud y drug during the blinded phase and refuse to 
continue in t he study through the Unblinding Visit will be asked to return to the clinic 30 days 
after the completion of the Earl y Study Drug sDiscontinuation Visit for the 30- Day Follow-Up 
Visit.
Those subjects who permanently discontinue study drug and continue in th e study through 
at least one subsequent visit after the Early Study Drug Discontinuation Visit will notbe 
required to complete the 30 -Day Follow -Up Visit.
For the purpose of scheduling a 30 -Day Follow-Up Visit, a  6 days window may  be used. 
Thefollowing evaluations are to be completed at the 30- Day Follow-Up Visit:
Review of AEs and changes in concomitant medications
Symptom-directed phy sical examination
Vital signs measurement (blood pressure, pulse, respiration rate, and temperature), including 
weight
Urine collection for the following laboratory  procedures:
Urinalysis
Urine pregnancy  test (females of childbearing potential only ); positive urine pregnancy  
tests will be confirmed with a serum test.
Blood samplecollection for the following laboratory  analyses:
Chemistry  profile: alkaline phosphatase, AST, ALT, GGT, total bilirubin, direct and 
indirect bilirubin, total protein, albumin, L
DH, CPK, bicarbonate, BUN, calcium, 
chloride, creatinine, glucose, phosphorus, magnesium, potassium, sodium, uric acid , and 
amylase (reflex lipase testing is performed in subjects with total amy lase 1.5ULN).
Estimated glomerular filtration rate according to the Cockcroft -Gault formula
Hematology  profile: complete blood count (CBC) with differential and platelet count
Plasma HIV -1 RNA
CD4+ cell count
GS-9883/F/TAF 
Protocol GS -US-380-1490 Final
Gilead Sciences, Inc. Original
CONFIDENTIAL Page59 21 October 2015At the 30-Day Follow-Up Visit, any  evaluations showing abnormal results believed to be a 
reasonable possibility  of a causal relationship with the study  drugs will be repeated weekl y (or as 
often as deemed prudent by  the Investigator) until the abnormality  is resolved, returns to 
baseline, or is otherwise explained. 
6.7. Criteria for Discontinuation of Study Treatment
Study medication may  be discontinued in the following instances:
Intercurrent illness that would, in the judgmen t of the investigator, affect assessments of 
clinical status to a significant degree . Following resolution of intercurrent illness, the subject 
may resume study  dosing at the discretion of the investigator
Unacceptable toxicity , ortoxicity that, in the ju dgment of the investigator, compromises the 
ability to continue study -specific procedures or is considered to not be in the subject’s best 
interest
Lack of efficacy
Subject request to discontinue for an y reason
Subject noncompliance
Pregnancy  during the st udy; refer to Appendix 6
Development of active tuberculosis infection
Discontinuation of the study  at the request of Gilead, a regulatory  agency or an institutional 
review board or independent ethics committee (IRB/IEC)
6.8. Blood and Urine Storage
A portion of the blood and urine samples drawn at all visits (except the Screening Visit, 30- day 
follow-up VisitandUnscheduled Visits) will be frozen and stored. These stored blood and urine 
samples may  beused by the Sponsor or its research partners for HIV -1 genotyping/phenot yping 
assays or their development, for retesting the amount of HIV -1 in the blood, for measurement of 
antiviral drug levels in the blood, or for testing to learn more about how the study  drug has 
worked against HIV-1 or clinical laboratory testing to provide additional safety  data. No human 
genetic testing will be performed without expressed consent of study  subjects. At the conclusion 
of this study ,these samples may  be retained in storage by  Gilead Sciences for a period up to 
15years.
6.9. Assessments for Premature Discontinuation from Study
If a subject discontinues study  dosing (for example, as a result of an AE), every  attempt should 
be made to keep the subject in the study  and continue to perform the required study -related 
follow-up and 
procedures (see Section 6.7, Criteria for Discontinuation of Study  Treatment ).If 
this is not possible or acceptable to the subject or investigator, the subject may  be withdrawn 
from the study .
GS-9883/F/TAF 
Protocol GS -US-380-1490 Final
Gilead Sciences, Inc. Original
CONFIDENTIAL Page60 21 October 20156.10. End of Study
The end of stud y will be the last patient’s last observation (or visit). 
6.11. Post Study Care
After a subject has completed/terminated their participation in the study , long-term care for the 
subject will remain the responsibility  of their primary  treating ph ysician.
6.12. Virologic Failure
Virologic failure is defined as virologic rebound or having HIV -1 RNA≥ 50 copies/mL at study
drug discontinuation, Week 48 or Week 96 .
6.12.1. Management of Virologic Rebound
Subjects who meet the criteria listed below will be considered to have virologic rebound:
At any visit, after a chieving HIV -1 RNA < 50 copies/mL , a rebound in HIV -1 RNA 
≥ 50copies/mL , which is subsequently  confirmed at the following scheduled or unscheduled 
visit; OR
At any visit, a  1log10increase in HIV -1 RNA from the nadir which is subsequently  
confirmed at the following scheduled or unscheduled visit
Following the unconfirmed virologic rebound, subjects will be asked to return to the clinic for a 
scheduled or unscheduled blood draw (2 to 3 weeks after the date of the original test that resulted 
in HIV-1 RNA virologic rebound) for confirmation of virologic rebound. If virologic rebound is 
confirmed at the scheduled or unscheduled visit and the HIV -1 RNA is ≥ 200 copies/mL , the 
blood sample from the confirmation visitwill be the primary  sample used for HIV -1 genotypic 
and phenotypictesting.  Subjects with documented non -adherence within 72 hours of the visit 
may not be tested for resistance. After a subject’s first post -baseline resistance test, additional 
testing will be conducted on a case -by-case basis. Any subject may  be discontinued at 
Investigator’s discretion or per local treatment guidelines.
If no resistance is detected from the genot ype or phenotype, the subject may remain on study 
drugs and a repeat HIV -1 RNA should be repeated (2 to 3 weeks after date of test with HIV -
1 
RNA ≥ 50 copies/mL). Investigators should carefully  evaluate the benefits and risks of 
remaining on stud y drug for each individual subject and document this assessment in the on -site 
medical record. 
Subjects who are noncompliant on a n ongoing basis will be considered for discontinuation per 
the Investigator’s discretion or local treatment guidelines. Investigators who opt to discontinue 
study drugs for an individual subject must discuss with the Medical Monitor prior to study  drug 
discontinuation. 
For subjects who are off study  drug but remain on study , it will be the Investigator’s discretion to 
manage virologic rebound.
GS-9883/F/TAF 
Protocol GS -US-380-1490 Final
Gilead Sciences, Inc. Original
CONFIDENTIAL Page61 21 October 2015Please refer to Figure6-1for the management of subjects who meet the criteria for virologic 
rebound.
Figure6-1. Virologic Rebound Schema
a.If virologic rebound is not confirmed, the subject will remain on their current regimen.
b.If virologic rebound is confirmed and the HIV -1 RNA is ≥ 200 copies/mL, the HIV -1 genotype and phenotype (reverse 
transcriptase, protease and integrase) will be analyzed.
c.Based on the results of the genotypic and phenotypic assays, the subject will remain on study drugs or study drugs will be 
discontinued. If genotyping or phenotyping a ssay fails, a new ARV regimen may be configured at the discretion of the 
Investigator.
d.If no resistance is detected, HIV -1 RNA will be repeated (2 -3 weeks later).  Investigator reviews study drug 
continuation/discontinuation options and discuss with the Me dical Monitor prior to study drug discontinuation
e.A new ARV regimen will be configured, at the Investigator’s discretion, and the subject will remain in the study.
6.12.2. Subjects with HIV -1 RNA ≥ 50 copies/mL at Study Discontinuation, Week 48 
or Week 96
Subjectswith HIV-1 RNA ≥ 50 copies/mL  at study discontinuation or last visit will be 
considered virologic failures. Subjects with HIV -1 RNA ≥ 50 copies/mL  at Week 48 or Week 96 
will be asked to return for an unscheduled visit within the visit window for a retest.
Subjects with HI V-1 RNA ≥ 200 copies/mL  at study drug discontinuation, last visit, Week 48, or 
Week96 will also have resistance testing conducted . 

GS-9883/F/TAF 
Protocol GS -US-380-1490 Final
Gilead Sciences, Inc. Original
CONFIDENTIAL Page62 21 October 20157. ADVERSE EVENTS AND TOXICITY  MANAGEMENT
7.1. Definition sof Adverse Events , Adverse Reactions, and Serious Adve rse 
Events
7.1.1. Adverse Events
An adverse event (AE) is any  untoward medical occurrence in a clinical study  subject 
administered a medicinal product, which does not necessarily  have a causal relationship with the 
treatment. An AE can therefore be an y unfavorabl e and/or unintended sign, sy mptom, or disease 
temporally  associated with the use of a medicinal product, whether or not considered re lated to 
the medicinal product. AEs may also include pre -or post-treatment complications that occur as a 
result of protocol specified procedures, lack of efficacy , overdose ,drug abuse/misuse reports , or 
occupational exposure .Preexisting events that increase in severit y or change in nature during or 
as a consequence of participation in the clinical study  will also be conside red AEs.
An AE does not include the following:
Medical or surgical procedures such assurgery, endoscopy ,tooth extraction, and transfusion. 
The condition that ledto the procedure may  be an adverse event and must be reported.
Pre-existing diseases, conditions, or laboratory  abnormalities present or detected beforethe 
screening visit that donot worsen
Situations where an untoward medical occurrence has not occurred (e.g. ,hospitalization for 
elective surgery , socialand/or convenience admissions)
Overdose without clinical sequelae (see Section 7.6.1)
Any medical condition or clinically  significant laboratory  abnormality  with an onset date 
before the consent form is signed and not related to a protocol -associated procedure is not an 
AE. It is consid ered to be pre -existing and should be documented on the medical history  
eCRF.
7.1.2. Serious Adverse Events
A serious adverse event (SAE) is defined as an event that, at any dose, results in the following:
Death
Life-threatening (Note: The term “life -threatening” in the definition of “serious” refers to an 
event in which the subject was at risk of death at the time of the event; it does not refer to an 
event that h ypotheticall y might have caused death if it were more severe.)
In-patient hospitalization or prolongation of existing hospitalization
GS-9883/F/TAF 
Protocol GS -US-380-1490 Final
Gilead Sciences, Inc. Original
CONFIDENTIAL Page63 21 October 2015Persistent or significant disability /incapacit y
A congenital anomal y/birth defect
A medically important eventor reaction: such events may  not be immediately  
life-threatening or result in death or hospitalization but may  jeopardize the subjector may 
require intervention to prevent one of the other outcomes constituting SAEs. Medical and 
scientific judgment mustbe exercised to determine whether such an event is reportable under 
expedited r eporting rules. Examples of m edically important e vents include intensive 
treatment in an emergency room or at home for allergic bronchospasm; blood dyscrasias or 
convulsions that do not result in hospitalization; anddevelopment of drug dependency  or 
drug abuse. For the avoidance of doubt, infections resulting from contaminated medicinal 
product will be considered a m edically important e vent and subject to expedited reporting 
requirements.
7.1.3. Clinical Laboratory Abnormalities and Other Abnormal Assessments as 
Adverse Events or Serious Adverse Events
Laboratory  abnormalities without clinical significance are not recorded as AEs or SAEs. 
However, laboratory  abnormalities (eg, clinical chemistry , hematology , and urinaly sis) that 
require medical or surgical interve ntion or lead to IMP interruption, modification, or 
discontinuation must be recorded as an AE, as well as an SAE, if applicable. I n addition, 
laboratory  or other abnormal assessments (eg, electrocardiogram, x- rays, vital signs) that are 
associated with sig ns and/or sy mptoms must be recorded as an AE or SAE if they  meet the 
definition of an AE or SAE as described in Sections 7.1.1and 7.1.2. If the laboratory  
abnormality is part of a sy ndrome, record the s yndrome or diagnosis (eg, anemia), not the 
laboratory result (ie, decreased hemoglobin).
For specific information on handling of clinical laboratory  abnormalities in this study , please 
refer to Section 7.5
.
7.2. Assessment of Adverse Events and Serious Adverse Events
The investigator or qualified subinvestigator is responsible for assessing AEs and SAEs for 
causality and severity , and for final review and confirmation of accuracy  of event information 
and assessments
.
7.2.1. Assessment of Causality for Study Drugs and Procedures
The investigator or qualified subinvestigat or is responsible for assessing t he relationship to IMP
therapy using clinical judgment and the following considerations:
No: Evidence exists that the adverse event has an etiology  other than the IMP. For SAEs, an 
alternative causality  must be provided (eg , pre-existing condition, underl ying disease, 
intercurrent illness, or concomitant medication).
Yes:There is reasonable possibility  that the event may  have been caused by the 
investigational medicinal product.
GS-9883/F/TAF 
Protocol GS -US-380-1490 Final
Gilead Sciences, Inc. Original
CONFIDENTIAL Page64 21 October 2015It should be emphasized that ineffective trea tment should not be considered as causall y related in 
the context of adverse event reporting. 
The relationship to study  procedures (eg, invasive procedures such as venipuncture or biops y) 
should be assessed using the following considerations:
No: Evidence exists that the adverse event has an etiology  other than the study  procedure.
Yes:The adverse event occurred as a result of protocol procedures, (eg,venipuncture)
7.2.2. Assessment of Severity
AE severit y should be recorded and graded according to the GSI Grading Scale for Severity  of 
Adverse Events and Laboratory  Abnormalities ( Appendix 4). For adverse events associated with 
laboratory  abnormalities, the event should be graded on the basis of the clinical severit y in the 
context of the underly ing condition s; this may  or may not be in agreement with the grading of 
the laboratory abnormality .
The distinction between the seriousness and the severity  of an adverse event should be noted. 
Severe is a measure of intensity ; thus, a severe reaction is not necessaril y a serious reaction. For 
example, a headache may be severe in intensity, but would not be classified as serious unless it 
met one of the criteria for serious events.
For AEs associated with laboratory  abnormalities, the event should be graded on the basis of the 
clinical severit y in the context of the underlying conditions; this may or may not be in agreement 
with the grading of the laboratory  abnormality .
7.3.
Investigator Requirements and Instructions for Reporting Adverse Events 
and Serious Adverse Events to Gilead 
Requirements for collection prior to study  drug initiation:
After informed consent, but prior to initiation of study  medication, the following t ypes of events 
should be reported on the eCRF:
all SAEs and adverse events related to protocol -mandated procedures.
7.3.1. Adverse Events
Following initiation of study  medication, collect a ll AEs, regardless of cause or relationship, 
until 30-days after last administration of study  IMP must be reported to the eCRF database as 
instructed.
All AEs should be followed up until resolution or until the adverse event is stable, if possible. 
Gilead Sciences may  request that certain AEs be followed bey ond the protocol defined follow up 
period.
GS-9883/F/TAF 
Protocol GS -US-380-1490 Final
Gilead Sciences, Inc. Original
CONFIDENTIAL Page65 21 October 20157.3.2. Serious Adverse Events
All SAEs, regardless of cause or relationship, that occu rsafter the subject first consents to 
participate in the stud y (i.e, signing the informed consent) and throughout the duration of the 
study, including the protocol -required post treatment follow -up period, must be reported to the 
eCRF database and Gilead Drug Safet y and Public Health (DSPH) as instructed. This also 
includes an y SAEs resulting from protocol- associated procedures performed after informed 
consent is signed.
Any SAEs and deaths that occur after the post treatment follow -up visit but within 
30-days or 
4weeks of the last dose of study  IMP, regardless of causalit y, should also be reported . 
Investigators are not obligated to activel y seek SAEs after the protocol defined follow up period 
however, if the investigator learns of an y SAEs that occur after stud y participation has concluded 
and the event is deemed relevant to the use of IMP, he/she should promptly  document and report 
the event to Gilead DSPH .
Electronic Serious Adverse Event (eSAE) Reporting Process
Site personnel record all SAE data in the eCRF database and from there transmit the SAE 
information to Gilead DSPH within 24 hours of the investigator’s knowledge of the event. 
Detailed instructions can be found in the eCRF completion guidelines.
If it is not possible to record and submit the SAE information electronicall y, because the 
eCRF database cannot be accessed or is not available (including at study  start),record the 
SAE on the paper serious adverse event report form and submit by fax or email within 
24hoursof the investigator’s knowledge of the event to:
Gilead DSPH contact information:Email: Safety_FC@gilead.com
Fax: +1 (650) 522-5477
As soon as it is possible to do so, any SAE reported via paper must be transcribed into the 
eCRF Database according to instructions in the e CRF completion guidelines.
If an SAE has been reported via a paper form because the eCRF database has been locked, no 
further action is necessary.
All AEs and SAEs will be recorded in the eCRF database within the timelines outlined in the
eCRF completion guideline. 
For fatal or life -threatening events, copies of hospital case reports, autops y reports, and other 
documents are also to be submitted by  e-mail or fax only  when requested and applicable. 
Transmission of such documents should occur without personal subject identification, 
maintaining the traceability  of a document to the subject identifiers.
GS-9883/F/TAF 
Protocol GS -US-380-1490 Final
Gilead Sciences, Inc. Original
CONFIDENTIAL Page66 21 October 2015Additional information may  be requested to ensure the timely  completion of accurate safet y 
reports.
Any medications necessary  for treatment of the SAE must be recorded onto the concomitant 
medication section of the subject’s eCRF and the event description section of the SAE form.
7.4. Gilead Reporting Requirements
Depending on relevant local legislation or regulations, including the applicable US FDA Code of 
Federal Regulations, the EU Clinical Trials Directive (2001/20/EC) and relevant updates, and 
other country -specific legislation or regulations, Gilead may  berequired to expedite to 
worldwide regulatory  agencies reports of SAEs, serious adverse drug r eactions (SADRs) ,or 
suspected 
unexpected serious adverse reactions (SUSARs). In accordance with the EU Clinical 
Trials Directive (2001/20/EC), Gilead or a specified designee will notify  worldwide regulatory  
agenciesand the relevant IECin concerned Member States of applicable SUSARs as outlined in 
current regulations.
Assessment of e xpectedness forSAEs will be determined by  Gilead using reference safety  
information specified in the i nvestigator’s brochure or relevant local label as applicable. 
All investigators will receive a safet y letter notifying them of relevant SUSAR reports associated 
with any study IMP. The investigator should notify  the IRB or IEC of SUSAR reports as soon as 
is practical, where this is required b y local regulatory agencies, and in accordance with the local 
institutional policy . 
7.5. Toxicity Management 
All clinical and clinically significant laboratory toxicities will be managed according to uniform 
guidelines detailed in Appendix 3as outlined below.
Clinical events and clinica lly significant laboratory  abnormalities will be graded according to 
the GSIGrading Scale for Severit y of Adverse Events and Laboratory Abnormalities 
(Appendix 4). 
Grade 3 and 4 clinicall y significant laboratory  abnormalities should be confirmed by  repeat 
testing within 3 calendar days of receipt of results and before investigational medicinal 
product discontinuation, unless such a delay  is not consistent with good medical practice
Any questions regarding toxicity  management should be directed to the Gilead Medical 
Monitor.
7.5.1. Grades 1 and 2 Laboratory Abnormality or Clinical Event
Continue study  drug at the discretion of the Investigator.
GS-9883/F/TAF 
Protocol GS -US-380-1490 Final
Gilead Sciences, Inc. Original
CONFIDENTIAL Page67 21 October 20157.5.2. Grade 3 Laboratory Abnormality or Clinical Event
For Grade 3 clinically  significant laboratory  abnormality  or clinical event, investigational 
medicinal product may  be continued if the event is considered to be unrelated to
investigational medicinal product.
For a Grade 3 clinical event, or clinicall y significant laboratory abnormality confirmed b y 
repeat testing, that is c onsidered to be related to investigational medicinal product, 
investigational medicinal product should be withheld until the toxicity  returns to Grade2.
When restarting investigational medicinal product following resolution of the adverse event, 
the investigational medicinal product should be restarted at full dose upon discussion with 
the Gilead Sciences Medical Monitor.
If a laboratory  abnormality  recurs to Grade 3 following rechallenge with investigational 
medicinal product and is considered related to investigational medicinal product, then 
investigational medicinal product should be permanently  discontinued and the subject 
managed according to local practice. Recurrence of laboratory  abnormalities considered 
unrelated to investigational medicinal p roduct may not require permanent discontinuation but 
requires discussion with the Gilead Sciences Medical Monitor.
7.5.3. Grade 4 Laboratory Abnormality or Clinical Event
For a Grade 4 clinical event or clinicall y significant Grade 4 laboratory abnormality 
confirmed b y repeat testing that is considered related to investigational medicinal product, 
investigational medicinal product should be permanently  discontinued and the subject 
managed according to local practice. The subject should be followed as clinica lly indicated 
until the laboratory  abnormality  returns to baseline or is otherwise explained, whichever 
occurs first. A clinically  significant Grade 4 laboratory abnormalit y that is not confirmed b y 
repeat testing should be managed according to the algorit hm for the new toxicity  grade.
Investigational medicinal product may  be continued without dose interruption for a clinically  
non-significant Grade 4 laboratory  abnormality  (eg, Grade 4 CK after strenuous exercise, or 
triglyceride elevation that is nonfasti ng or that can be medicall y managed) or a clinical event 
considered unrelated to investigational medicinal product requires discussion with the Gilead 
Sciences Medical Monitor.
7.5.4. On-Treatment ALT Flare and Post -
Treatment Exacerbation of Hepatitis B
Managemen t
In On-Treatment ALT Flare is defined as:
Confirmed (within 3 days of receipt of initial laboratory  results) serum ALT 
>2 ×Day1 
value and >10 × ULN, with or without associated sy mptoms.
GS-9883/F/TAF 
Protocol GS -US-380-1490 Final
Gilead Sciences, Inc. Original
CONFIDENTIAL Page68 21 October 20157.5.4.1. Management of ALT Flare in Subjects Receiving Study  Medication
If laboratory  results indicate elevation of ALT  2 × Day 1 value and 10 × ULN, the following 
is recommended:
Schedule the subject to return to the clinic as soon as possible (ideall y within 3 days after
initial laboratory  results were drawn). During the vis it, a clinical assessment of the subject 
will be performed. The assessment should include a phy sical examination and evaluation of 
the subject’s mental status.
If the ALT elevation is confirmed, request the central clinical laboratory  to conduct reflex
testing for plasma HBV DNA, HBV serology  (HBsAg and HBsAb), HDV, HAV IgM, and 
HCV serology
Check the following laboratory  parameters: serum AL T and AST, total bilirubin, I NR, and serum 
albumin. Based on the results of the confirmatory  tests, the following treatment modifications are 
recommended:
Elevated Liver Enzymes, Normal or Stable relative to Day 1 Liver Function Tests 
If ALT levels are elevated (i.e., 2 ×Day 1 and 10 ×ULN) with normal or stable total 
bilirubin and I NR relative to Day  1, the subject may  remain on study  medication and should be 
monitored weekl y as long as ALT levels return to normal or Day  1 level.  During monitoring, if 
the ALT values remain persistently elevated, the Investigator should discuss with the Gilead 
Medical Monitor whether the study drug should be discontinued.  
Elevated Liver Enzymes, Elevated Liver Function Tests
If ALT values are elevated (i.e., 2 ×Day 1 and 10 ×ULN), and total bilir ubin is confirmed to 
be 2 x Day  1 value, and INR is 0.5 above Day  1, provided both are > ULN,  the investigator 
should consider discontinuing stud y medication (upon discussion with the Gilead Medical 
Monitor, unless the safety  of the patient is of immediate concern).  The subject should be 
monitored weekl y as long as ALT, total bilirubin, and INR values remain elevated or above 
Day1 values.
During monitoring, if the AL T values and the liver function tests remain persistently  elevated, 
the Investigator should discuss with the Gilead Medical Monitor whether the study  drug should 
be discontinued.
7.5.4.2. Management of Exacerbation of Hepatitis B in Subjects who have Discontinued 
Study Medication
If laboratory  results indicate (1) an ALT elevation 2 ×Day 1 and 10 
×ULN alone OR 
associated with (2) abnormal laboratory  parameters suggestive of worsening hepatic function  
(total bilirubin 2 × Day  1, INR 0.5 above Day  1, provided both are > ULN) and the subject is on 
no post-study therapy for HBV, the following is reco mmended:
Schedule the subject to return to the clinic as soon as possible (ideall y no later than 3 days 
after the initial laboratory values were drawn). During the visit, perform a clinical assessment 
of the subject.
GS-9883/F/TAF 
Protocol GS -US-380-1490 Final
Gilead Sciences, Inc. Original
CONFIDENTIAL Page69 21 October 2015Check the following laboratory  paramete rs: serum AL T and AST, bilirubin, INR, and
albumin.
If the ALT elevation is confirmed, request the clinical laboratory  to conduct reflex testing 
for plasma HBV DNA, HBV serology  (HBsAg and HBsAb), HDV, HAV IgM and HCV. If 
serum HBV DNA is increasing, the investigator should consider immediate initiation of 
approved therap y.
The subject should be followed until laboratory  parameters (ALT, total bilirubin, I NR)return 
to normal or Day 1up to a maximum of 6 months after the initial occurrence of the event.
7.5.5. On-Treatment Hepatitis C Management 
If a subject tests positive for HCV RNA at screening or develops signs or sy mptoms of active 
Hepatitis C virus Gilead recommends that local medical practice is followed at the discretion of 
the Investigator. Investigat ional medicinal product may  be continued without dose 
interruption. Should the Investigator decide to initiate Hepatitis C treatment the I nvestigator 
must contact the Gilead Medical Monitor to confirm that no drug-drug interactions are expected. 
Subjects should return to the clinic for scheduled or unscheduled follow up visit(s) according to 
local medical practice for laboratory  evaluations. If Hepatitis C treatment is initiated, 
Investigators should use the Gilead provided retest laboratory  kits to manage the active 
Hepatitis C.
7.6. Special Situations Reports
7.6.1. Definitions of Special Situations
Special situation reports includ e all reports of medication error, abuse, misuse, overdose, reports 
of adverse events associated with product complaints, and pregnancy  reports regardless of an 
associated AE.  
Medication error is any unintentional error in the prescribing, dispensing , oradministration of a 
medicinal product while in the control of the health care provider , subject, or consumer.
Abuse is defined as persistent or sporadic intentional excessive use of a medicinal product by  a 
subject.
Misuse is defined as an y intentional a nd inappropriate useof a medicinal p roduct tha t is not in 
accordance with the protocol instructions or the local prescribing information .
An overdose is defined as an accidental or intentional administration of a quantity  of a medicinal 
product given per administration or cumulatively  which is above the maximum recommended 
dose as per protocol or in the product labelling (as it applies to the daily  dose of the subject in 
question). In cases of a discrepancy  in drug accountability , overdose will be establis hed only 
when it is clear that the subject has taken the excess dose(s). Overdose cannot be established 
when the subject cannot account for the discrepancy  except in cases in which the investigator has 
reason to suspect that the subject has taken the addit ional dose(s).
Product complaint is defined as complaints arising from potential deviations in the manufacture, 
packaging, or distribution of the medicinal product.  
GS-9883/F/TAF 
Protocol GS -US-380-1490 Final
Gilead Sciences, Inc. Original
CONFIDENTIAL Page70 21 October 20157.6.2. Instructions for Reporting Special Situations
7.6.2.1. Instructions for Reporting Pregnancies
The investigator should report pregnancies in female study  subjects that are identified after 
initiation of study  medication and throughout the study , including the post study  drug follow -up 
period, to Gilead DSPH using the pregnancy  report form within 24 hours of becoming aware of 
the pregnancy . 
Refer to below and the eCRF completion guidelines for full instructions on the mechanism of 
pregnancy  reporting.
The pregnancy  itself is not considered an AE nor is an induced elective abortion to terminate a 
pregnancy without medical reasons.
Any premature termination of pregnancy  (e.g., a spontaneous abortion, an induced therapeutic 
abortion due to complications or other medical reasons) must be reported with in 24hours as an 
SAE. The underl ying medical reason fo r this procedure should be recorded as the AE term.
A spontaneous abortion is alway s considered to be an SAE and will be reported as described in 
Section7.3. 
Furthermore, any  SAE occurring as an adverse pregnancy  outcome post study  must 
be reported to Gil ead DSPH .
The subject should receive appropriate monitoring and care until the conclusion of the 
pregnancy . The outcome should be reported to Gilead DSPH using the pregnancy  outcome report 
form. If the end of the pregnancy  occurs after the study  has been c ompleted, the outcome should 
be reported directl y to Gilead DSPH. Gilead DSPH contact information is as follows: 
Email: Safety _FC@gilead.com and Fax: +1 (650) 522 -5477. 
Pregnancies of female partners of male study subjects exposed to Gilead or other stud y drugs 
must also be reported and relevant info rmation should be submitted to 
Gilead DSPH using the 
pregnancy  and pregnancy  outcome forms within 24 hours. Monitoring of the subject should 
continue until the conclusion of the pregnancy . If the end of the pr egnancy occurs after the study  
has been completed, the outcome should be reported directl y to Gilead DSPH, fax number 
+1650-522-5477 or email Safety _FC@gilead.com. 
Refer to Appendix 6for Pregnancy  Precautions, Definition for Female of Childbearing Potential, 
and Contraceptive 
Requirements.
7.6.2.2. Reporting Other Special Situations
All other special situation reports must be reported on the special situations report form and 
forwarded 
to Gilead DSPH within 24 hours of the investigator becoming aware of the situation. 
These reports must consist of situations that involve study  IMPand/or Gilead concomitant 
medications, but do not apply to non-Gilead concomitant medications. 
GS-9883/F/TAF 
Protocol GS -US-380-1490 Final
Gilead Sciences, Inc. Original
CONFIDENTIAL Page71 21 October 2015Special situations involvin g non-Gilead concomitant medications doesnot need to be reported on 
the special situations report form; however, for special situations that result in AEs due to a 
non-
Gilead concomitant medication, the AE should be reported on the AE form . 
Any inappropr iate use of concomitant medications prohibited by  this protocol should not be 
reported as “misuse,” but may  be more appropriately  documented as a protocol deviation.
Referto 7.6.2.1 and the eCRF completion guidelines for full instructions on the mechanism of 
special situations reporting.
All clinical sequelae in relation to these special situation reports will be reported as AEs or SAEs 
at the same time using the AE eCRF and/or the SAE report form. Details of the sy mptoms and 
signs, clinical management, an d outcome will be reported, when available.
GS-9883/F/TAF 
Protocol GS -US-380-1490 Final
Gilead Sciences, Inc. Original
CONFIDENTIAL Page72 21 October 20158. STATISTICAL  CONSIDER ATIONS
8.1. Analysis Objectives and Endpoints
8.1.1. Analysis Objectives
The primary  objective of this study  is to evaluate the efficacy of a FDC of GS -9883/F/TAF 
versus DTG + F/TAF in HIV- 1 infected, ant iretroviral treatment naïve -adult subjects as 
determined b y the achievement of HIV -1 RNA < 50 copies/mL  at Week 48
The secondary  objectives of this study  are to evaluate the efficacy , safety and tolerability  of the 
two treatment groups through Weeks 48 and 96.
8.1.2. Primary Endpoint
The primary  endpoint is the proportion of subjects who achieve HIV- 1 RNA <50copies/mL at 
Week 48 as defined b y the US FDA snapshot algorithm.
8.1.3. Secondary Endpoint
The secondary  endpoints include:
The proportion of subjects who achieve HIV-1 RNA < 50 copies/mL at Week 96 as defined 
by the US FDA snapshot algorithm
The proportion of subjects who achieve HIV -1 RNA < 20 copies/mL at Weeks 48 and96 as 
defined b y the US FDA snapshot algorithm
The changefrom baseline in log 10HIV-1 RNAand CD4+ cell count at Weeks 48 and96
8.2. Analysis Conventions
8.2.1. Analysis Sets
8.2.1.1. All Randomized
The randomized anal ysis set includes all subjects who are randomized into the study . This is the 
primary analysis set for by -subject listings.
8.2.1.2. Efficacy
8.2.1.2.1. Full Anal ysis Set (FAS)
The primary  analysis set for efficacy  analyses is defined as fullanalysis set(FAS), which will 
includeall subjects who (1) are randomized into the study  and (2) have received at least 1 dose 
of study drug. Subjects will be grouped according to the treatment to which they  were 
randomized.
GS-9883/F/TAF 
Protocol GS -US-380-1490 Final
Gilead Sciences, Inc. Original
CONFIDENTIAL Page73 21 October 20158.2.1.2.2. Per- Protocol (PP) Anal ysis Set
The secondary  analysis set for efficacy  analyses is defined as per-protocol (PP)analysis set, 
which will include all subjects who (1) are randomized into the study , (2) have received at least 
1dose of study drug, and (3) have not committed any  major protocol violation, including the 
violation of key  entry criteria. Subjects will be grouped according to the treatment they  actually 
received.
Subjects meeting an y of the following criteri a will be excluded from the 
Week48 PPanalysis
set:
1.Subjects who do not have on- treatment HIV- 1 RNA in the Week 48 analysis window, except 
when missing 
data is due to discontinuation of study  drug for lack of efficacy . 
2.Subjects who do not meet the inclusion criterion that the screening genot ype report provided 
by Gilead Scienc es must show sensitivity  to FTC, T FV.
3.Subjects who meet the exclusion criterion for receiving ongoing therap y with any of the 
medications listed in the table in protocol Section 4.3including drugs not to be used with 
GS-9883, FTC, TAF, and DTG.
4.Nonadherence to stud y drug: subjects with adherence rate for active study  drugup to the 
Week 48 Visit below the 2.5th percentile
8.2.1.3. Safety
The primary  analysis set for safety anal yses is defined as safety 
analysis set, whichwill include 
all subjects who (1) are randomized into the study  and (2) have 
received at least 1dose of stud y 
drug. All the data collected up to 30 day s after subjects permanently  discontinue their study  drug 
will be included in the safety  summaries, unless specified otherwise. Subjects will be grouped 
according to the treatment they  actually received.
8.2.1.4. Pharmacokinetics
8.2.1.4.1. Pharmacokinetic (PK) Substudy  Analysis Set
The primary  analysis set for intensive PK anal yses is defin ed as the PK substudy  analysis set, 
which will include all subjects who (1) are randomized into the study , (2) enrolled into the PK 
Substudy, (3) have received at least 1 dose of study  drug, and (4) have at least 1 nonmissing 
intensive PK concentration dat a for the anal yte under evaluation reported by  the PK lab. 
8.2.1.4.2. Pharmacokinetic (PK) Analy sis Set
The primary  analysis set for general PK analy ses is defined as the PK analysis set, whichwill 
include all subjects who (1) are randomized into the study , (2) have received at least 1 dose of 
study drug, and (3) have at least 1 nonmissing PK concentration data for the anal yte under 
evaluation reported b y the PK lab. 
GS-9883/F/TAF 
Protocol GS -US-380-1490 Final
Gilead Sciences, Inc. Original
CONFIDENTIAL Page74 21 October 20158.3. Data Handling Conventions
HIV-1 RNA results of ‘No HIV -1 RNA detected’ and “<20 cp/mL  HIV-1 RNA Detected” will 
be imputed as 19 copies/mL  for analysis purpose .  Logarithm (base 10) transformation will be 
applied to HIV -1 RNA levels for efficacy  analysis. 
Natural logarith mic transformation of plasma concentrations and PK parameters will be applied 
for PK anal ysis.
Laboratory  data that are continuous in nature but are less than the lower limit of quantitation or 
above the upper limit of quantitation will be imputed to the value of the lower or upper limit plus 
or minus one significant digit, respective ly (eg, if the result of a continuous laboratory  test is 
<20, a value of 19 will be assigned).
Missing data can have an impact upon the interpretation of the trial data. In general, values for 
missing data will not be imputed. However, a missing pre -treatment laboratory  result would be 
treated as normal (ie, no toxicity  grade) for the laboratory  abnormality  summary .
All available data for subjects that do not complete the study will be included in data listings.
8.4. Demographic Data and Baseline Characteristics
Demographic and baseline characteristics will be summarized using standard descriptive 
methods including sample size, mean, SD, median, Q1, Q3, minimum, and maximum for 
continuous variables and frequency  and percentages for categorical variables.
Demographic data will include sex, race, ethnicity , and age. 
Baseline characteristics will include body  weight, height, bod y mass index, eGFR , HIV-1 
infection, and enrollment distribution by  randomization stratum will be summarized
.
For categorical demographic and baseline characteristics, the Cochran –
Mantel–Haenszel (CMH)
test will be used to compare treatment groups. For continuous demographic and baseline 
characteristics, the Wilcoxon rank sum test will be used to compare treatment groups.
8.5. Efficacy Analysis
8.5.1. Primary Analys is
8.5.1.1. Primary Efficacy Endpoint
The primary  efficacy endpoint is the proportion of subjects who achieve HIV-1 RNA 
50copies/mL  at Week 48as determined b y the US 
FDAsnapshot algorithm . The primary  
analysis of the efficacy  will be based on the FAS.
GS-9883/F/TAF 
Protocol GS -US-380-1490 Final
Gilead Sciences, Inc. Original
CONFIDENTIAL Page75 21 October 20158.5.1.2. FDA Snapshot Algorithm
The analysis window at Week 48 is defined as from Study  Day 294 to Study  Day 377. All HIV -1 
RNA data collected on -treatment (ie, including data collected up to 1 day  after the last dose date 
of study drug) will be used in the snapshot algorithm. Virologic outcome will be defined as the 
following categories:
Virologic Success: this includes subjects who have the last available HIV- 1 RNA 
<50copies/mL in the Week 48analysis window while on randomized treatment
Virologic Failure: this includes subjects
a.Who have the last available HIV -1 RNA  50 copies/mL  in the Week 48analysis 
window while on randomized treatment, or
b. Who do not have on -treatment HIV -1 RNA data in the Week 48 analysis window and 
1)Who discontinue study  drug prior to or in the Week 48 analysis window due to lack 
of efficacy , or
2)Who discontinue study  drug prior to or in the Week 48 analysis window due to 
reasons other than adverse event (AE), death, or lack of efficacy  and have the last 
available HIV -1 RNA up to 1 day  after the premature discontinuation of the study  
drug 50copies/mL
No Virologic Data in the Week 48analysis window: this includes subjects who do not 
have on-treatment HIV -1 RNA data in the Week 48analysis window because of the 
following: 
a.Discontinuation of study drug prior to or in the Week 48 analysis window due to AE or 
death (regardless of whether the last available HIV- 1 RNA up to 1 day  after the 
premature discontinuation of the study  drug < 50 copies/mL  or not) or,
b. Discontinuation of study  drug prior to or in the Week 48 analysis window due to reasons 
other than A E, death, or lack of efficacy  (
eg, withdrew 
consent and loss to follow -up) and 
the last available HIV -1 RNA up to 1 day  after the premature discontinuation of the study  
drug < 50 copies/mL or,
c.Missing data during the window but on study  drug.
8.5.1.3. Analysis of Primary  Efficacy Endpoint
The null hy pothesis is that the proportion of subjects achieving HIV -1 RNA < 50copies/mL (as 
defined b y the US FDA snapshot algori thm) at Week 48 in GS -9883/F/TAF is at least 12% lower 
than the response rate in DTG + F/TAF; the alternative hy pothesis is that the response rate in 
GS-9883/F/TAF is less than 12% lower than that in DTG + F/TAF.
GS-9883/F/TAF 
Protocol GS -US-380-1490 Final
Gilead Sciences, Inc. Original
CONFIDENTIAL Page76 21 October 2015Non-inferiority will be assessed using the conventional confidence interval approach.  The point 
estimate of treatment difference ( GS-9883/F/TAF group –DTG + F/TAF group) and the 
associated 2- sided 95% confidence interval will be constructed using a normal approximation 
method based on stratum -stratified Mantel -Haenszel proportions, where stratification factors 
include baseline HIV -1 RNA level ( 100,000copies/mL , vs.100,000copies/mL )and region 
(US vs. Ex -US).Note that to avoid small or missing cells in anal ysis strata, CD4+ cell count is 
not stratified in the analysis because HIV -1 RNA and CD4 +cell count arehighly correlated.
If non-inferiority  of GS-9883/F/TAF to DTG + F/TAF is established, the lower bound of the 
95% CI will be compared to 0; if the lower bound of the 95% CI is greater th an 0, then 
superiority  of GS-9883/F/TAF over DTG + F/TAF will be established.
8.5.2.
Secondary Analyses
The proportion of subjects who achieve HIV-1 RNA < 50 copies/mL at Week 96 and the 
proportion of subjects who achieve HIV-1 RNA < 20 copies/mL at Weeks 48 and96,as defined 
by theUSFDA snapshot algorithm , will be analyzed using the same method as for the primary  
efficacy endpoint.
The changes from baseline in log10HIV-1 RNAand CD4+ cell count at Weeks 48 and 96 will be 
summarized by  treatment using desc riptive statistics. The differences in changes from baseline in 
log10HIV-1 RNAand CD4+ cell count between 2 treatments groups and the associated 95% 
confidence intervals will be constructed using ANOVA models, including treatment 
(GS-9883/F/TAF vs. DTG + F/TAF), baseline HIV -1 RNA level 
(100,000copies/mL vs.
100,000copies/mL ),and region (US vs. Ex- US) as fixed effects in the model.
In addition, missing CD4+ cell count will be imputed using Last Observation Carried Forward 
(LOCF) methodand analy zed similarly .
8.6. Safety Analysis
All safety analyses will be performed using the safety  analysis set.
All safety data collected on or after the date that the study drug was first administered up to the 
date of the last dose of study  drug plus 30 da ys, unless specified otherwise, will be summarized 
for subjects in the safet y analysis set according to the study  drug received.
Data for the pretreatment period and the period post the date of last dose of study  drug plus 
30days will be included in data 
listings for all enrolled subjects.
8.6.1. Extent of Exposure
A subject’s extent of exposure to study drugwill be generated from the study drug
administration page in eCRF . Exposure data will be summarized by  treatment.
Duration of exposure to study  drug will be expressed as the number of weeks between the first 
and last dose of the stud y drug, inclusive, regardless of temporary  interruptions in study  drug
administration and summarized by treatment.
Dosing information for individual subjects will be listed.
GS-9883/F/TAF 
Protocol GS -US-380-1490 Final
Gilead Sciences, Inc. Original
CONFIDENTIAL Page77 21 October 20158.6.2. Adverse Events
Clinical and laboratory  adverse events will be coded using the Medical Dictionary  for 
Regulatory  Activities (MedDRA). Sy stem Organ Class (SOC), High -Level Group Term 
(HLGT), High -Level Term (HL T), Preferred Term (PT), and Lower -Level Term (LLT) w ill be 
attached to the clinical database.
Events will be summarized on the basis of the date of onset for the event. A treatment -emergent 
adverse event will be defined as an y adverse event with onset date on or after the stud y drug start 
date and no later than 30 day s after the study  drug stop date; or any  adverse event leading to 
study drug discontinuation.
Summaries (number and percentage of subjects) of treatment -emergent adverse events (b y SOC, 
HLT[if applicable] , and PT) will be provided by  treatment. Additional summaries will include 
summaries for adverse events by  grade, Investigator’s assessment of relationship to study  drug, 
and effect on stud y drug dosing.
On an ongoing basis adverse events will be reviewed for events that might meet the definitio n of 
Stage 3 Opportunistic I llnesses in HIV are indicative of an AIDS -Defining Diagnoses.  The 
Gilead medical personnel will review the possible Stage 3 events and approve the events that 
meet the definition.  Those events that do meet the Stage 3 Opportun istic Illness definition of an 
AIDS-Defining Diagnosis will be listed.
A listing of Stage 3 Opportunistic I llnesses in HIV , can be found in Appendix 5.
8.6.3. Laboratory Evaluations
Selected laboratory  data (using conventional units) will be summarized using onl yobserved data. 
Absolute values and changes from baseline at all scheduled visits will be summarized.
Graded laboratory  abnormalities will be defined using the grading scheme defined in Grading of 
laboratory  abnormalities attached in Appendix 4.
Incidence of treatment -emergent laboratory  abnormalities, defined as values that increase at least 
1toxicity grade from baseline at an y time post baseline up to and including the date of last dose 
of study drugplus 30days, will be summarized by treatment. If baseline data are missing, then 
any graded abnormalit y (i.e., at least a Grade 1) will be considered treatment emergent. The 
maximum post baseline toxicity  grade will be summarized by  laboratory  parameter.
Laboratory  abnormalities that occur before the first dose of study drugor after the last dose of 
study drug plus 30 day s will be included in a data listing.
8.6.4. Other Safety Evaluations
Vital signs and safety ECG data will be summarized as appropriate .
GS-9883/F/TAF 
Protocol GS -US-380-1490 Final
Gilead Sciences, Inc. Original
CONFIDENTIAL Page78 21 October 20158.7. Pharmacokinetic Analysis
For the intensive PK substudy , plasma concentrations of GS- 9883 may  be summarized by  
nominal sampling time using descriptive statistics. Pharmacokinetic parameters (C max, Tmax, Ctau, 
AUCtau,and T½, as appropriate ) will be listed a nd summarized using descriptive statistics (eg, 
samplesize, arithmetic mean, geometric mean, coefficient of variation %, SD, median, Q1, Q3, 
minimum, and maximum).Plasma concentrations over time will be plotted in semi- logarithmic 
and linear formats as m ean ± standard deviation, and median (Q1, Q3). 
For the general PK anal yses, the pharmaco kinetics of GS -9883 may be evaluated using 
descriptive statistics or population approaches.
TAF and FTC concentrations may  be analyzed and PK parameters summarized as applicable.  
8.8. Patient Reported Outcomes (PRO)
The PRO measures based on questionnaires (e.g. SF- 36 and HI VSymptomsDistress Module) 
will be summarized using descriptive statistics.
8.9. Sample Size
A total of approximately  600 HIV -1 infected subjects, randomized in a 1:1 ratio to 2 treatment 
groups (300 subjects per treatment group), achieves at least 95% power to detect a 
non-inferiority margin of 12% in Week 48 response rate (HIV -1 RNA < 50copies/mL  as defined 
by the US FDA snapshot algori thm) difference between the 2 treatment groups. For the sample 
size and power computation
s, it is assumed that both treatment groups have a response rate of 
0.91 (based on Gilead Studies GS-US-292-0104 and GS -US-292-0111), that the non-inferiority  
margin is 0.12, and that the significance level of the test is at a one- sided 0.025 level.
8.10. Data Monitoring Committee
An external Independent Data Monitoring Committee (IDMC) will review the progress, efficacy , 
and safety data of this study while the stud y is ongoi ng. The committee will convene after the 
first 300 subjects enrolled have completed Week 12 of the study  or prematurely  discontinues 
from the study  drug, as well as after all subjects have completed Week 24 of the study  or 
prematurel y discontinues from the study drug. However, Gilead will defer to the I DMC for any  
decision to convene earlier or more frequently . The IDMC will examine the safet y results of the 
trial and also focus on logistical issues such as accrual, retention, quality  of clinical and 
laboratory data, and implications of results of external studies. Blinding will be preserved during 
the conduct of the stud y and access to unblinded data will be limited to designated parties.
No formal stopping rules will be used by  the IDMC for safet y outcomes . Rather, a clinical 
assessment will be made to determine if the nature, frequency , and severit y of adverse events 
associated with a stud y regimen warrant the earl y termination of the study  in the best interest of 
the participants.
For each IDMC anal ysis performed prior to the analy sis of the primary  efficacy endpoint, an 
alpha penalt y of 0.00001 will be applied for the primary anal ysis of the primary  endpoint.
GS-9883/F/TAF 
Protocol GS -US-380-1490 Final
Gilead Sciences, Inc. Original
CONFIDENTIAL Page79 21 October 20159. RESPONSIBILITIES
9.1. Investigator Responsibilities
9.1.1. Good Clinical Practice
The investigator will ensur e that this study  is conducted in accordance with the principles of the 
Declaration of Helsinki (as amended in Edinburgh, Toky o, Venice, Hong Kong, and 
SouthAfrica), International Conference on Harmonisation (I CH) guidelines, or with the laws and 
regulations of the country in which the research is conducted, whichever affords the greater 
protection to the study  subjectThese standards are consistent with the European Union Clinical 
Trials Directive 2001/20/EC and Good Clinical Practice Directive 2005/28/EC.
The investigator will ensure adherence to the basic principles of Good Clinical Practice, as 
outlined in 21 CFR312, subpart D, “Responsibilities of Sponsors and Investigators,” 21 CFR, 
part50, 1998, and 21 CFR, part 56, 1998.
The investigator and all applicable subinvestigators will comply  with 21CFR, Part 54, 1998, 
providing documentation of their financial interest or arrangements with Gilead, or proprietary  
interests in the investigational drug under stud y. This documentation must be provided prior to 
the investigator’s (and any  subinvestigator’s) participation in the study . The investigator and 
subinvestigator agree to notify  Gilead of an y change in reportable interests during the stud y and 
for 1 year following completion of the study. Study comple tion is defined as the date when the 
last subject completes the protocol- defined activities.
9.1.2. Institutional Review Board (IRB)/Independent Ethics Committee (IEC) 
Review and Approval
The investigator (or sponsor as appropriate according to local regulations) will submit this 
protocol, informed consent form, and an y accompanying material to be provided to the subject 
(such as advertisements, subject information sheets, or descriptions o f the study  used to obtain 
informed consent) to an IRB/IEC. The investigator will not begin an y study subject activities 
until approval from the IRB/IEC 
has been documented and provided as a letter to the 
investigator.
Before implementation, the investiga tor will submit to and receive documented approval from 
the IRB/IEC an y modifications made to the protocol or any accompan ying material to be 
provided to the subject after initial IRB/IEC approval, with the exception of those necessary  to 
reduce immediat e risk to study  subjects.
9.1.3. Informed Consent
The investigator is responsible for obtaining written informed consent from each individual 
participating in this study after adequate explanation of the aims, methods, objectives, and 
potential hazards of the study  and before undertaking an y study-related procedures. The 
GS-9883/F/TAF 
Protocol GS -US-380-1490 Final
Gilead Sciences, Inc. Original
CONFIDENTIAL Page80 21 October 2015investigator must use the most current IRB-or IEC-approved consent form fo r documenting 
written informed consent. Each informed consent (or assent as applicable) will be appropriatel y 
signed and dated b y the subject or the subject’s legally authorized representative and the person 
conducting the consent discussion, and also by  an impartial witness if required by IRB or IEC or
local requirements. The consent form will inform subjects about pharmacogenomic testing and 
sample retention, and their right to receive clinically relevant pharmacogenomic anal ysis results.
9.1.4. Confidentiality
The investigator must assure that subjects’ anon ymity will be strictly  maintained and that their 
identities are protected from unauthorized parties. Only subject initials, date of birth, another 
unique identifier (as allowed b y local law) and an identifica tion code will be recorded on any  
form or biological sample submitted to the Sponsor ,or laboratory . Laboratory  specimens must 
be labeled in such a way as to protect subject identity  while allowing the results to be recorded to 
the proper subject. Refer to specific laboratory  instructions . NOTE: The investigator must keep a 
screening log showing codes, names, and addresses for all subjects screened and for all subjects 
enrolled in the trial. Subject data will be processed in accordance with all applicable r egulations. 
The investigator agrees that all information received from Gilead, including but not limited to the 
investigator brochure, this protocol, eCRF, the IMP, and any  other study  information, remain the 
sole and exclusive property  of Gilead during t he conduct of the study and thereafter. This 
information is not to be disclosed to any  third party  (except employ ees or agents directl y 
involved in the conduct of the study  or as required by  law) without prior written consent from 
Gilead. The investigator further agrees to take all reasonable precautions to prevent the 
disclosure b y any employee or agent of the stud y site to any  third party  or otherwise into the 
public domain.
9.1.5. Study Files and Retention of Records
The investigator must maintain adequate and accurate records to enable the conduct of the study  
to be fully  documented and the study
 data to be subsequently  verified. These documents should 
be classified into at least the following two categories: (1)investigator’s study  file, and 
(2)subject clini cal source documents.
The investigator’s stud y file will contain the protocol/amendments, eCRF and query  forms, IRB 
or IEC and governmental approval with correspondence, informed consent, drug records, staff 
curriculum vitae and authorization forms, and ot her appropriate documents and correspondence.
The required source data should include sequential notes containing at least the following 
information for each subject:
Subject identification (name, date of birth, gender);
Documentation that subject meets el igibility criteria, ie, history , physical examination, and 
confirmation of diagnosis (to support inclusion and exclusion criteria);
GS-9883/F/TAF 
Protocol GS -US-380-1490 Final
Gilead Sciences, Inc. Original
CONFIDENTIAL Page81 21 October 2015Documentation of the reason(s) a consented subject is not enrolled
Participation in study  (including study  number);
Study discussed and date of informed consent;
Dates of all visits;
Documentation that protocol specific procedures were performed;
Results of efficacy  parameters, as required b y the protocol;
Start and end date (including dose regimen) of IMP, including dates of d ispensing and return;
Record of all adverse events and other safety parameters (start and end date, and including 
causality and severity );
Concomitant medication (including start and end date, dose if relevant; dose changes);
Date of stud y completion and r eason for earl y discontinuation, if it occurs.
All clinical study  documents must be retained b y the investigator until at least 2 years or 
according to local laws, whichever is longer, after the last approval of a marketing application in 
an ICH region (ie , United States, Europe, or Japan) and until there are no pending or planned 
marketing applications in an I CH region; or, if no application is filed or if the application is not 
approved for such indication, until 2 years after the investigation is discontinued and regulatory  
authorities have been notified. Investigators may  be required to retain documents longer if 
specified b y regulatory  requirements, by  local regulations, or by  an agreement with Gilead. The 
investigator must notify  Gilead before destro ying any clinical study  records.
Should the investigator wish to assign the stud y records to another part y or move them to another 
location, Gilead must be notified in advance.
If the investigator cannot provide for this archiving requirement at the study si te for any or all of 
the documents, special arrangements must be made between the investigator and Gilead to store 
these records securel y away from the site so that they can be returned sealed to the investigator 
in case of an inspection. When source documents are required for the continued care of the 
subject, appropriate copies should be made for storage away  from the site.
9.1.6. Case Report Forms
For each subject consented, an eCRF casebook will be completed b y an authorized study staff 
member whose training f or this function is completed in EDC. The Inclusion/Exclusion Criteria 
and Enrollment eCRFs should be completed onl y after all data related to eligibility  have been 
received. Subsequent to data entry , a study monitor will perform source data verification within 
the EDC sy stem.System-generated or manual queries will be issued to the investigative site 
GS-9883/F/TAF 
Protocol GS -US-380-1490 Final
Gilead Sciences, Inc. Original
CONFIDENTIAL Page82 21 October 2015staff as data discrepancies are identified by the monitor or internal Gilead staff, who routinely 
review the data for completeness, correctness, and consistency . The site coordinator is 
responsible for responding to the queries in a timely manner, within the s ystem, either by  
confirming the data as correct or updating the original entry, and providing the reason for the 
update (e.g. data entry  error). Origi nal entries as well as any  changes to data fields will be stored 
in the audit trail of the system. Prior to any  interim time points or database lock (as instructed by  
Gilead), the investigator will use his/her log in credentials to confirm that the forms have been 
reviewed, and that the entries accurately reflect the information in the source documents. At the 
conclusion of the trial, Gilead will provide the site with a read -only archive copy  of the data 
entered by that site. This archive must be stored in accordance with the records retention 
requirements outlined in Section 9.1.5.
9.1.7. Investigational Medicinal Product Accountability and Return
Gilead recommends that used and unused IMP supplies be returned to the shipping facility  from 
which it came for eventual destruction. The stud y monitor will provide instructions for return. If 
return is not possible, the study monitor will evaluate each st udy center’s IMPdisposal 
procedures and provide appropriate instruction for destruction of unused IMPsupplies. I f the site 
has an appropriate standard operating procedure (SOP) for drug destruction as determined b y 
Gilead QA , the site may  destroy used (emptyor partially  empty) and unused IMPsupplies in 
accordance with th atsite’s approved SOP. A cop y of the site’s approved 
SOP will be obtained 
for central files. 
If IMPis destroyed on site, the investigator must maintain accurate records for all IMP 
destroyed. Records must show the identification and quantity  of each unit destroy ed, the method 
of destruction, and the person who disposed of the IMP. Upon study  completion, copiesof the 
IMPaccountability  records must be filed at the site. Another copy  will be returned to Gilead.
The study  monitor will review IMP supplies and associated records at periodic intervals.
9.1.8. Inspections
The investigator will make available all source documents and other records for this trial to 
Gilead’s appointed stud y monitors , to IRBs or IECs, or to regulatory  authority  or health authority 
inspectors.
9.1.9. Protocol Compliance
The investigator is responsible for ensuring the study  is conducted in accordance with the 
procedures and evaluations described in this protocol.
9.2. Sponsor Resp onsibilities
9.2.1. Protocol Modifications
Protocol modifications, except those intended to reduce immediate risk to study  subjects, may  be 
made only  by Gilead. The investigator must submit all protocol modifications to the IRB or IEC 
in accordance with local req uirements and receive documented IRB or IEC approval before 
modifications can be implemented.
GS-9883/F/TAF 
Protocol GS -US-380-1490 Final
Gilead Sciences, Inc. Original
CONFIDENTIAL Page83 21 October 20159.2.2. Study Report and Publications
A clinical study  report (CSR) will be prepared and provided to the regulatory  agency. Gilead will 
ensure that the report meets the s tandards set out in the I CH Guideline for Structure and Content 
of Clinical Study  Reports (I CHE3). Note that an abbreviated report may  be prepared in certain 
cases. 
Investigators in this study  may communicate, orally  present, or publish in scientific jou rnals or 
other scholarl y media only after the following conditions have been met:
the results of the study in their entiret y have been publicly disclosed b y or with the consent of 
Gilead in an abstract, manuscript, or presentation form or the stud y has been completed at all 
study sites for at least 2 years
The investigator will submit to Gilead any  proposed publication or presentation alongwith the 
respective scientific journal or presentation forum at least 30 day s before submission of the 
publication or presentation. 
No such communication, presentation, or publication will include Gilead’s confidential 
information (see Section 9.1.4).
The investigator will comply  with Gilead’s request to delete references to its confidential 
information (other than the study  results) in any  paper or presentation and agrees to withhold 
publication or presentation for an additional 60 days in order to obtain patent protection if 
deemed necessary .
9.3. Joint Investigator/Sponsor Responsibilities
9.3.1. Payment Reporting
Investigators and their study  staff may  be asked to provide services performed under this 
protocol, e.g. attendance at I nvestigator's Meetings.  If req uired under the applicable statutory  
and regulatory  requirements, Gilead will capture and disclose to Federal and State agencies any  
expenses paid or reimbursed for such services, including an y clinical trial payments, meal, travel 
expenses or reimbursemen ts, consulting fees, and any  other transfer of value.
9.3.2. Access to Information for Monitoring
In accordance with regulations and guidelines, the study  monitor must have direct access to the 
investigator’s source documentation in order to verify  the accuracy  o
f the data recorded in the 
eCRF.
The monitor is responsible for routine review of the eCRF at regular intervals throughout the 
study to verify adherence to the protocol and the completeness, consistency, and accuracy  of the 
data being entered on them. The monitor should have access to an y subject records needed to 
verify the entries on the eCRF. The investigator agrees to cooperate with the monitor to ensure 
that any problems detected through any  type of monitoring (central, on site) are resolved.
GS-9883/F/TAF 
Protocol GS -US-380-1490 Final
Gilead Sciences, Inc. Original
CONFIDENTIAL Page84 21 October 20159.3.3. Access to Information for Auditing or Inspections
Representatives of regulatory  authorities or of Gilead may  conduct inspections or audits of the 
clinical study . If the investigator is notified of an inspection by  a regulatory authority  the 
investigator agrees to notify the Gilead medical monitor immediately . The investigator agrees to 
provide to representatives of a regulatory  agency or Gilead access to records, facilities, and 
personnel for the effective conduct of an y inspection or audit.
9.3.4. Study Discontinuation
Both the sponsor and the investigator reserve the right to terminate the stud y at any time. Should 
this be necessary , both parties will arrange discontinuation procedures and notify  the appropriate 
regulatory  authority(ies), IRBs, and IECs. In terminating t he study, Gilead and the investigator 
will assure that adequate consideration is given to the protection of the subjects’ interests.
GS-9883/F/TAF 
Protocol GS -US-380-1490 Final
Gilead Sciences, Inc. Original
CONFIDENTIAL Page85 21 October 201510. REFERENCES
2202 Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum 
creatinine. Nephron 1976;16:31 -41.
5125 Mocroft A, Vella S, Benfield TL , Chiesi A, Miller V, Gargalianos P, et al. 
Changing patterns of mortality  across Europe in patients infected with HIV -1. 
Lancet 1998;352 (9142):1725-30.
8284 Sterne J, Hernán M, Ledergerber B, Tilling K, Weber R, Sendi P, et al. Long -term 
effectiveness of potent antiretroviral therapy  in preventing AIDS and death: a 
prospective cohort study . Lancet 2005;366 (9483):378-84.
13585 Schneider E, Whitmore S, Gly nn KM, Dominguez K, Mitsch A, McKenna MT. 
Revised surveillance case definitions for HIV infection among adults, 
adolescents, and children aged <18 months and for HIV infection and AIDS 
among children aged 18 months to <13 y ears--United States, 2008. MMWR 
Recomm Rep 2008;57 (RR- 10):1-12.
21053 Sterrantino G, Santoro L, Bartolozzi D, Trotta M, Zaccarelli M. Self- reported 
adherence supports patient preference for the single tablet regimen (STR) in the 
current cART era. Patient preference and adherence 2012;6:427 -33.
27881 Palella FJ, Delaney  KM, Moorman AC, L oveless MO, Fuhrer J, Satten GA, et al. 
Declining Morbidity  and Mortality  Among Patients With Advanced Human 
Immunodeficiency  Virus Infection. N Eng J Med 1998;338 (13):853-60.
29702 Aldir I, Horta A, Serrado M. Single -tablet regimens in HI V: does it reall y make a 
difference? Curr Med Res Opin 2013;30 (1):89 -97.
29705 Costagliola D. Demographics of HIV and aging. Curr Opin HIV AIDS 2014;9 
(4):294-301.
34898 Department for Health and Human Services (DHHS). Guidelines for the Use of 
Antiretroviral Agents in H IV-1-Infected Adults and Adolescents. Developed by  
the DHHS Panel on Antiretroviral Guidelines for Adults and Adolescents –A 
Working Group of the Office of AIDS Research Advisory  Council (OARAC). 
Downloaded from http://aidsinfo.nih.gov/guidelines on 5/11/ 2015. Last Updated 
08 April, 2015.
36201 The Joint United Nations Programme oHAU. Fact Sheet: 2014 Global Statistics. 
Available at: 
http://www.unaids.org/sites/default/files/media_asset/20150714_FS_MDG6_Rep
ort_en.pdf.  2014.
GS-9883/F/TAF 
Protocol GS -US-380-1490 Final
Gilead Sciences, Inc. Original
CONFIDENTIAL Page86 21 October 201511. APPENDICES
Appendix 1.Investigator Signature Page
Appendix 2.Study Procedures Table (Blinded Phase)
Appendix 3.Management of Clinical and Laboratory Adverse Events
Appendix 4.GSI Grading Scale for Severity of Adverse Events and Laboratory Abnormalities
Appendix 5.Definitions of Stage 3 Opportunistic Illnesses in HIV (CDC Gui delines)
Appendix 6.Pregnancy Precautions, Definition for Female of Childbearing Potential, and 
Contraceptive Requirements
GS-9883 /F/TAF 
Protocol GS-US-380- 1490 Final 
Gilead Sciences, Inc. Original 
Appendix 1. Investigator Signature Page 
GILEAD SCIENCES, INC. 
333 LAKESIDE DRIVE 
FOSTER CITY, CA 94404 
STUDY ACKNOWLEDGEMENT 
A Phase 3, Randomized , Double-Blind Study to Evaluate the Safety and Efficacy of 
GS-9883/Emtricitabinerfenofovir Alafenamide Versus Dolutegravir + 
Emtricitabine/Tenofovir Alafenamide in HJV-1 Infected, Antirett·oviral Treatment-Nai've 
Adults 
GS-US-380-1490 Original Protocol, 21 October 2015 
This protocol has been approved by Gilead Sciences , lnc. The following signature documents 
this approval. 
PPD 
Devi SenGupta , MD Pnnted) Signature 
INVESTIGAT OR STATEMENT 
I have read the protocol, including all appendices, and I agree that it contains all necessary 
details for me and my staff to conduct this study as described. I will conduct this study as 
outlined herein and will make a reasonable effort to complete the study within the time 
designated. 
l will provide all study personnel under my supervision copies of the protocol and access to all 
information provided by Gilead Sciences, Inc. l will discuss this material with them to ensure 
that they are fully informed about the drugs and the study. 
Principallnvestigator Name (Printed) Signature 
Date Site Number 
CONFIDENT IAL Page 87 2 I October 20 15 
GS-9883/F/TAF
Protocol GS -US-380-1490 Final
Gilead Sciences, Inc. Original
CONFIDENTIAL Page88 21 October 2015Appendix 2. Study Procedures Table (Blinded Phase)
Study Procedures ScreeningaDay1bEnd of Weeke, qPost-Week 
96e, r
Unblinding 
Visit30-Day 
Follow-uppEarly 
Study 
Drugs 
DCc4 8 12 24 36 48 60 72 84 96Every 
12Weeks
Informed Consent X
Medical History X
Concomitant Medications X X X X X X X X X X X X X X X X
Adverse Events X X X X X X X X X X X X X X XfXf
Complete /Symptom -Directed 
Physical ExamX X XdXdXdXXdXXdXdXdXdXdX Xd,fXf
12-Lead ECG (performed 
supine)X X X X X X
Questionnaires X X X X
Height X
Vital signs (blood pressure, 
pulse, respiration rate, and 
temperature), including 
WeightX X X X X X X X X X X X X X X X
Urinalysis X X X X X X X X X X X X X X XfXf
Urine Pregnancy TestgX X X X X X X X X X X X X X X
Serum Pregnancy Test X
Chemistry ProfilehX X X X X X X X X X X X X X XfXf
Metabolic AssessmentsiX X X X X X XtX
GS-9883/F/T AF 
Protocol GS-US-380-1490 
Gilead Sciences, Inc. 
Study Procedures 
Estimated Glomemlar 
Filtration Rate 
Hematology Profilei 
Plasma HIV -1 RNA 
CD4+ Cell Connt 
Plasma & Urine Storage 
Sample 
HCV Serology 
HIV -1 Genotypek 
HIV -1 Genotype/Phenotype e 
Single PK Sample1 
Trough and Post Dose PK 
Samplem 
Optional PPD 
~· I r 
Randomiza tionv 
Provide subject dosing diaty 
to subjects 
Optional PK Substudyl' 
Optional PBMC Substudy0 
CONFIDENTIAL Screening• 
X 
X 
X 
X 
X 
XI End ofWeek•,q 
Day lb 4 8 12 24 36 48 60 
X X X X X X X X 
X X X X X X X X 
X X X X X X X X 
X X X X X X X X 
X X X X X X X X 
X X X 
X X 
X 
X 
X X X X X 
X X 
X X 
Page 89 Post-Week 
96e,r 
Every Unblinding 
72 84 96 12 Weeks Visit 
X X X X X 
X X X X X 
X X X X X 
X X X X X 
X X X X X 
X 30-Day 
Follow-upP 
xr 
xr 
X 
X Final 
Original 
Early 
Study 
Drugs 
DC 
X 
xr 
X X 
X 
xe 
21 October 2015 
GS-9883/F/TAF
Protocol GS -US-380-1490 Final
Gilead Sciences, Inc. Original
CONFIDENTIAL Page90 21 October 2015Study Procedures ScreeningaDay1bEnd of Weeke, qPost-Week 
96e, r
Unblinding 
Visit30-Day 
Follow-uppEarly 
Study 
Drugs 
DCc4 8 12 24 36 48 60 72 84 96Every 
12Weeks
HBV blood paneltX
Plasma HBV DNAuX X X X X X X X X X X X X X
Study Drug Dispensation XbX X X X X X X X X X X Xs
Study Drug Accountability X X X X X X X X X X X X X
a.Evaluations to be completed within 30 days prior to Day 1. 
b.Initiation of the first dose of study drug is to take place in -clinic following completion of study procedures at the Day 1 visit, with the exception of DXA.
c.Early Study Drugs Discontinuation visit to occur within 72hours of last dose of study drug. Subjects will be asked to continu e attending the scheduled study visits through the 
Unblinding Visit even if the subject discontinues study drug.
d.Symptom-directed physical examination as needed.
e.HIV-1 genotype and phenotype testing for subjects with virologic failure. Following virologic rebound, subjects will be asked to return to the clinic (2-3 weeks later) prior to 
the next scheduled visit or at the next scheduled study visit, for a HIV -1 RNA and HIV -1 genotype and phenotype (reverse transcriptase , protease and integrase genotype and 
phenotype) blood draw. Based on the results of this testing, subjects should be managed according to the Virologic Rebound Schema (Section6.12). 
f.Any adverse event or test showing abnormal results that is believed to have a possible or probable causal rela tionship with the study drug will be repeated weekly (or as often 
as deemed prudent by the Investigator) until the abnormality is resolved, returns to Day 1, or is otherwise explained. 
g.Females of childbearing potential only. Positive urine pregnancy tests will be confirmed with a serum test.
h.Chemistry profile: alkaline phosphatase, AST, ALT, GGT, total bilirubin, direct and indirect bilirubin, total protein, albumin, LDH, CPK, bicarb onate, BUN, calcium, 
chloride, creatinine, glucose, phosphorus, magnesium, potassium, sodium, uric acid and amylase (reflex lipase testing is performed in subjects with total amylase 
1.5ULN).At Day 1, Weeks 12, 24, 48, 72 and 96, and Unblinding Visit, analyses of glucose will be done as part of the fasting metaboli c assessments and not as part of 
the chemistry profile. Additiona lly: TSH will be analyzed at Screening, Day 1, Weeks24, 48, 72 and 96 followed by every 24 weeks post Week 96, Unblinding Visit and 
Early Study Drugs Discontinuation visit.
i.Fasting (no food or drinks, except water, at least 8 hours prior to blood collecti on) glucose and lipid panel (total cholesterol, HDL, direct LDL, triglycerides). If the subject has 
not fasted prior to the visit, the visit may proceed, but the subject must return within 72 hours in a fasted state to draw blood for the metabolic assessme nts.
j.CBC with differential and platelet count.
k.The Investigator must have received the results from the screening genotype report before proceeding with the Day 1 visit.  Screening genotype report must show sensitivity 
to TFV, FTC, 3TC and ABC. 
l.A single P K blood sample will be collected at any time pre or post- dose 
m.A trough PK blood sample will be collected between 20 -
28 hours following the last dose. Following an observed dose, a single post dose blood sample will be collected 
between 1 and 4 hours post dose.
n.A pharmacokinetic (P K)substudy will be performed in a subset of subjects (n=30) at selected study sites. The PKsubstudy visit must occur at the Week4 or Week 8visits. 
The substudy will include intensive PK profiling in plasma.
GS-9883/F/TAF
Protocol GS -US-380-1490 Final
Gilead Sciences, Inc. Original
CONFIDENTIAL Page91 21 October 2015o.A PBMC substudy will be performed in a subset of subjects (n =50) at selected study sites.  A blood sample will be collected at Day 1, Weeks 36 and 84.
p.Only required for those subjects not enrolling in the open -label rollover extension or those subjects who permanently dis continue study drugs and do not continue in the study 
through at least one subsequent visit after the Early Study Drugs Discontinuation Visit. For the purpose of scheduling a 30 -Day Follow -Up Visit, a 6days window may be 
used.
q.Study visits are to be com pleted within ± 2 days of the protocol -specified visit date based on the Day 1 visit through Week 12 and completed within ± 6 days through to 
Week96, unless otherwise specified. The visit window at Weeks 48 and 96 will be ± 6 weeks of the protocol-specifi ed visit date. 
r.After Week 96, subjects will continue to take their blinded study drug and attend visits every 12 weeks until treatment assignments have been unblinded.  Visit window of 
6days for study visits post Week 96.  After Week 96 Visit, subjects in the countries such as the United Kingdom (UK) will stop taking study drug and complete a 30 day 
follow up visit.
s.Open label study drug, GS-9883/F/TAF FDC will be dispensed to subjects participating in the Open-Label Rollover extension.
t.HBV blood panel will be performed at Screening (Hepatitis B virus surface antigen (HBsAg), Hepatitis B virus surface antibody (HBsAb) and Hep atitis B virus core antibody 
(HBcAb)). 
u.To be performed for subjects who meet the definition of HBV infection . At Weeks 12, 24 and 48, the following additional tests will be conducted by the central laboratory: 
HBsAb, HBsAg (qualitative and quantitative) and HBeAg (if negative, reflex HBeAb).
v.Randomization may be perform ed up to 3 days prior to the in -clinic Day 1 visit provided that all screening procedures have been completed and subject eligibility has been 
confirmed .
GS-9883/Fff AF 
Protocol GS-US-380-1490 Final 
Gilead Sciences, Inc. Original 
Appendix 3. Management of Clinical and Laborator y Adverse Events 
Grade 1 
L_ _____ G_ra_d_e_2----~ ~ ~~ ______ G_rn_d_e_3----~~ ~~ ---------G-ra_d_e-4--------~ 
! ! 
May continue dosing Repeat lab to 
at the discretion of confirm toxicity 
the investigator grade 
If confirmed and possibly and/or probably related to investigational 
medicinal products: 
I. Withhold investigational medicinal products until ~ Grade 2 
2. Restart all investigational medicinal products at full dose 
1 
If Grade 3 or 4 recurrence that is confirmed and possibly or probably 
related to investigational medicinal products, discontinue all 
investigational medicinal products dosing permanently 1 Repeat lab to 
confirm toxicity 
grade 
1 
lfc 
inve 
dos 
oft onfirmed and unrelated to 
stigational medicinal products, 
mg may continue at the discretion 
he investigator If confirmed and 
possibly or probably -. related to 
investigational 
medicinal products, 
discontinue 
investigational 
medicinal products 
dosing permanently and 
follow at periodic 
intervals at least weekly 
until a return to 
haseline or is otherwise 
explained 
If Grade 3 or 4 recurrence that is considered unrelated to 
investigational medicinal products, continue all investigational 
medicinal products at the same dose at the discretion of the 
investigator 
CONFIDENTIAL Page 92 21 October 2015 
GS-9883/F/TAF
Protocol GS -US-380-1490 Final
Gilead Sciences, Inc. Original
CONFIDENTIAL Page93 21 October 2015Appendix 4. GSI Grading Scale for Severity of Adverse Events and Laboratory Abnormalities
Antiviral Toxicity Grading Scale Version: 01 April 2015
HEMATOLOGY
Grade 1 Grade 2 Grade 3 Grade 4
Hemoglobin
HIV POSITIVE
Adult and Pediatric 57 Days8.5to10.0g/dL 
85 to 100 g/L7.5to 8.5g/dL 
75to85g/L6.5 to 7.5g/dL 
65 to 75g/L6.5g/dL
65g/L
HIV NEGATIVE
Adult and Pediatric 57 Days 10.0to10.9g/dL
100to109g/L
OR
Any decrease from Baseline
2.5 to 3.5g/dL
25 to 35g/L9.0 to 10.0g/dL
90 to 100g/L
OR
Any decrease from Baseline
3.5 to 4.5g/dL
35 to 45g/L7.0 to 9.0g/dL
70 to 90g/L
OR
Any decrease from Baseline
4.5g/dL
45g/L7.0g/dL
70g/L
Infant, 36 –56 Days
(HIV POSITIVE OR
NEGATIVE )8.5 to 9.4 g/dL
85 to 94g/L7.0 to 8.5g/dL
70 to 85g/L6.0 to 7.0 g/dL
60 to < 70 g/L6.0 g/dL
< 60 g/L
Infant, 22 –35 Days
(HIV POSITIVE OR
NEGATIVE )9.5 to 10.5 g/dL
95 to 105 g/L8.0 to 9.5g/dL
80 to 95g/L7.0 to 8.0g/dL
70 to 80g/L7.0g/dL
70g/L
Infant, 1–21 Days
(HIV POSITIVE OR
NEGATIVE )12.0 to 13.0 g/dL
120 to 130 g/L10.0 to 12.0g/dL
100 to 120g/L9.0 to 10.0g/dL
90 to 100g/L9.0g/dL
90g/L
Absolute Neutrophil Count  
(ANC)
Adult and Pediatric, 
≥ 7 Months# 1000to1300/mm3750to1000/mm3500to750/mm3500/mm3
1.00to 1.30GI/L 0.75to 1.00 GI/L 0.50to0.75 GI/L 0.50 GI/L
GS-9883/F/TAF
Protocol GS -US-380-1490 Final
Gilead Sciences, Inc. Original
CONFIDENTIAL Page94 21 October 2015HEMATOLOGY
Grade 1 Grade 2 Grade 3 Grade 4
Absolute CD4+ Count
HIV NEGATIVE ONLY
Adult and Pediatric 
>13Years300to400/mm3
300to400/μL200to300/mm3
200to 300/μL100to200/mm3
100to200/μL100/mm3
100/μL
Absolute Lymphocyte Count
HIV NEGATIVE ONLY
Adult and Pediatric 
13Years600 to 650/mm3
0.60 to 0.65 GI/L500 to 600/mm3
0.50 to 0.60 GI/L350 to 500/mm3
0.35 to 0.50 GI/L350/mm3
0.35 GI/L
Platelets 100,000 to < 125,000/mm3
100to125 GI/L50,000 to 100,000/mm3
50to 100 GI/L25,000 to 50,000/mm3
25 to 50 GI/L25,000/mm3
25GI/L
WBCs 2000/mm3to 2500/mm31,500 to  2,000/mm31000 to 1,500/mm31000/mm3
2.00GI/Lto 2.50GI/L 1.50to 2.00GI/L 1.00 to 1.50GI/L 1.00 GI/L
Hypofibrinogenemia 100to200mg/dL 75 to 100mg/dL 50to 75mg/dL 50mg/dL
1.00to2.00g/L 0.75to 1.00g/L 0.50 to 0.75g/L 0.50g/L
Hyperfibrinogenemia ULN to 600mg/dL 600mg/dL — —
ULN  to 6.0 g/L 6.0g/L — —
Fibrin Split Product 20 to 40μg/mL 40to 50μg/mL 50to 60μg/mL 60μg/mL
20 to 40mg/L 40 to 50mg/L 50 to 60mg/L 60mg/L
Prothrombin Time (PT) 1.00 to 1.25 ULN 1.25 to 1.50 ULN 1.50 to 3.00 ULN 3.00 ULN 
International Normalized Ratio 
of prothrombin time (INR)1.1 to 1.5 x ULN >1.5 to 2.0 x ULN >2.0 to 3.0 x ULN >3.0 x ULN
GS-9883/F/TAF
Protocol GS -US-380-1490 Final
Gilead Sciences, Inc. Original
CONFIDENTIAL Page95 21 October 2015HEMATOLOGY
Grade 1 Grade 2 Grade 3 Grade 4
Activated Partial
Thromboplastin Time (APTT) 1.00to 1.66ULN 1.66to 2.33ULN 2.33to 3.00ULN 3.00 ULN
Methemoglobin 5.0to10.0% 10.0to15.0% 15.0to20.0% 20.0% 
#An overlap between the Grade 1 scale and the Lab’s normal range for absolute neutrophils may result for pediatric subjects.  Please follow the Gilead convention of grading 
any result within the LLN and ULN a 0.
GS-9883/F/TAF
Protocol GS -US-380-1490 Final
Gilead Sciences, Inc. Original
CONFIDENTIAL Page96 21 October 2015CHEMISTRY
Grade 1 Grade 2 Grade 3 Grade 4
Hyponatremia 130 to <LLN mEq/L 125 to130mEq/L 121 to125mEq/L 121 mEq/L
130 to<LLN mmol/L 125 to130mmol/L 121 to125mmol/L 121 mmol/L
Hypernatremia >ULN  to 150 mEq/L 150 to 154 mEq/L 154 to 159 mEq/L 159 mEq/L
>ULN  to 150 mmol/L 150 to 154 mmol/L 154 to 159 mmol/L 159 mmol/L
Hypokalemia 
Adult and Pediatric
1 Year3.0 to  <LLN mEq/L 2.5 to3.0mEq/L 2.0 to2.5mEq/L 2.0 mEq/L
3.0 to <LLN mmol/L 2.5 to3.0mmol/L 2.0 to2.5mmol/L 2.0 mmol/L
Infant  <1 Year 3.0 to 3.4 mEq/L
3.0 to 3.4 mmol/L2.5 to3.0mEq/L                
2.5 to <3.0 mmolL2.0 to2.5mEq/L                 
2.0 t o <2.5 mmolL2.0 mEq/L                         
<2.0 mmolL
Hyperkalemia 
Adult and Pediatric
1 Year5.6 to 6.0 mEq/L
5.6 to 6.0 mmol/L6.0 to 6.5 mEq/L
6.0 to 6.5 mmol/L6.5 to 7.0 mEq/L
6.5 to 7.0 mmol/L7.0 mEq/L
7.0 mmol/L
Infant  <1 Year >ULN to 6.0 mEq/L           
>ULN to 6.0 mmol/L> 6.0 to 6.5 mEq/L
> 6.0 to 6.5 mmol/L6.5 to 7.0 mEq/L             
6.5 to 7.0 mmol/L7.0 mEq/L                  
7.0 mmol/L
Hypoglycemia
Adult and Pediatric
1Month55 to 64mg/dL
3.03 to3.58mmol/L40 to55mg/dL
2.20 to3.03mmol/L30 to40mg/dL
1.64 to2.20mmol/L30 mg/dL
1.64 mmol/L
Infant,1Month 50 to 54mg/dL
2.8 to 3.0 mmol/L40 to 50mg/dL
2.2 to 2.8mmol/L30 to 40mg/dL
1.7 to 2.2mmol/L30 mg/dL
1.7 mmol/L
GS-9883/F/TAF
Protocol GS -US-380-1490 Final
Gilead Sciences, Inc. Original
CONFIDENTIAL Page97 21 October 2015CHEMISTRY
Grade 1 Grade 2 Grade 3 Grade 4
Hyperglycemia, Nonfasting 116to 160mg/dL 160 to 250 mg/dL 250 to 500 mg/dL 500 mg/dL
6.42 to 8.91 mmol/L 8.91 to 13.90 mmol/L 13.90 to 27.79 mmol/L 27.79 mmol/L
Hyperglycemia, Fasting 110 to 125 mg/dL
6.08 to 6.96 mmol/L>125 to 250 mg/dL
>6.96 to 13.90 mmol/L>250 to 500 mg/dL
>13.90 to 27.79 mmol/L>500 mg/dL
>27.79 mmol/L
Hypocalcemia 
(corrected for albumin if 
appropriate*)
Adult and Pediatric
2 Years7.8 <LLN mg/dL
1.94 to <LLN mmol/L7.0 to7.8 mg/dL
1.74 to1.94 mmol/L6.1 to7.0mg/dL
1.51 to1.74 mmol/L6.1mg/dL
1.51mmol/L
Pediatric ≥7 days -2 Years 7.8 to 8.4 mg/dL                               
1.94 to 2.10 mmol/L7.0 to <7.8 mg/dL              
1.74 to <1.94 mmolL6.1 to  <7.0 mg/dL                         
1.51 to < 1.74 mmolL< 6.1 mg/dL                           
< 1.51 mmol/L
Infant,7Days 6.5 to 7.5 mg/dL
1.61 to 1.88  mmol/L6.0 to 6.5 mg/dL
1.49 to < 1.61 mmol/L5.5 to 6.0 mg/dL
1.36 to < 1.49 mmol/L 5.5 mg/dL
< 1.36 mmol/L
Hypercalcemia (corrected 
for albumin if appropriate*)
Adult and Pediatric 
7Days>ULN to 11.5 mg/dL 11.5 to 12.5 mg/dL 12.5 to 13.5 mg/dL 13.5 mg/dL
>ULN to 2.88 mmol/L 2.88 to 3.13 mmol/L 3.13 to 3.38 mmol/L 3.38 mmol/L
Infant,7Days 11.5 to 12.4 mg/dL
2.86 to 3.10  mmol/L12.4 to 12.9 mg/dL
> 3.10 to 3.23  mmol/L12.9 to 13.5 mg/dL
> 3.23 to 3.38  mmol/L13.5 mg/dL
> 3.38 mmol/L
Hypocalcemia (ionized) 3.0 mg/dL to LLN 2.5 to < 3.0 mg/dL 2.0 to2.5 mg/dL 2.0 mg/dL
0.74 mmol/L to LLN 0.62 to0.74 mmol/L 0.49 to0.62 mmol/L 0.49 mmol/L
GS-9883/F/TAF
Protocol GS -US-380-1490 Final
Gilead Sciences, Inc. Original
CONFIDENTIAL Page98 21 October 2015CHEMISTRY
Grade 1 Grade 2 Grade 3 Grade 4
Hypercalcemia (ionized) ULN to 6.0 mg/dL 6.0 to 6.5 mg/dL 6.5 to 7.0 mg/dL 7.0 mg/dL
ULN to 1.50 mmol/L 1.50 to 1.63 mmol/L 1.63 to 1.75 mmol/L 1.75 mmol/L
Hypomagnesemia 1.40 to  <LLN mg/dL
1.2 to <LLN mEq/L1.04 to1.40 mg/dL
0.9 to   1.2 mEq/L0.67 to1.04 mg/dL
0.6 to 0.9 mEq/L0.67 mg/dL
0.6 mEq/L
0.58 to <LLN mmol/L 0.43 to0.58 mmol/L 0.28 to0.43 mmol/L 0.28 mmol/L
Hypophosphatemia
Adult and Pediatric
14Years2.0 to < LLN mg/dL
0.63  to LLN mmol/L1.5 to 2.0 mg/dL
0.47 to 0.63 mmol/L1.0 to 1.5 mg/dL
0.31 to 0.47 mmol/L1.0 mg/dL
0.31 mmol/L
Pediatric 1 Year– 14 Years 3.0 to <LLN mg/dL
0.96 to <LLN mmol/L2.5 to 3.0 mg/dL
0.80 to < 0.96mmol/L1.5 to 2.5 mg/dL
0.47 to < 0.80 mmol/L1.5 mg/dL
<0.47 mmol/L
Pediatric 1Year 3.5 to <LLN mg/dL
1.12 to <LLN mmol/L2.5 to 3.5mg/dL
0.80 to < 1.12mmol/L1.5 to 2.5 mg/dL
0.47 to < 0.80 mmol/L1.5 mg/dL
<0.47 mmol/L
Hyperbilirubinemia 
Adult and Pediatric 
>14Days1.0 to 1.5 ULN 1.5 to 2.5 ULN 2.5 to 5.0 ULN 5.0 ULN 
Infant, 14Days
(non-hemolytic)NA 20.0 to 25.0 mg/dL
342 to 428 μmol/L25.0 to 30.0 mg/dL
> 428 to 513 μmol/L30.0 mg/dL
> 513 μmol/L
Infant, 14Days
(hemolytic)NA NA 20.0 to 25.0 mg/dL
342 to 428 μmol/L25.0 mg/dL
> 428 μmol/L
GS-9883/F/TAF
Protocol GS -US-380-1490 Final
Gilead Sciences, Inc. Original
CONFIDENTIAL Page99 21 October 2015CHEMISTRY
Grade 1 Grade 2 Grade 3 Grade 4
Blood Urea Nitrogen 1.25 to 2.50 ULN 2.50 to 5.00 ULN 5.00 to 10.00 ULN 10.00 ULN
Hyperuricemia >ULN to 10.0 mg/dL 10.0 to 12.0 mg/dL 12.0 to 15.0 mg/dL 15.0 mg/dL
>ULN to 597 μmol/L 597 to 716 μmol/L 716 to 895 μmol/L 895 μmol/L
Hypouricemia               
Adult and Pediatric           
≥ 1 year   
Infant  < 1 Year1.5 mg/dL to LLN
87 μmol/L to LLN1.0 to1.5 mg/dL
57 to87 μmol/L0.5 to1.0 mg/dL
27 to57 μmol/L0.5 mg/dL
27 μmol/L
N/A 1.0 mg/dl to <LLN -
57 μmol to <LLN0.5 to1.0 mg/dL
27 to57 μmol/L0.5 mg/dL
27 μmol/L
Creatinine** 1.50 to 2.00 mg/dL
133 to 177 μmol/L2.00 to 3.00 mg/dL
177 to 265 μmol/L3.00 to 6.00 mg/dL 
265 to 530 μmol/L6.00 mg/dL
530 μmol/L
Bicarbonate
Adult and Pediatric 
≥ 4 Years16.0 mEq/L to LLN 11.0 to16.0 mEq/L 8.0 to11.0 mEq/L 8.0 mEq/L
16.0 mmol/L to LLN 11.0 to16.0 mmol/L 8.0 to11.0 mmol/L 8.0 mmol/L
Pediatric < 4 Years NA 11.0 mEq/Lto <LLN 8.0 to11.0 mEq/L 8.0 mEq/L
11.0 mmol/L to <LLN 8.0 to11.0 mmol/L 8.0 mmol/L
Triglycerides
(Fasting)NA 500 to 750 mg/dL
5.64–8.47 mmol/L750 to 1200 mg/dL
8.47–13.55 mmol/L1200 mg/dL
13.55 mmol/L
GS-9883/F/TAF
Protocol GS -US-380-1490 Final
Gilead Sciences, Inc. Original
CONFIDENTIAL Page100 21 October 2015CHEMISTRY
Grade 1 Grade 2 Grade 3 Grade 4
LDL (Fasting)
Adult130 to 160 mg/dL >160 to 190 mg/dL > 190 mg/dL NA
3.35 to 4.15 mmol/L >4.15 to 4.92 mmol/L >4.92 mmol/L
LDL (Fasting)
Pediatric >2 to <18 years110 to 130 mg/dL >130 to 190 mg/dL > 190 mg/dL NA
2.84 to 3.37 mmol/L >3.37 to  4.92 mmol/L >4.92 mmol/L
Hypercholesterolemia
(Fasting)200 to 239 mg/dL 239 to 300 mg/dL 300 mg/dL NA
5.16 to 6.19 mmol/L 6.19 to 7.77 mmol/L 7.77 mmol/L
Pediatric 18 Years 170 to 199 mg/dL
4.39 to 5.15 mmol/L199 to 300 mg/dL
5.15 to 7.77 mmol/L300 mg/dL
7.77 mmol/LNA
Creatine Kinase 3.0 to6.0 ULN 6.0 to10.0 ULN 10.0 to20.0 ULN 20.0 ULN
*Calcium should be corrected for albumin if albumin is < 4.0 g/dL
**An overlap between the Grade 1 scale and the Lab’s normal range for creatinine may result for Male subjects >70 yrs.  Please follow the Gilead convention of grading any 
result within the LLN and ULN a 0.  
GS-9883/F/TAF
Protocol GS -US-380-1490 Final
Gilead Sciences, Inc. Original
CONFIDENTIAL Page101 21 October 2015ENZYMES
Grade 1 Grade 2 Grade 3 Grade 4
AST (SGOT) 1.25 to 2.50 ULN 2.50 to 5.00 ULN 5.00 to 10.00 ULN 10.00 ULN
ALT (SGPT) 1.25 to 2.50 ULN 2.50 to 5.00 ULN 5.00 to 10.00 ULN 10.00 ULN
GGT 1.25 to 2.50 ULN 2.50 to 5.00 ULN 5.00 to 10.00 ULN 10.00 ULN
Alkaline Phosphatase 1.25 to 2.50 ULN 2.50 to 5.00 ULN 5.00 to 10.00 ULN 10.00 ULN
Total Amylase 1.0 to 1.5 ULN 1.5 to 2.0 ULN 2.0 to 5.0 ULN 5.0 ULN
Pancreatic Amylase 1.0 to 1.5 ULN 1.5 to 2.0 ULN 2.0 to 5.0 ULN 5.0 ULN
Lipase 1.0 to 1.5 ULN 1.5 to 3.0 ULN 3.0 to 5.0 ULN 5.0 ULN
Albumin
Pediatrics <16 years 
≥ 16 years- 2.0 to LLN g/dL
20 to LLN g/L2.0 g/dL
20 g/LNA
3.0 g/dL to LLN
30 g/L to LLN2.0 to 3.0 g/dL
20 to 30 g/L2.0 g/dL
20 g/LNA
GS-9883/F/TAF
Protocol GS -US-380-1490 Final
Gilead Sciences, Inc. Original
CONFIDENTIAL Page102 21 October 2015URINALYSIS
Grade 1 Grade 2 Grade 3 Grade 4
Hematuria (Dipstick) 1 2 3-4+ NA
Hematuria (Quantitative) 
See Note below
                              Females >ULN -10RBC/HPF 10-75RBC/HPF > 75 RBC/HPF NA
                              Males 6-10 RBC/HPF 10-75RBC/HPF > 75 RBC/HPF NA
Proteinuria (Dipstick) 1 2–3 4 NA
Proteinuria, 24 Hour Collection
Adult and Pediatric 
10 Years200 to999 mg/24 h >999 to1999 mg/24 h >1999to3500 mg/24 h 3500 mg/24 h
Pediatric 3 Mo to 
<10Years201 to499 mg/m2/24h >499to799 mg/m2/24 h >799to1000 mg/m2/24 h 1000 mg/ m2/24 h
Glycosuria (Dipstick) 1+ 2-3 4 NA
Notes:
Toxicity grades for Quantitative and Dipstick Hematuria will be assigned by Covance Laboratory, however for other laboratorie s, toxicity grades will only be assigned to 
Dipstick Hematuria.
With the exception of lipid tests, any graded laboratory test with a result that is between the LLN and ULN should be assigned Grade 0.
If the severity of a clinical AE could fall under either one of two grades (e.g., the severity of an AE could be either Grade 2 or Grade 3), select the higher of the two grades for 
the AE.
GS-9883/F/TAF
Protocol GS -US-380-1490 Final
Gilead Sciences, Inc. Original
CONFIDENTIAL Page103 21 October 2015CARDIOVASCULAR
Grade 1 Grade 2 Grade 3 Grade 4
Cardiac Arrhythmia (general)
(By ECG or physical exam)Asymptomatic AND No 
intervention indicatedAsymptomatic AND Non -
urgent medical intervention 
indicatedSymptomatic, non -life-
threatening AND Non -
urgent medical intervention 
indicated Life-threatening arrhythmia 
OR Urgent intervention 
indicated
Cardiac-ischemia/Infarction NA NA Symptomatic ischemia 
(stable angina) OR Testing 
consistent with ischemia Unstable angina OR Acute 
myocardial infarction
Hemorrhage (significant acute 
blood loss)NA Symptomatic AND No 
transfusion indicatedSymptomatic AND 
Transfusion of 2units 
packed RBCs (for children 
10cc/kg) indicated Life-threatening hypotension 
OR Transfusion of 2units 
packed RBCs indicated (for 
children 10cc/kg) indicated
Hypertension (with repeat 
testing at same visit)140–159mmHg systolic 
OR 
90–99 mmHg diastolic159–179 mmHg systolic 
OR 
99–109 mmHg diastolic179mmHg systolic 
OR 
109mmHg diastolicLife-threatening consequences 
(eg, malignant hypertension) 
OR Hospitalization (other than 
ER visit) indicated
Pediatric 17Years (with 
repeat testing at same visit)NA 91st–94th percen tile adjusted 
for age, height, and gender 
(systolic and/or diastolic)≥95th percentile adjusted 
for age, height, and gender 
(systolic and/or diastolic)Life-threatening consequences 
(eg, malignant hypertension) 
OR Hospitalization indicated 
(other than emergency room 
visit)
Hypotension NA Symptomatic, corrected w ith 
oral fluid replacementSymptomatic, IV fluids 
indicatedShock requiring use of 
vasopressors or mechanical 
assistance to maintain blood 
pressure
Pericardial Effusion Asymptomatic, small 
effusion requiring no 
interventionAsymptomatic, moderate or 
larger effusion requiring no 
interventionEffusion with non -life-
threatening physiologic 
consequences OR Effusion 
with nonurgent intervention 
indicatedLife-threatening consequences 
(eg, tamponad e) OR Urgent 
intervention indicated
GS-9883/F/TAF
Protocol GS -US-380-1490 Final
Gilead Sciences, Inc. Original
CONFIDENTIAL Page104 21 October 2015CARDIOVASCULAR
Grade 1 Grade 2 Grade 3 Grade 4
Prolonged PR Interval PR interval 
0.21 to 0.25 secPR interval
0.25 secType II 2nd degree AV 
block OR Ventricular pause 
3.0 secComplete AV block 
Pediatric 16 Years 1st degree AV block
(PR > normal for age and
rate)Type I 2nd degree AV block Type II 2nd degree AV 
block Complete AV block
Prolonged QTc Asymptomatic, QTc interval 
0.45 to 0.47 sec OR Increase 
interval 0.03 sec above 
baselineAsymptomatic, QTc interval 
0.48 to 0.49 sec OR Increase 
in interval 0.03 to 0.05 sec 
above baselineAsymptomatic, QTc interval 
0.50sec OR Increase in 
interval 0.06sec above 
baselineLife-threatening 
consequences, eg, Torsade de 
pointes or other associated 
serious ventricular 
dysrhythmia
Pediatric 16Years Asymptomatic, QTc interval 
0.450 to 0.464 sec Asymptomatic, QTc interval 
0.465 to 0.479 sec Asymptomatic, QTc interval 
0.480 sec Life-threatening 
consequences, eg, Torsade de 
pointes or other associated 
serious ventricular 
dysrhythmia
Thrombosis/Embolism NA Deep vein thrombosis AND 
No intervention indicated (eg, 
anticoagulation, lysis filter, 
invasive procedure) Deep vein thrombosis AND 
Intervention indicated (eg, 
anticoagulation, lysis filter, 
invasive procedure) Embolic event (eg, p ulmonary 
embolism, life -threatening 
thrombus) 
Vasovagal Episode (associated 
with a procedure of any kind)Present without loss of 
consciousness Present with transient loss of 
consciousnessNA NA
Ventricular Dysfunction 
(congestive heart failure, 
CHF)NA Asymptomatic diagnostic 
finding AND intervention 
indicatedNew onset with symptoms 
OR Worsening symptomatic 
CHFLife-threatening CHF
GS-9883/F/TAF
Protocol GS -US-380-1490 Final
Gilead Sciences, Inc. Original
CONFIDENTIAL Page105 21 October 2015RESPIRATORY
Grade 1 Grade 2 Grade 3 Grade 4
Bronchospasm (acute) FEV1 or peak flow  reduced to 
70% to 80%FEV1 or peak flow  50% to 69% FEV1 or peak flow  25% to 
49% Cyanosis OR FEV1 or peak flow  
25% OR Intubation
Dyspnea or Respiratory 
DistressDyspnea on exertion with no 
or minimal interference with 
usual social & functional 
activities Dyspnea on exertion causing 
greater than minimal interference 
with usual social & functional 
activities Dyspnea at rest causing 
inability to perform usual 
social & functional activities Respiratory failure with 
ventilatory support indicated
Pediatric 14 Years Wheezing OR minimal 
increase in respiratory rate for 
ageNasal flaring OR Intercostal 
retractions OR Pulse oximetry 
90% to 95%Dyspnea at rest causing 
inability to perform usual 
social & functional activities 
OR Pulse oximetry 90%Respiratory f ailure with 
ventilatory support indicated
OCULAR/VISUAL
Grade 1 Grade 2 Grade 3 Grade 4
Uveitis Asymptomatic but detectable 
on examSymptomatic anterior uveitis OR 
Medical intervention indicatedPosterior or pan -uveitis OR 
Operative intervention 
indicatedDisabling visual loss in affected 
eye(s) 
Visual Changes (from 
baseline)Visual changes causing no or 
minimal interference with 
usual social & functional 
activitiesVisual changes causing greater 
than minimal interference with 
usual social & functional 
activitiesVisual changes causing 
inability to perform usual 
social & functional activitiesDisabling visual loss in affected 
eye(s)
GS-9883/F/TAF
Protocol GS -US-380-1490 Final
Gilead Sciences, Inc. Original
CONFIDENTIAL Page106 21 October 2015SKIN
Grade 1 Grade 2 Grade 3 Grade 4
Alopecia Thinning detectable by 
study participant or  
caregiver (for disabled 
adults)Thinning or patchy hair loss 
detectable by health care 
providerComplete hair loss NA
Cutaneous Reaction –Rash Localized macular rash Diffuse macular, 
maculopapular, or 
morbilliform rash OR Target 
lesions Diffuse macular, 
maculopapular, or morbilliform 
rash with vesicles or limited 
number of bullae OR 
Superficial ulcerations of 
mucous membrane limited to 
one siteExtensive or generalized 
bullous lesions OR 
Stevens-Johnson syndrome 
OR Ulceration of mucous 
membrane involving two 
or more distinct mucosal 
sites OR Toxic epidermal 
necrolysis (TEN)
Hyperpigmentation Slight or localized Marked or generalized NA NA
Hypopigmentation Slight or localized Marked or generalized NA NA
Pruritis (itching –no skin 
lesions) 
(See also Injection Site 
Reactions: Pruritis associated 
with injection)Itching causing no or 
minimal interference with 
usual social & functional 
activitiesItching causing greater than 
minimal interference with 
usual social & functional 
activitiesItching causing i nability to 
perform usual social & 
functional activities NA
GS-9883/F/TAF
Protocol GS -US-380-1490 Final
Gilead Sciences, Inc. Original
CONFIDENTIAL Page107 21 October 2015GASTROINTESTINAL
Grade 1 Grade 2 Grade 3 Grade 4
Anorexia Loss of appetite w ithout 
decreased oral intakeLoss of appetite associated with 
decreased oral intake without 
significant weight loss Loss of appetite associated 
with significant weight loss Life-threatening consequences 
OR Aggressive intervention 
indicated [eg, tube feeding or 
total parenteral nutri tion]
Ascites Asymptomatic Symptomatic AND Intervention 
indicated (eg, diuretics or 
therapeutic paracentesis)Symptomatic despite 
interventionLife-threatening consequences
Cholecystitis NA Symptomatic AND Medical 
intervention indicatedRadiologic, endoscopic, or 
operative intervention 
indicatedLife-threatening consequences 
(eg, sepsis or perforation) 
Constipation NA Persistent constipation requiring 
regular use of dietary 
modifications, laxatives, or 
enemas Obstipation with manual 
evacuation indicatedLife-threatening consequences 
(eg, obstruction)
Diarrhea 
Adult and Pediatric 
1YearTransient or intermittent 
episodes of unformed stools 
OR Increase of 3stools 
over baseline/24 hrPersistent episodes of unformed 
to watery stools OR Increase of 
4–6 stools over baseline per 
24hrs. Bloody diarrhea OR Increase 
of 7stools per 24 -hour 
period OR IV fluid 
replacement indicatedLife-threatening consequences 
(eg, hypotensive shock)
Pediatric 1Year Liquid stools (more 
unformed than usual) but 
usual number of stoolsLiquid stools with increased 
number of stools OR Mild 
dehydrationLiquid stools with moderate 
dehydrationLiquid stools resulting in 
severe dehydration with 
aggressive r ehydration 
indicated OR Hypotensive 
shock
Dysphagia-Odynophagia Symptomatic but able to eat 
usual dietSymptoms causing altered 
dietary intake without medical 
intervention indicatedSymptoms causing severely 
altered dietary intake with 
medical intervention indicatedLife-threatening reduction in 
oral intake
GS-9883/F/TAF
Protocol GS -US-380-1490 Final
Gilead Sciences, Inc. Original
CONFIDENTIAL Page108 21 October 2015GASTROINTESTINAL
Grade 1 Grade 2 Grade 3 Grade 4
Mucositis/Stomatitis 
(clinical exam)
See also Proctitis, 
Dysphagia-OdynophagiaErythema of the mucosa Patchy pseudomembranes or 
ulcerations Confluent pseudomembranes 
or ulcerations OR Mucosal 
bleeding with minor traumaTissue necrosis OR Diffuse 
spontaneous mucosal bleeding 
OR Life-threatening 
consequences (eg, aspiration, 
choking)
Nausea Transient ( 24hours) or 
intermittent nausea with no 
or minimal interference with 
oral intakePersistent nausea resulting in 
decreased oral intake for 24 –48 
hoursPersistent nausea resulting in 
minimal oral intake for  48 
hours OR Aggressive 
rehydration indicated (eg, 
IVfluids)Life-threatening consequences 
(eg, hypotensive shock)
Pancreatitis NA Symptomatic AND 
Hospitalization not indicated 
(other than ER visit)Symptomatic AND 
Hospitalization indicated 
(other than ER visit)Life-threatening consequences 
(eg, sepsis, circulatory failure, 
hemorrhage)
Proctitis (functional -
symptomatic)
Also seeMucositis/ 
Stomatitis for Clinical 
ExamRectal discomfort AND No 
intervention indicatedSymptoms causing greater than 
minimal interference with usual 
social & functional activities OR 
Medical intervention indicated Symptoms causing inability to 
perform usual social/ 
functional activities OR 
Operative intervention 
indicated Life-threatening consequences 
(eg, perforation)
Vomiting Transient or intermittent 
vomiting with no or 
minimal interference with 
oral intakeFrequent episodes of vomiting 
with no or mild dehydrationPersistent vomiting resulting 
in orthostatic hypotension OR 
Aggressive rehydration 
indicatedLife-threatening consequences 
(eg, hypotensive shock)
GS-9883/F/TAF
Protocol GS -US-380-1490 Final
Gilead Sciences, Inc. Original
CONFIDENTIAL Page109 21 October 2015NEUROLOGICAL
Grade 1 Grade 2 Grade 3 Grade 4
Alteration in Personality -
Behavior or in Mood (eg, 
agitation, anxiety, 
depression, mania, 
psychosis)Alteration causing no or 
minimal interference with 
usual social & functional 
activities Alteration causing greater than 
minimal interference with 
usual social & functional 
activities Alteration causing inability to 
perform usual social & 
functional activities Behavior potentially harmful 
to self or others (eg, 
suicidal/homicidal ideation or 
attempt, acute psychosis) OR 
Causing inability to perform 
basic self-care functions
Altered Mental Status 
For Dementia, see Cognitive 
and Behavioral/Attentional 
Disturbance (including 
dementia and ADD)Changes causing no or 
minimal interference with 
usual social & functional 
activitiesMild lethargy or somnolence 
causing greater than minimal 
interference with usual social 
& functional activitiesConfusion, memory 
impairment, lethargy, or 
somnolence causing inability 
to perform usual social & 
functional activitiesDelirium OR obtundation, OR 
coma
Ataxia Asymptomatic ataxia 
detectable on exam OR 
Minimal ataxia causing no 
or minimal interference with 
usual social & functional 
activitiesSymptomatic ataxia causing 
greater than minimal 
interference with usual social 
& functional activitiesSymptomatic ataxia causing 
inability to perform usual 
social & functional activities Disabling ataxia causing 
inability to perform basic self -
care functions
Cognitive and 
Behavioral/Attentional 
Disturbance (including 
dementia and Attention 
Deficit Disorder) Disability cau sing no or 
minimal interference with 
usual social & functional 
activities OR Specialized 
resources not indicatedDisability causing greater than 
minimal interference with 
usual social & functional 
activities OR Specialized 
resources on part -time basis 
indicatedDisability causing inability to 
perform usual social & 
functional activities OR 
Specialized resources on a 
full-time basis indicatedDisability causing inability to 
perform basic self -care 
functions OR 
Institutionalization indicated
CNS Ischemia
(acute)NA NA Transient ischemic attack Cerebral vascular accident 
(CVA, stroke) with 
neurological deficit 
GS-9883/F/TAF
Protocol GS -US-380-1490 Final
Gilead Sciences, Inc. Original
CONFIDENTIAL Page110 21 October 2015NEUROLOGICAL
Grade 1 Grade 2 Grade 3 Grade 4
Developmental delay –
Pediatric 16 YearsMild developmental delay, 
either motor or cognitive, as 
determined by comparison 
with a developmental 
screening tool appropriate 
for the setting Moderate developmental 
delay, either motor or 
cognitive, as determined by 
comparison with a 
developmental screening tool 
appropriate for the setting Severe developmental delay, 
either motor or cognitive, as 
determined by comparison 
with a developmental 
screening tool appropriate for 
the setting Developmental regression, 
either motor or cognitive, as 
determined b y comparison 
with a developmental 
screening tool appropriate for 
the setting
Headache Symptoms causing no or 
minimal interference with 
usual social & functional 
activitiesSymptoms causing greater 
than minimal interference with 
usual social & functional 
activitiesSymptoms causing inability to 
perform usual social & 
functional activitiesSymptoms causing inability to 
perform basic self -care 
functions OR Hospitalization 
indicated (other than ER visit) 
OR Headache with significant 
impairment of alertness or
other neurologic function 
Insomnia NA Difficulty sleeping causing 
greater than minimal 
interference with usual 
social/functional activitiesDifficulty sleeping causing 
inability to perform usual 
social & functional activitiesDisabling insomnia causing 
inability to perform basic self -
care functions
Neuromuscular Weakness 
(including myopathy & 
neuropathy) Asymptomatic with 
decreased strength on exam 
OR Minimal muscle weak -
ness causing no or minimal 
interference with usual 
social & functional activitiesMuscle weakness causing 
greater than minimal 
interference with usual social 
& functional activitiesMuscle weakness causing 
inability to perform usual 
social & functional activities Disabling muscle weakness 
causing inability to perform 
basic self -care functions OR 
Respiratory muscle weakness 
impairing ventilation
Neurosensory Alteration 
(including paresthesia and 
painful neuropathy)Asymptomatic with sensory 
alteration on exam or 
minimal paresthesia causing 
no or minimal interference 
with usual social &
functional activities Sensory alteration or 
paresthesia causing greater 
than minimal interference with 
usual social & functional 
activities Sensory alteration or 
paresthesia causing inability to 
perform usual social & 
functional activitiesDisabling sen sory alteration or 
paresthesia causing inability to 
perform basic self -care 
functions
GS-9883/F/TAF
Protocol GS -US-380-1490 Final
Gilead Sciences, Inc. Original
CONFIDENTIAL Page111 21 October 2015NEUROLOGICAL
Grade 1 Grade 2 Grade 3 Grade 4
Seizure: (new onset) NA 1 seizure 2–4 seizures Seizures of any kind that are 
prolonged, repetitive (eg, 
status epilepticus), or difficult 
to control (eg, refractory 
epilepsy)
Seizure: (pre- existing) 
For Worsening of Existing 
Epilepsy the Grades Should 
Be Based on an Increase 
from Previous Level of 
Control to Any of These 
LevelsNA Increased frequency of pre-
existing seizures (non -
repetitive) without change in 
seizure character OR 
infrequent breakthrough 
seizures while on stable meds 
in a previously controlled 
seizure disorderChange in seizure character 
from baseline either in 
duration or quality (eg, 
severity or focality) Seizures of any kind that are 
prolonged, repetitive (eg, 
status epilepticus), or difficult 
to control (eg, refractory 
epilepsy)
Seizure 
–Pediatric 18 YearsSeizure, generalized onset 
with or without secondary 
generalization, lasting 
< 5minutes with < 24hours 
post ictal stateSeizure, generalized onset 
with or without secondary 
generalization, lasting 5 –20 
minutes with 
< 24 hours post ictal stateSeizure, generalized onset 
with or without secondary 
generalization, lasting 
> 20 minutes Seizure, generalized onset 
with or witho ut secondary 
generalization, requiring 
intubation and sedation
Syncope (not associated 
with a procedure)NA Present NA NA
Vertigo Vertigo causing no or 
minimal interference with 
usual social & functional 
activitiesVertigo causing greater than 
minimal interference with 
usual social & functional 
activities Vertigo causing inability to 
perform usual social & 
functional activitiesDisabling vertigo causing 
inability to perform basic self -
care functions
GS-9883/F/TAF
Protocol GS -US-380-1490 Final
Gilead Sciences, Inc. Original
CONFIDENTIAL Page112 21 October 2015MUSCULOSKELETAL
Grade 1 Grade 2 Grade 3 Grade 4
Arthralgia
See also ArthritisJoint pain causing no or 
minimal interference with 
usual social & functional 
activitiesJoint pain causing greater than 
minimal interference with usual 
social & functional activitiesJoint pain causing inability 
to perform usual social & 
functional activitiesDisabling joint pain causing 
inability to perform basic self -
care functions
Arthritis
See also ArthralgiaStiffness or joint sw elling 
causing no or minimal 
interference with usual 
social & functional activitiesStiffness or joint sw elling causing 
greater than minimal interference 
with usual social & functional 
activitiesStiffness or joint sw elling 
causing inability to perform 
usual social & functional 
activitiesDisabling joint stiffness or 
swelling causing inability to 
perform basic self -care 
functions
Bone Mineral Loss BMD t-score or z- score
–2.5 to –1.0 BMD t-score or z- score–2.5 Pathological fracture 
(including loss of vertebral 
height)Pathologic fracture causing 
life-threatening consequences 
Pediatric 21Years BMD z-score 
–2.5 to –1.0BMD z-score < –2.5 Pathological fracture 
(including loss of vertebral 
height)Pathologic fracture causing 
life-threatening consequences 
Myalgia
(non-injection site)Muscle pain causing no or 
minimal interference with 
usual social & functional 
activitiesMuscle pain causing greater than 
minimal interference with usual 
social & functional activitiesMuscle pain causing 
inability to perform usual 
social & functional activitiesDisabling muscle pain causing 
inability to perform basic self -
care functions
Osteonecrosis NA Asymptomatic with radiographic 
findings AND No operative 
intervention indicatedSymptomatic bone pain with 
radiographic findings OR 
Operative intervention 
indicatedDisabling bone pain with 
radiographic findings causing 
inability to perform basic self -
care functions
GS-9883/F/TAF
Protocol GS -US-380-1490 Final
Gilead Sciences, Inc. Original
CONFIDENTIAL Page113 21 October 2015SYSTEMIC
Grade 1 Grade 2 Grade 3 Grade 4
Acute Systemic Allergic 
Reaction Localized urticaria 
(wheals) with no medical 
intervention indicatedLocalized urticaria with medical 
intervention indicated OR Mild 
angioedema with no medical 
intervention indicatedGeneralized urticaria OR 
Angioedema with medical 
intervention indicated OR 
Symptomatic mild 
bronchospasmAcute anaphylaxis OR Life -
threatening bronchospasm OR 
laryngeal edema
Chills Symptoms causing no or 
minimal interference with 
usual social & functional 
activitiesSymptoms causing greater than 
minimal interference with usual 
social & functional activities Symptoms causing inability to 
perform usual social & 
functional activitiesNA
Fatigue
MalaiseSymptoms causing no or 
minimal interference with 
usual social & functional 
activitiesSymptoms causing greater than 
minimal interference with usual 
social & functional activitiesSymptoms causing inability to 
perform usual social & 
functional activitiesIncapacitating fatigue/malaise 
symptoms causing inability to 
perform basic self -care 
functions
Fever (nonaxillary) 37.7C to 38.6C
99.8F to 101.5F38.7C to 39.3C
101.6F to 102.8F39.4C to 40.5C
102.9F to 104.9F40.5C 
104.9F
Pain-Indicate Body Site
See also Injection Site 
Pain, Headache, 
Arthralgia, and MyalgiaPain causing no or 
minimal interference with 
usual social & functional 
activitiesPain causing greater than minimal 
interference with usual social & 
functional activitiesPain causing inability to 
perform usual social & 
functional activitiesDisabling pain causing 
inability to perform basic self -
care functions OR 
Hospitalization (other than ER 
visit) indicated
Unintentional Weight 
LossNA 5% to 9% loss in body weight from 
baseline10% to 19% loss in body 
weight from baseline20% loss in body weight 
from baseline OR  Aggressive 
intervention indicated [eg, 
tube feeding or total parenteral 
nutrition]
GS-9883/F/TAF
Protocol GS -US-380-1490 Final
Gilead Sciences, Inc. Original
CONFIDENTIAL Page114 21 October 2015INJECTION SITE REACTION
Grade 1 Grade 2 Grade 3 Grade 4
Injection Site Pain (pain 
without touching)
Or Tenderness (pain when 
area is touched) Pain/tenderness causing no 
or minimal limitation of use 
of limbPain/tenderness limiting use of 
limb OR Pain/tenderness 
causing greater than minimal 
interference with usual social 
& functional activitiesPain/tenderness causing 
inability to perform usual 
social & functional activitiesPain/tenderness causing inability 
to perform basic self -care 
function OR Hospitalization 
(other than ER visit) indicated 
for management of 
pain/tenderness
Injection Site Reaction 
(Localized), 15YearsErythema OR Induration
of 55cm to 99cm (or 
2581 cm2)Erythema OR Induration OR 
Edema 9cm any diameter 
(or 81cm2)Ulceration OR Secondary 
infection OR Phlebitis OR 
Sterile abscess OR DrainageNecrosis (involving dermis and 
deeper tissue)
Pediatric 15Years Erythem a OR Induration 
OR Edema present but 
2.5cm diameterErythem a OR Induration 
OR Edema > 2.5cm 
diameter but < 50% surface 
area of the extrem ity 
segment (eg, upper 
arm/thigh)Erythem a OR Induration 
OR Edema involving 
50% surface area of the 
extremity segment (eg, 
upper arm/thigh) OR 
Ulceration OR Secondary 
infection OR Phlebitis OR 
Sterile abscess OR 
DrainageNecrosis (involving dermis and 
deeper tissue)
Pruritis Associated with 
Injection 
See also Skin: Pruritis 
(itching—no skin lesions)Itching localized to injection 
site AND Relieved 
spontaneously or w ith 
48h treatment Itching beyond the injection 
site but not generalized OR 
Itching localized to injection 
site requiring 48h treatment Generalized itching causing 
inability to perform usual 
social & functional activitiesNA
GS-9883/F/TAF
Protocol GS -US-380-1490 Final
Gilead Sciences, Inc. Original
CONFIDENTIAL Page115 21 October 2015ENDOCRINE/METABOLIC
Grade1 Grade 2 Grade 3 Grade 4
Lipodystrophy (eg, back 
of neck, breasts, 
abdomen)Detectable by study 
participant or caregiver 
(for young children and 
disabled adults)Detectable on physical exam by 
health care providerDisfiguring OR Obvious 
changes on casual visual 
inspectionNA
Diabetes Mellitus NA New onset without need to initiate 
medication OR Modification of 
current meds to regain glucose 
controlNew onset with initiation of 
indicated med OR Diabetes 
uncontrolled despite treatment 
modificationLife-threatening consequences 
(eg, ketoacidosis, 
hyperosmolar non -ketotic 
coma) 
Gynecomastia Detectable by study 
participant or caregiver 
(for young children and 
disabled adults)Detectable on physical exam by 
health care providerDisfiguring OR Obvious on 
casual visual inspectionNA
Hyperthyroidism Asymptomatic Symptomatic causing greater than 
minimal interference with usual 
social & functional activities OR 
Thyroid suppression therapy 
indicatedSymptoms causing inability to 
perform usual social & 
functional activities OR 
Uncontrolled despite treatment 
modification Life-threatening consequences 
(eg, thyroid storm)
Hypothyroidism Asymptomatic Symptomatic causing greater than 
minimal interference with usual 
social & functional activities OR 
Thyroid replacement therapy 
indicatedSymptoms causing inability to 
perform usual social & 
functional activities OR 
Uncontrolled despite treatment 
modification Life-threatening consequences 
(eg, myxedema coma)
Lipoatrophy (eg, fat loss 
from the face, extremities , 
buttocks)Detectable by study 
participant or caregiver 
(for young children and 
disabled adults)Detectable on physical exam by 
health care providerDisfiguring OR Obvious on 
casual visual inspectionNA
GS-9883/F/TAF
Protocol GS -US-380-1490 Final
Gilead Sciences, Inc. Original
CONFIDENTIAL Page116 21 October 2015GENITOURINARY
Grade 1 Grade 2 Grade 3 Grade 4
Intermenstrual Bleeding 
(IMB)Spotting observed by participant 
OR Minimal blood observed 
during clinical or colposcopic 
examIntermenstrual bleeding not 
greater in duration or amount 
than usual menstrual cycleIntermenstrual bleeding greater 
in duration or amount than usual 
menstrual cycleHemorrhage with life -
threatening hypotension OR 
Operative intervention 
indicated
Urinary Tract 
obstruction (eg, stone)NA Signs or symptoms of urinary 
tract obstruction without 
hydronephrosis or renal 
dysfunctionSigns or symptoms of urinary 
tract obstruction with 
hydronephrosis or renal 
dysfunctionObstruction causing life -
threatening consequences
INFECTION
Grade 1 Grade 2 Grade 3 Grade 4
Infection (any other 
than HIV infection)Localized, no systemic antiμbial 
treatment indicated AND 
Symptoms causing no or 
minimal interference with usual 
social & functional activitiesSystemic antiμbial treatment 
indicated OR Symptoms 
causing greater than minimal 
interference with usual social 
& functional activitiesSystemic an tiμbial treatment 
indicated AND Symptoms 
causing inability to perform 
usual social & functional 
activities OR Operative 
intervention (other than simple 
incision and drainage) indicatedLife-threatening 
consequences (eg, septic 
shock)
Basic Self-care Functions: Activities such as bathing, dressing, toileting, transfer/movement, continence, and feeding.
Usual Social & Functional Activities: Adaptive tasks and desirable activities, such as going to work, shopping, cooking, use of transportation, pursuing a hobby, etc.
GS-9883/F/TAF
Protocol GS -US-380-1490 Final
Gilead Sciences, Inc. Original
CONFIDENTIAL Page117 21 October 2015Appendix 5. Definitions of Stage 3 Opportunistic Illnesses in HIV (CDC 
Guidelines)
1. Candidiasis of bronchi, trachea, or lungs 
2.Candidiasis of esophagus
3.Cervical cancer, invasive
4.Coccidioidomy cosis, disseminated or extrapulmonary
5.Cryptococcosis, extrapulmonary
6.Cryptosporidiosis, chronic intestinal ( 1month duration)
7.Cytomegalovirus disease (other than liver, spleen or nodes)
8.Cytomegalovirus retinitis (with loss of vision)
9.Encephalopath y, HIV-
related
10. Herpes simplex: chronic ulcer(s) ( 1month duration); or bronchitis, pneumonitis or 
esophagitis
11.Histoplasmosis, disseminated or extrapulmonary
12.Isosporiasis, chronic intestinal ( 1month duration)
13.Kaposi’s sarcoma
14.Lymphoma, Burkitt’s (or equivalent term)
15.Lymphoma, immunoblastic (or equivalent term)
16.Lymphoma, primary , of brain
17.Mycobacterium avium complex or Myobacterium kansasii , disseminated or extrapulmonary
18.Mycobacterium tuberculosis , of any site,  pulmonary , disseminated or extrapulmonary
19.Mycobacterium , other species or unidentified species, disseminated or extrapulmonary
20.Pneumocy stis jirovecii (previously  known as “ Pneumocystis carinii) pneumonia
21.Pneumonia, recurrent
22. Progressive multifocal leukoencephalopathy
GS-9883/F/TAF
Protocol GS -US-380-1490 Final
Gilead Sciences, Inc. Original
CONFIDENTIAL Page118 21 October 201523.Salmonella septicemia, recurrent
24.Toxoplasmosis of brain
25.Wasting sy ndrome attributed to HIV infection
CDC Stage -3-Defining Opportunistic I llnesses in HIV Infection -2014 {13585}
GS-9883/F/TAF
Protocol GS -US-380-1490 Final
Gilead Sciences, Inc. Original
CONFIDENTIAL Page119 21 October 2015Appendix 6. Pregnancy Precautions, Definition for Female of Childbearing 
Potential, and Contraceptive Require ments
1)Definitions
a.Definition of Childbearing Potential
For the purposes of this study , a female born subject is considered of childbearing potential 
following the initiation of pubert y (Tanner stage 2) until becoming post -menopausal, unless 
permanentl y sterile or with medically  documented ovarian failure.  
Women are considered to be in a postmenopausal state when they  are >54years of age with 
cessation of previously  occurring menses for > 12 months without an alternative cause.  In 
addition, women of an yage with amenorrhea of >12 months may  also be considered 
postmenopausal if their follicle stimulating hormone (FSH) level is in the postmenopausal range 
and they are not using hormonal contraception or hormonal replacement therapy .
Permanent sterilizatio n includes h ysterectomy , bilateral oophorectom y, or bilateral 
salpingectomy  in a female subject of an y age.
b.Definition of Male Fertility
For the purposes of this study , a male born subject is considered to befertile after the initiation 
of puberty unless permanently  sterile by bilateral orchidectom y or medical documentation.
2)Contraception Requirements for Female Subjects
a.Study Drug Effects on Pregnancy and Hormonal Contraception
The data on GS -9883/F/TAF in pregnant women is limited or not available. There is no 
suspicion of human teratogenicity  based on class effects or genotoxic potential. Relevant non -
clinical reproductive studies for human pregnancy  do not indicate a strong s uspicion of human 
teratogenicit y/fetotoxicity .Data from clinical pharmacokinetic interaction studies of GS -9883 
and F/TAF have demonstrated that there is no reduction in the clinical efficacy  of hormonal 
contraception or that the effect on hormonal c ontraception is insignificant. Please refer to the 
latest version of the GS-9883/F/TAF investigator’s brochure , the F/TAF investigator’s brochure
and the current Prescribing Information and local product labeling for DTG foradditional 
information.
b.Contraception Requirements for Female Subjects of Childbearing Potential
The inclusion of female subjects of childbearing potential requires the use of highl y effective 
contraceptive measures.  They  must have a negative serum pregnancy  test at Screening and a 
negativepregnancy  test on the Day  1 visit prior to randomization.  At minimum a pregnancy  test 
will be performed at the end of relevant s ystemic exposure. In the event of a delay ed menstrual 
period (over one month between menstruations), a pregnancy test must be performed to rule out 
pregnancy . This is true even for women of childbearing potential with infrequent or irregular 
GS-9883/F/TAF
Protocol GS -US-380-1490 Final
Gilead Sciences, Inc. Original
CONFIDENTIAL Page120 21 October 2015periods.  Female subjects must agree to one of the following from Screening until 30 days 
following the end of relevant sy stemic exposure.
Complete abstinence from intercourse of reproductive potential.  Abstinence is an acceptable 
method of contraception only  when it is in line with the subject’s preferred and usual 
lifestyle. 
Or
Consistent and correct use of 1 of the following methods of birth control listed below. 
Intrauterine device (IUD) with a failure rate of <1% per year
Intrauterine hormone -releasing s ystem (IUS) with a failure rate of <1% per y ear
Tubal sterilization
Essure micro- insert system (provided confirmation of success 3 months after procedure)
Vasectom y in the male partner (provided that the partner is the sole sexual partner and 
had confirmation of surgical success 3 months after procedure)
Or
Consistent and correct use of one hormonal method and one barrier method
Barrier methods
■ Diaphragm with spermicide
■Cervical cap with spermicide
■Male condom (with or without spermicide)
Hormonal methods
■Oral contraceptives (either combined or progesterone only )
■Injectable progesterone
■Implants of levonorgestrel
■Transdermal contraceptive patch
■Contraceptive vaginal ring
Female subjects must also refrain from egg donation and in vitro fertilization during treatment 
and until at least 30 day s after the end of relevant sy stemic exposure.
GS-9883/F/TAF
Protocol GS -US-380-1490 Final
Gilead Sciences, Inc. Original
CONFIDENTIAL Page121 21 October 20153) Contraception Requirements for Male Subjects
It is theoreticall y possible that a relevant s ystemic concentration may  be achieved in a female 
partner from exposure of the male subject’s seminal fluid.  Therefore, male subjects with female 
partners of childbearing potential must use condoms during treatment and until 90 days after the 
end of relevant s ystemic exposure.  Additional contraception recommendations should also be 
considered if the female partner is not pregnant.
Male subjects must also refrain from sperm donation during treatment and until at leas t 90days 
after the end of relevant systemic exposure.
4) Unacceptable Birth Control Methods
Birth control methods that are unacceptable include periodic abstinence (e.g., calendar, 
ovulation, sy mptothermal, post -ovulation methods), withdrawal (coitus interruptus), spermicides 
only, and lactational amenorrhea method (LAM).  Female condom and male condom should not 
be used together.
5) Procedures to be Followed in the Event of Pregnancy
Subjects will be instructed to notify  the investigator if they  become pregnant at any  time during 
the study, or if they  become pregnant within 30days of last study  drug dose. Subjects who 
become pregnant or who suspect that they  are pregnant during the st udy must report the 
information to the investigator and discontinue study  drug immediatel y. Subjects whose partner 
has become pregnant or suspects she is pregnant during the stud y must report the information to 
the investigator.  Instructions for reporting pregnancy , partner pregnancy , and pregnancy  
outcome are outlined in Section 7.3.